{
  "cells": [
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "view-in-github",
        "colab_type": "text"
      },
      "source": [
        "<a href=\"https://colab.research.google.com/github/NikkiLa1/genAI_project/blob/main/Self_RAG_Biomedical_QA.ipynb\" target=\"_parent\"><img src=\"https://colab.research.google.com/assets/colab-badge.svg\" alt=\"Open In Colab\"/></a>"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "YOKyb4aBdfna"
      },
      "source": [
        "# Self-RAG: Biomedical Question Answering with Self-Reflection\n",
        "\n",
        "This notebook implements and compares:\n",
        "1. **Baseline RAG**: Standard retrieval-augmented generation\n",
        "2. **Self-RAG**: RAG with self-reflection loop for improved accuracy\n",
        "\n",
        "**Time to complete**: ~30-45 minutes\n",
        "\n",
        "---\n",
        "\n",
        "## Table of Contents\n",
        "1. Setup & Installation\n",
        "2. Load Data\n",
        "3. Data Preprocessing\n",
        "4. Building FAISS Index\n",
        "5. Baseline RAG Implementation\n",
        "6. Self-RAG Implementation\n",
        "7. Run Full Experiments\n",
        "8. Evaluation & Comparison\n",
        "9. Detailed Example Comparison\n",
        "10. Cost Analysis\n",
        "11. Save Results\n",
        "12. Summary & Key Takeaways"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "aRzt_Q7Edfnc"
      },
      "source": [
        "## 1. Setup & Installation"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "5rx2rKVEdfnc",
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "outputId": "38b09664-a9ef-4225-bb99-fb4d2394a311"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "  Preparing metadata (setup.py) ... \u001b[?25l\u001b[?25hdone\n",
            "\u001b[2K   \u001b[90m━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━━\u001b[0m \u001b[32m23.6/23.6 MB\u001b[0m \u001b[31m112.4 MB/s\u001b[0m eta \u001b[36m0:00:00\u001b[0m\n",
            "\u001b[?25h  Building wheel for rouge-score (setup.py) ... \u001b[?25l\u001b[?25hdone\n"
          ]
        }
      ],
      "source": [
        "# Install required packages\n",
        "!pip install -q openai sentence-transformers faiss-cpu rouge-score python-dotenv tqdm"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "_Jy_qR61dfnd"
      },
      "outputs": [],
      "source": [
        "# Import libraries\n",
        "import json\n",
        "import os\n",
        "import numpy as np\n",
        "from typing import List, Dict, Any, Tuple\n",
        "from tqdm.notebook import tqdm\n",
        "import warnings\n",
        "warnings.filterwarnings('ignore')"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "kiLxOVE-dfne"
      },
      "outputs": [],
      "source": [
        "from google.colab import userdata\n",
        "OPENAI_API_KEY = userdata.get('OPENAI_API_KEY')"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "NVeYc0mrdfne"
      },
      "source": [
        "## 2. Load BioASQ from Drive"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "from google.colab import drive\n",
        "drive.mount('/content/drive')\n",
        "\n",
        "# Load BioASQ from Drive\n",
        "import json\n",
        "\n",
        "# My file path\n",
        "file_path = '/content/drive/My Drive/Colab Notebooks/RAG_Project/BioASQ-trainingDataset2b.json'\n",
        "\n",
        "with open(file_path, 'r') as f:\n",
        "    bioasq_raw = json.load(f)\n",
        "\n",
        "sample_data = {\"questions\": []}\n",
        "\n",
        "for q in bioasq_raw['questions']:\n",
        "    snippets = []\n",
        "    for snippet in q.get('snippets', []):\n",
        "        snippets.append({\n",
        "            \"text\": snippet['text'],\n",
        "            \"document\": snippet['document'],\n",
        "            \"beginSection\": snippet.get('beginSection', 'abstract')\n",
        "        })\n",
        "\n",
        "    formatted_q = {\n",
        "        \"id\": q['id'],\n",
        "        \"body\": q['body'],\n",
        "        \"type\": q.get('type', 'factoid'),\n",
        "        \"ideal_answer\": q.get('ideal_answer', [''])[0] if q.get('ideal_answer') else '',\n",
        "        \"exact_answer\": q.get('exact_answer', []),\n",
        "        \"snippets\": snippets\n",
        "    }\n",
        "\n",
        "    sample_data['questions'].append(formatted_q)\n",
        "\n",
        "print(f\"Total snippets: {sum(len(q['snippets']) for q in sample_data['questions'])}\")\n",
        "print(f\"\\nFirst 5 questions:\")\n",
        "for i, q in enumerate(sample_data['questions'][:5], 1):\n",
        "    print(f\"  {i}. {q['body']} ({len(q['snippets'])} snippets)\")"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mrNlNXF6voJB",
        "outputId": "44606712-4d0b-4cce-8626-e111f034f2c4"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Mounted at /content/drive\n",
            "Total snippets: 5781\n",
            "\n",
            "First 5 questions:\n",
            "  1. Is Rheumatoid Arthritis more common in men or women? (16 snippets)\n",
            "  2. Are there any DNMT3 proteins present in plants? (5 snippets)\n",
            "  3. What is the most prominent sequence consensus for the polyadenylation site? (7 snippets)\n",
            "  4. What is the function of the mammalian gene Irg1? (18 snippets)\n",
            "  5. Is thrombophilia related to increased risk of miscarriage? (17 snippets)\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "HVMpH2dzdfnf"
      },
      "source": [
        "## 3. Data Preprocessing\n",
        "\n",
        "Extract snippets and format questions for the QA task."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "QgU-CKtwdfnf",
        "outputId": "03440d50-00eb-4303-b4af-65e0bc9945c1"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Extracted 5781 snippets for retrieval corpus\n",
            "\n",
            "Example snippet:\n",
            "  Our results show a high prevalence of RA in LAC women with a ratio of 5.2 women per man...\n"
          ]
        }
      ],
      "source": [
        "# Extract all unique snippets from questions\n",
        "all_snippets = []\n",
        "snippet_id = 0\n",
        "\n",
        "for question in sample_data['questions']:\n",
        "    for snippet in question['snippets']:\n",
        "        snippet_dict = {\n",
        "            'snippet_id': f\"snippet_{snippet_id}\",\n",
        "            'text': snippet['text'],\n",
        "            'document': snippet.get('document', ''),\n",
        "            'question_id': question['id']\n",
        "        }\n",
        "        all_snippets.append(snippet_dict)\n",
        "        snippet_id += 1\n",
        "\n",
        "print(f\"Extracted {len(all_snippets)} snippets for retrieval corpus\")\n",
        "print(f\"\\nExample snippet:\")\n",
        "print(f\"  {all_snippets[0]['text'][:100]}...\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "lL0FURsidfnf",
        "outputId": "21d9d07f-d095-43aa-cd80-1e85047e652e"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Formatted 310 questions\n"
          ]
        }
      ],
      "source": [
        "# Format questions for QA\n",
        "formatted_questions = []\n",
        "\n",
        "for q in sample_data['questions']:\n",
        "    formatted_q = {\n",
        "        'id': q['id'],\n",
        "        'question': q['body'],\n",
        "        'type': q.get('type', 'factoid'),\n",
        "        'ideal_answer': q.get('ideal_answer', ''),\n",
        "        'exact_answer': q.get('exact_answer', []),\n",
        "        'gold_snippets': [s['text'] for s in q.get('snippets', [])]\n",
        "    }\n",
        "    formatted_questions.append(formatted_q)\n",
        "\n",
        "print(f\"Formatted {len(formatted_questions)} questions\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "76wNPLrqdfnf"
      },
      "source": [
        "## 4. Build FAISS Retrieval Index\n",
        "\n",
        "Create dense vector embeddings and build a FAISS index for fast similarity search."
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 418,
          "referenced_widgets": [
            "d6ff0d71a0034c029857815d4abfde22",
            "d755d07a3bb248cda818e65052e52bb8",
            "c5d6401498be4e2bacd00bb771a5f010",
            "12f9c0c9cfe0444b91f3ebd2344121a8",
            "c5b9180c063e4adbaa640f06599e04c3",
            "de29b508a7dc480d9d8b235fb98f13b2",
            "7a201a89917846c1b939457e1f6fb00a",
            "61626b42599f427f8ad2d54b41782734",
            "5442059401504b759542a7b6b0b3f87e",
            "8a85cbec512f4c9fa3268729d85c5287",
            "455e557bbd744bdd90b2457f06978c06",
            "4e74e0979e6d4c58bc9f487ccb3e7ca6",
            "3cd4ccb8b7bf495ea0d7feb89d5e6ae3",
            "6bc4dcb7d78c420d8ab0c8bef6b8b36d",
            "bfc01a3e41fb4015bd7f9419b10a797d",
            "5575ac5b172b4667bf7c08e79776e4b2",
            "3a6b55d0862645a8b016885377b2c0ee",
            "0aa8fb6f2a0743fa840f11bdb1e5332d",
            "0ae7fd9bca404efc8f00339863d8c186",
            "45ce807ba9bd4081b60a2ee2bd29e644",
            "f7d78d50d99b4c1aba88abf12906dcb0",
            "c09510a9082c475ea4e22d93c53593d0",
            "0c34721ffcc1458cbc38bf82ad96af9b",
            "4815d70798d841ea915ef33163de7550",
            "7533b3ef720f4b8a8591d5628ac33a6e",
            "36fde2694aaa4512b1d71a7576b5b2f2",
            "530623b1924044e8bcf19c885a6104fd",
            "091a5cef870a49daba36a128716f707f",
            "676b22d2d0d24d0896179a5c9c1d8abf",
            "c839105fbfdf43ad97fb13f90d829010",
            "c97bd31884c04845a8f3e4e9140df3cb",
            "59aec64d73e941bfbbfdaca581b73bb9",
            "c3d64e8c06d64b33af4134c4355376c2",
            "8b4b4c83c21b4fe5bba06c923ac4cf08",
            "89c43be710404d11835aacd1590f8dc9",
            "7fa64d696a01454bbd23db19f890e975",
            "26fd9161fbbf4a08a14d3b8911ed514b",
            "79346c66a04c4e5599090b8886dbecef",
            "a0b9825417ca4d4f9e43fee63b1e153f",
            "f69c473f1c0d4743927311b021e21e4a",
            "36f36d324e0b4e1b97329dcb9cfa3eb1",
            "6e7c700bcba84ca4ad693d7fff1c12f4",
            "1ed922d793d6413ca021f36dda3b621d",
            "bc7864eef1ee47c6813f0c36194125df",
            "c87f85cad1154a5b93391dfb16de643d",
            "b8d8b5e4f3eb4fbbafa6caec37eb6fcb",
            "66c439fe12d4412eb6b2b170264f68d7",
            "450ed0de6abc451293f8e41c4aa46cf6",
            "8f85a970570d444c99d813591d9b6a2e",
            "0812d6324edb481e8fa0e7bc3c64505b",
            "79a42462349542dcb34460e74bc84bca",
            "3075d3386aea42309a5f186dd8df09b1",
            "938067455f984d55b21b3c7806b70772",
            "6c50fbffeb58411196e18351e5bc96a4",
            "29996aa0a7634c78a34ccf9a483a0c4b",
            "3a06b40411634b1aba41cfe8be4e0062",
            "61a1f62c03c3452db1e9ac7244ccde70",
            "83bb2e8d13614ff5af748ad40718fc5d",
            "842352a62c6a48a988b4801f4c229e77",
            "787cfa65745b4ab2ac65bf91cf1c8337",
            "de2f15ee252b4883b22a31f69aee3abb",
            "d96e4ac9f31646b1b7ef8a038cf5c434",
            "189240616c2a41daa085a9d27e0fb5db",
            "a75f8e7214e2499cbc3b7d8978742cd3",
            "29d55688bb704f6daae829be9e32e87a",
            "3b015c0dea5447a59c80f62a8065d533",
            "e948794adc1b4b5f932021e04d37c2eb",
            "c20df740df7f413c8270d6aae684b018",
            "c133f1f810df4fe7ac862526c04b31ee",
            "d09c51240ce44586aaa27af82a624244",
            "dc3e17fce7a946cdad58df6cec06381e",
            "8d240053902746af9da57a727277e082",
            "8f4549d3d49d47feac5673805ad36508",
            "368713cfa91c48daaf244b536fda278d",
            "179f44b6155c4b31bef93e924db007ae",
            "eb7e555987e54221aa853dab81735a68",
            "f2bc85da32da4c8ca85b30055706a1cf",
            "3855db11a6274023a42436915aff6410",
            "37d2b7c5481445eb9be819b8505a55a9",
            "f5668710bbe2472ca5410a95850193af",
            "e3b10ee06823495aaec7fbbdfc98cba4",
            "54464a9d342346c0a21a1d668f781f05",
            "8ca8c8ea93824ccdb1b822f0ab3eb874",
            "a485bfc6847747819c04b90b30e2cac2",
            "bb8b845904714a8f9e3f29ad70953576",
            "d9eed644488f49e7a90c0a50bba3d312",
            "f25671aab90d4ce0adbd38dbb242a2d9",
            "34e436945ebc452bb4e4605b4e5b0c6a",
            "b2fedf203b9e430fbbc605a32937dc97",
            "b6a3b73896eb47ea80d9000829246ca7",
            "5e90d3bc27ff43ec80a262663af0d523",
            "24d1225c700a42e79387968862f2a2ae",
            "0ff08adecd774a93bf41916a9e755de8",
            "d94a3f4aa6b645fbb510d926e4239843",
            "cc8d264270824cd996bb5d0d4d63a074",
            "e6f39323bbd344dc8355b4cef48bee9f",
            "a7a53555a77c44569ab4de1cc86a01e0",
            "786ad26c50e54e63b82b6441a7d34474",
            "10f0f39230474fabaf9cd53e41d35bd8",
            "8a9d29f55b7c45b89f2209bad5fc924e",
            "2b07ffdd6d1b4c809185497c28c7f73e",
            "13febc0a030d4f4ab655aaf5e77e5d04",
            "a623618fa84b463f81ddb9f8be163744",
            "73a785dbabef4b7985a3c2b4bc156746",
            "20c4f5c155e7463490957a5a1e321ff8",
            "d406381b63a44660bf9d109a453f10df",
            "22c33c05a50a4cbeaa4609b5a2ca8143",
            "038c52c2f9374ea897f1991c852fe603",
            "0cfceaa8979043418fc537b392e67734",
            "7e1d287bd06146b6aa14f9890f0b962b",
            "74b3c94dce264be8a0a4632eea3ca8a5",
            "07958068b7d04109a4fc984530d02024",
            "b8df89847b5c4d3ca3b1998d4bc8ced9",
            "df4a762f76bc49f2bc035f0a181cd46b",
            "f0605306287c448cb325eac9af9df392",
            "d94ddc40c6c0497692b47f34c31a62ba",
            "84daaf1ab6da46da893fe0cd9e17fed4",
            "ad3ce1673b544f2b801afb4ea8b844a8",
            "1076d3378ed94a4f8f68087f0a09b7e6",
            "a057f3e449964951a3933995399b7ca0",
            "1f64284422c046798effef051462ef8a",
            "d8272666fda94e09820c897842dc0964",
            "10c314a05e3f4020820b48680710be92",
            "bb3ec7f8dec54c2e81fb9cb8d69670f6",
            "a1fa50856c7d4c9fab99f587423fa3f5",
            "1ff03b36372d42759950961d74a2aa14",
            "9a92340df23a4a8a94e951085ef1cd40",
            "e175f32f3ec948c8957ca215c69353d6",
            "c10607130af24939865a04c11294a169",
            "9da398406a17462289af7d05bcdfc96a",
            "935fb54735d941ad82b9fc0af4fe6c4f",
            "fedd9330595043b6ae04a9df48d35569"
          ]
        },
        "id": "1fBTluY3dfnf",
        "outputId": "4891ad23-579f-486e-b0e8-86901491ce61"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "modules.json:   0%|          | 0.00/349 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "d6ff0d71a0034c029857815d4abfde22"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config_sentence_transformers.json:   0%|          | 0.00/116 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "4e74e0979e6d4c58bc9f487ccb3e7ca6"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "README.md: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "0c34721ffcc1458cbc38bf82ad96af9b"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "sentence_bert_config.json:   0%|          | 0.00/53.0 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8b4b4c83c21b4fe5bba06c923ac4cf08"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/612 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "c87f85cad1154a5b93391dfb16de643d"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "model.safetensors:   0%|          | 0.00/90.9M [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "3a06b40411634b1aba41cfe8be4e0062"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer_config.json:   0%|          | 0.00/350 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "e948794adc1b4b5f932021e04d37c2eb"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "vocab.txt: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "3855db11a6274023a42436915aff6410"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "tokenizer.json: 0.00B [00:00, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "b2fedf203b9e430fbbc605a32937dc97"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "special_tokens_map.json:   0%|          | 0.00/112 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "8a9d29f55b7c45b89f2209bad5fc924e"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "config.json:   0%|          | 0.00/190 [00:00<?, ?B/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "74b3c94dce264be8a0a4632eea3ca8a5"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Batches:   0%|          | 0/723 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "d8272666fda94e09820c897842dc0964"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Generated embeddings: shape (5781, 384)\n"
          ]
        }
      ],
      "source": [
        "from sentence_transformers import SentenceTransformer\n",
        "import faiss\n",
        "\n",
        "# Load sentence transformer model\n",
        "encoder = SentenceTransformer('sentence-transformers/all-MiniLM-L6-v2')\n",
        "\n",
        "# Extract texts for encoding\n",
        "texts = [doc['text'] for doc in all_snippets]\n",
        "\n",
        "# Generate embeddings\n",
        "embeddings = encoder.encode(\n",
        "    texts,\n",
        "    show_progress_bar=True,\n",
        "    batch_size=8,\n",
        "    convert_to_numpy=True\n",
        ")\n",
        "embeddings = embeddings.astype('float32')\n",
        "\n",
        "print(f\"Generated embeddings: shape {embeddings.shape}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "DDf__6UVdfnf",
        "outputId": "6569c512-8de8-42af-c8d4-12b57ddb2be5"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "FAISS index built with 5781 vectors\n"
          ]
        }
      ],
      "source": [
        "# Build FAISS index\n",
        "# Normalize embeddings for cosine similarity\n",
        "faiss.normalize_L2(embeddings)\n",
        "\n",
        "# Create index (using inner product for cosine similarity)\n",
        "dimension = embeddings.shape[1]\n",
        "index = faiss.IndexFlatIP(dimension)\n",
        "index.add(embeddings)\n",
        "\n",
        "print(f\"FAISS index built with {index.ntotal} vectors\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "vK1iMzICdfnf",
        "outputId": "00f2fa78-edc6-4b3e-bcf3-37d073a5b01f"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "Query: 'What is programmed cell death?'\n",
            "\n",
            "Top result (score: 0.5338):\n",
            "  Programmed cell death 4 (PDCD4) is a tumor suppressor gene whose expression is controlled by miR-21....\n"
          ]
        }
      ],
      "source": [
        "# Test retrieval function\n",
        "def retrieve_documents(query: str, top_k: int = 3) -> List[Tuple[Dict, float]]:\n",
        "    \"\"\"Retrieve top-k most relevant documents for a query.\"\"\"\n",
        "    # Encode query\n",
        "    query_embedding = encoder.encode([query], convert_to_numpy=True).astype('float32')\n",
        "    faiss.normalize_L2(query_embedding)\n",
        "\n",
        "    # Search\n",
        "    scores, indices = index.search(query_embedding, top_k)\n",
        "\n",
        "    # Format results\n",
        "    results = []\n",
        "    for idx, score in zip(indices[0], scores[0]):\n",
        "        if idx < len(all_snippets):\n",
        "            results.append((all_snippets[idx], float(score)))\n",
        "\n",
        "    return results\n",
        "\n",
        "# Test retrieval\n",
        "test_query = \"What is programmed cell death?\"\n",
        "test_results = retrieve_documents(test_query, top_k=2)\n",
        "\n",
        "print(f\"\\nQuery: '{test_query}'\")\n",
        "print(f\"\\nTop result (score: {test_results[0][1]:.4f}):\")\n",
        "print(f\"  {test_results[0][0]['text'][:100]}...\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "LD0enoq2dfng"
      },
      "source": [
        "## 5. Baseline RAG Implementation\n",
        "\n",
        "Standard RAG: Retrieve → Generate"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "aYLarLN4dfng"
      },
      "outputs": [],
      "source": [
        "# Define baseline RAG model\n",
        "from openai import OpenAI\n",
        "\n",
        "# Initialize OpenAI client\n",
        "client = OpenAI(api_key=OPENAI_API_KEY)\n",
        "\n",
        "def baseline_rag(question: str, top_k: int = 3) -> Dict[str, Any]:\n",
        "    \"\"\"Standard RAG: Retrieve relevant docs and generate answer.\"\"\"\n",
        "\n",
        "    # Step 1: Retrieve documents\n",
        "    retrieved = retrieve_documents(question, top_k=top_k)\n",
        "\n",
        "    # Step 2: Format context\n",
        "    context_parts = []\n",
        "    for i, (doc, score) in enumerate(retrieved, 1):\n",
        "        context_parts.append(f\"[Document {i}]\\n{doc['text']}\")\n",
        "    context = \"\\n\\n\".join(context_parts)\n",
        "\n",
        "    # Step 3: Create prompt\n",
        "    prompt = f\"\"\"You are a biomedical expert answering questions based on scientific literature.\n",
        "\n",
        "Context from PubMed articles:\n",
        "{context}\n",
        "\n",
        "Question: {question}\n",
        "\n",
        "Instructions:\n",
        "1. Answer the question based ONLY on the information in the provided context\n",
        "2. Be precise and concise\n",
        "3. If the context doesn't contain enough information, state that clearly\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "    # Step 4: Generate answer\n",
        "    response = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=[\n",
        "            {\"role\": \"system\", \"content\": \"You are a biomedical expert providing accurate, evidence-based answers.\"},\n",
        "            {\"role\": \"user\", \"content\": prompt}\n",
        "        ],\n",
        "        max_tokens=300,\n",
        "        temperature=0.1\n",
        "    )\n",
        "\n",
        "    answer = response.choices[0].message.content.strip()\n",
        "\n",
        "    return {\n",
        "        'question': question,\n",
        "        'answer': answer,\n",
        "        'retrieved_documents': [(doc['text'], score) for doc, score in retrieved],\n",
        "        'num_retrieved': len(retrieved),\n",
        "        'tokens_used': response.usage.total_tokens\n",
        "    }\n"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "Xlekr97wdfng"
      },
      "source": [
        "### Test Baseline RAG"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "mkluh2K0dfng",
        "outputId": "317e13b8-1d35-46cc-9142-8a2a59ae1e90"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Question: Is Rheumatoid Arthritis more common in men or women?\n",
            "\n",
            "Answer: Rheumatoid Arthritis is more commonly seen in women.\n",
            "\n",
            "Retrieved 3 documents\n",
            "Tokens used: 188\n"
          ]
        }
      ],
      "source": [
        "# Test baseline RAG on one question\n",
        "test_question = formatted_questions[0]['question']\n",
        "\n",
        "print(f\"Question: {test_question}\\n\")\n",
        "\n",
        "baseline_result = baseline_rag(test_question)\n",
        "\n",
        "print(f\"Answer: {baseline_result['answer']}\\n\")\n",
        "print(f\"Retrieved {baseline_result['num_retrieved']} documents\")\n",
        "print(f\"Tokens used: {baseline_result['tokens_used']}\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "wM4L7a2kdfng"
      },
      "source": [
        "## 6. Self-RAG Implementation\n",
        "\n",
        "Self-RAG: Retrieve → Generate → **Reflect** → **Revise**"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "gYx4LXOVdfng"
      },
      "outputs": [],
      "source": [
        "# Define Self-RAG function\n",
        "def self_rag(question: str, top_k: int = 3) -> Dict[str, Any]:\n",
        "    \"\"\"Self-RAG: Retrieve, Generate, Reflect, and Revise.\"\"\"\n",
        "\n",
        "    # Step 1 & 2: Retrieve and format context (same as baseline)\n",
        "    retrieved = retrieve_documents(question, top_k=top_k)\n",
        "    context_parts = []\n",
        "    for i, (doc, score) in enumerate(retrieved, 1):\n",
        "        context_parts.append(f\"[Document {i}]\\n{doc['text']}\")\n",
        "    context = \"\\n\\n\".join(context_parts)\n",
        "\n",
        "    # Step 3: Generate initial answer (same as baseline)\n",
        "    initial_prompt = f\"\"\"You are a biomedical expert answering questions based on scientific literature.\n",
        "\n",
        "Context from PubMed articles:\n",
        "{context}\n",
        "\n",
        "Question: {question}\n",
        "\n",
        "Instructions:\n",
        "1. Answer the question based ONLY on the information in the provided context\n",
        "2. Be precise and concise\n",
        "\n",
        "Answer:\"\"\"\n",
        "\n",
        "    initial_response = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=[\n",
        "            {\"role\": \"system\", \"content\": \"You are a biomedical expert providing accurate answers.\"},\n",
        "            {\"role\": \"user\", \"content\": initial_prompt}\n",
        "        ],\n",
        "        max_tokens=300,\n",
        "        temperature=0.1\n",
        "    )\n",
        "\n",
        "    initial_answer = initial_response.choices[0].message.content.strip()\n",
        "\n",
        "    # Step 4: REFLECT - Critique the initial answer\n",
        "    reflection_prompt = f\"\"\"You are a scientific fact-checker evaluating an answer to a biomedical question.\n",
        "\n",
        "Question: {question}\n",
        "\n",
        "Initial Answer:\n",
        "{initial_answer}\n",
        "\n",
        "Evidence from PubMed articles:\n",
        "{context}\n",
        "\n",
        "Task: Critically evaluate the initial answer by checking:\n",
        "1. FACTUAL ACCURACY: Is every claim supported by the evidence?\n",
        "2. COMPLETENESS: Does it address all parts of the question?\n",
        "3. GROUNDING: Does it reference specific evidence?\n",
        "4. HALLUCINATIONS: Does it include unsupported claims?\n",
        "\n",
        "Provide a brief critique focusing on strengths and weaknesses:\n",
        "\n",
        "Critique:\"\"\"\n",
        "\n",
        "    reflection_response = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=[\n",
        "            {\"role\": \"system\", \"content\": \"You are a rigorous scientific fact-checker.\"},\n",
        "            {\"role\": \"user\", \"content\": reflection_prompt}\n",
        "        ],\n",
        "        max_tokens=300,\n",
        "        temperature=0.1\n",
        "    )\n",
        "\n",
        "    critique = reflection_response.choices[0].message.content.strip()\n",
        "\n",
        "    # Step 5: REVISE - Improve based on critique\n",
        "    revision_prompt = f\"\"\"You are a biomedical expert revising an answer based on critical feedback.\n",
        "\n",
        "Question: {question}\n",
        "\n",
        "Initial Answer:\n",
        "{initial_answer}\n",
        "\n",
        "Critical Feedback:\n",
        "{critique}\n",
        "\n",
        "Evidence from PubMed articles:\n",
        "{context}\n",
        "\n",
        "Task: Revise the initial answer to address the weaknesses identified in the feedback.\n",
        "\n",
        "Requirements:\n",
        "1. Fix any factual errors\n",
        "2. Add missing information from the evidence\n",
        "3. Remove or qualify unsupported claims\n",
        "4. Keep the answer concise and precise\n",
        "\n",
        "Revised Answer:\"\"\"\n",
        "\n",
        "    revision_response = client.chat.completions.create(\n",
        "        model=\"gpt-3.5-turbo\",\n",
        "        messages=[\n",
        "            {\"role\": \"system\", \"content\": \"You are a biomedical expert providing accurate answers.\"},\n",
        "            {\"role\": \"user\", \"content\": revision_prompt}\n",
        "        ],\n",
        "        max_tokens=300,\n",
        "        temperature=0.1\n",
        "    )\n",
        "\n",
        "    revised_answer = revision_response.choices[0].message.content.strip()\n",
        "\n",
        "    # Calculate total tokens\n",
        "    total_tokens = (\n",
        "        initial_response.usage.total_tokens +\n",
        "        reflection_response.usage.total_tokens +\n",
        "        revision_response.usage.total_tokens\n",
        "    )\n",
        "\n",
        "    return {\n",
        "        'question': question,\n",
        "        'initial_answer': initial_answer,\n",
        "        'critique': critique,\n",
        "        'revised_answer': revised_answer,\n",
        "        'final_answer': revised_answer,  # Final answer is the revised one\n",
        "        'retrieved_documents': [(doc['text'], score) for doc, score in retrieved],\n",
        "        'num_retrieved': len(retrieved),\n",
        "        'tokens_used': total_tokens\n",
        "    }"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "u6x-3a0jdfng"
      },
      "source": [
        "### Test Self-RAG"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "ymwEr54Vdfng",
        "outputId": "5c54d209-7d28-4a79-b8f2-95770533bccd"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Testing Self-RAG...\n",
            "\n",
            "Question: Is Rheumatoid Arthritis more common in men or women?\n",
            "\n",
            "Initial Answer:\n",
            "Rheumatoid Arthritis is more commonly seen in women.\n",
            "\n",
            "\n",
            "================================================================================\n",
            "\n",
            "Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that Rheumatoid Arthritis is more commonly seen in women, which is supported by the evidence provided from PubMed articles.\n",
            "2. The answer references specific evidence from multiple documents to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more explicit in stating that Rheumatoid Arthritis is more common in women compared to men. While the evidence provided clearly supports this claim, explicitly stating the comparison would enhance clarity.\n",
            "2. The answer could benefit from including a broader range of evidence to strengthen the argument further. While the evidence provided supports the claim, additional studies or data could provide a more comprehensive understanding of the prevalence of Rheumatoid Arthritis in men versus women.\n",
            "3. The answer does not explicitly address the potential reasons behind the gender disparity in Rheumatoid Arthritis prevalence. Including information on potential contributing factors could enhance the completeness of the response.\n",
            "\n",
            "Overall, the initial answer is generally accurate and grounded in specific evidence from PubMed articles. However, it could be improved by explicitly comparing the prevalence in men and women, including a broader range of evidence, and addressing potential contributing factors to the gender disparity in Rheumatoid Arthritis.\n",
            "\n",
            "\n",
            "================================================================================\n",
            "\n",
            "Revised Answer:\n",
            "Rheumatoid Arthritis is more commonly seen in women compared to men, as evidenced by studies showing a higher prevalence and more aggressive disease in women. For example, a study involving 244 female and 91 male patients with rheumatoid arthritis demonstrated this gender difference. Additionally, research indicates that disease patterns in RA vary between sexes, with women exhibiting a poorer long-term outcome. Factors such as BMI have also been associated with RA disease activity in women but not in men. Further investigation into the reasons behind this gender disparity could provide a more comprehensive understanding of the prevalence of Rheumatoid Arthritis.\n",
            "\n"
          ]
        }
      ],
      "source": [
        "# Test Self-RAG on the same question\n",
        "print(f\"Testing Self-RAG...\\n\")\n",
        "print(f\"Question: {test_question}\\n\")\n",
        "\n",
        "selfrag_result = self_rag(test_question)\n",
        "\n",
        "print(f\"Initial Answer:\\n{selfrag_result['initial_answer']}\\n\")\n",
        "print(f\"\\n{'='*80}\\n\")\n",
        "print(f\"Critique:\\n{selfrag_result['critique']}\\n\")\n",
        "print(f\"\\n{'='*80}\\n\")\n",
        "print(f\"Revised Answer:\\n{selfrag_result['revised_answer']}\\n\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "okV0wCz-dfnh"
      },
      "source": [
        "## 7. Run Full Experiments\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 118,
          "referenced_widgets": [
            "91959786c0084ecbb3d62a7cb2a57228",
            "a0acf0cb11f144788e94592d989987e5",
            "1f15e93774e4406c8db889cc98961ec4",
            "f90b51a698474e848ea82b9b38ccb3a9",
            "8ed32e0482c94176ba53ed7b038af481",
            "f73cebc52818445e9d8d0542257f9590",
            "d2f21d8c93884d1481de26e7efdf3611",
            "865c1eac162f40868e66d827a609ba5f",
            "db7c2d3a4e994896a69622b8242c0336",
            "d490293583a84ed28083f65ba887fe33",
            "73bc625713ca4712b74f700f5f5b9ffc"
          ]
        },
        "id": "1gjlmhemdfnh",
        "outputId": "12565d75-495f-443a-bf63-8dd2846afc32"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Running Baseline RAG on all questions...\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Baseline RAG:   0%|          | 0/310 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "91959786c0084ecbb3d62a7cb2a57228"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            " Baseline RAG completed: 310 questions\n"
          ]
        }
      ],
      "source": [
        "# Run baseline RAG on all questions\n",
        "print(\"Running Baseline RAG on all questions...\\n\")\n",
        "baseline_results = []\n",
        "\n",
        "for q in tqdm(formatted_questions, desc=\"Baseline RAG\"):\n",
        "    result = baseline_rag(q['question'])\n",
        "    result['question_id'] = q['id']\n",
        "    result['gold_answer'] = q['ideal_answer']\n",
        "    result['gold_snippets'] = q['gold_snippets']\n",
        "    baseline_results.append(result)\n",
        "\n",
        "print(f\"\\n Baseline RAG completed: {len(baseline_results)} questions\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 118,
          "referenced_widgets": [
            "1b36e3a881204cefb852f6b304e9af90",
            "224b399b2dc34b00ba2d40a0569783e0",
            "39cee23a70ed4874b826c69060b8a9a4",
            "b1be59dffe3a4250b09e6e76249664f9",
            "26b38568872f4051a2f103c1250cc29f",
            "0446068a527c4f00a95f87158fe82b42",
            "c22450a74590473fa49d83ec23961faf",
            "7bd1696d6c38464b9a5ad7288a8d201a",
            "37d1a39471de484d9e33f806a50dd685",
            "c9dc0b7298774e0b9123620c71b36f05",
            "f55e04102b114c73be6079954cb53267"
          ]
        },
        "id": "ASWLlRU4dfnh",
        "outputId": "83958104-cd17-48c1-f4bb-0c26559fe552"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "Running Self-RAG on all questions...\n",
            "\n"
          ]
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "Self-RAG:   0%|          | 0/310 [00:00<?, ?it/s]"
            ],
            "application/vnd.jupyter.widget-view+json": {
              "version_major": 2,
              "version_minor": 0,
              "model_id": "1b36e3a881204cefb852f6b304e9af90"
            }
          },
          "metadata": {}
        },
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            " Self-RAG completed: 310 questions\n"
          ]
        }
      ],
      "source": [
        "# Run Self-RAG on all questions\n",
        "print(\"Running Self-RAG on all questions...\\n\")\n",
        "selfrag_results = []\n",
        "\n",
        "for q in tqdm(formatted_questions, desc=\"Self-RAG\"):\n",
        "    result = self_rag(q['question'])\n",
        "    result['question_id'] = q['id']\n",
        "    result['gold_answer'] = q['ideal_answer']\n",
        "    result['gold_snippets'] = q['gold_snippets']\n",
        "    selfrag_results.append(result)\n",
        "\n",
        "print(f\"\\n Self-RAG completed: {len(selfrag_results)} questions\")"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "YxT4f5scdfnh"
      },
      "source": [
        "## 8. Evaluation & Comparison\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "id": "y8lmx352dfnh"
      },
      "outputs": [],
      "source": [
        "from rouge_score import rouge_scorer\n",
        "\n",
        "# Initialize ROUGE scorer\n",
        "scorer = rouge_scorer.RougeScorer(['rouge1', 'rouge2', 'rougeL'], use_stemmer=True)\n",
        "\n",
        "def evaluate_results(results, system_name):\n",
        "    \"\"\"Evaluate a set of results.\"\"\"\n",
        "    rouge1_scores = []\n",
        "    rouge2_scores = []\n",
        "    rougeL_scores = []\n",
        "    exact_matches = []\n",
        "    partial_matches = []\n",
        "\n",
        "    for result in results:\n",
        "        gold = result['gold_answer']\n",
        "        pred = result.get('final_answer', result.get('answer', ''))\n",
        "\n",
        "        if not gold or not pred:\n",
        "            continue\n",
        "\n",
        "        # ROUGE scores\n",
        "        scores = scorer.score(gold, pred)\n",
        "        rouge1_scores.append(scores['rouge1'].fmeasure)\n",
        "        rouge2_scores.append(scores['rouge2'].fmeasure)\n",
        "        rougeL_scores.append(scores['rougeL'].fmeasure)\n",
        "\n",
        "        # Exact match\n",
        "        exact_match = 1.0 if pred.lower().strip() == gold.lower().strip() else 0.0\n",
        "        exact_matches.append(exact_match)\n",
        "\n",
        "        # Partial match\n",
        "        partial_match = 1.0 if gold.lower().strip() in pred.lower().strip() else 0.0\n",
        "        partial_matches.append(partial_match)\n",
        "\n",
        "    metrics = {\n",
        "        'system': system_name,\n",
        "        'num_questions': len(results),\n",
        "        'exact_match': np.mean(exact_matches) if exact_matches else 0.0,\n",
        "        'partial_match': np.mean(partial_matches) if partial_matches else 0.0,\n",
        "        'rouge1': np.mean(rouge1_scores) if rouge1_scores else 0.0,\n",
        "        'rouge2': np.mean(rouge2_scores) if rouge2_scores else 0.0,\n",
        "        'rougeL': np.mean(rougeL_scores) if rougeL_scores else 0.0,\n",
        "    }\n",
        "\n",
        "    return metrics\n"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "-0336QAkdfnh",
        "outputId": "571cb68c-a191-4273-826c-d67c8ef6b231"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "================================================================================\n",
            "EVALUATION RESULTS\n",
            "================================================================================\n",
            "\n",
            "Baseline RAG:\n",
            "  Questions evaluated: 310\n",
            "  Exact Match: 0.0000\n",
            "  Partial Match: 0.0258\n",
            "  ROUGE-1 F1: 0.3391\n",
            "  ROUGE-2 F1: 0.1595\n",
            "  ROUGE-L F1: 0.2662\n",
            "\n",
            "Self-RAG:\n",
            "  Questions evaluated: 310\n",
            "  Exact Match: 0.0000\n",
            "  Partial Match: 0.0194\n",
            "  ROUGE-1 F1: 0.2861\n",
            "  ROUGE-2 F1: 0.1060\n",
            "  ROUGE-L F1: 0.1948\n"
          ]
        }
      ],
      "source": [
        "# Evaluate both systems\n",
        "baseline_metrics = evaluate_results(baseline_results, \"Baseline RAG\")\n",
        "selfrag_metrics = evaluate_results(selfrag_results, \"Self-RAG\")\n",
        "\n",
        "print(\"\\n\" + \"=\"*80)\n",
        "print(\"EVALUATION RESULTS\")\n",
        "print(\"=\"*80)\n",
        "\n",
        "print(\"\\nBaseline RAG:\")\n",
        "print(f\"  Questions evaluated: {baseline_metrics['num_questions']}\")\n",
        "print(f\"  Exact Match: {baseline_metrics['exact_match']:.4f}\")\n",
        "print(f\"  Partial Match: {baseline_metrics['partial_match']:.4f}\")\n",
        "print(f\"  ROUGE-1 F1: {baseline_metrics['rouge1']:.4f}\")\n",
        "print(f\"  ROUGE-2 F1: {baseline_metrics['rouge2']:.4f}\")\n",
        "print(f\"  ROUGE-L F1: {baseline_metrics['rougeL']:.4f}\")\n",
        "\n",
        "print(\"\\nSelf-RAG:\")\n",
        "print(f\"  Questions evaluated: {selfrag_metrics['num_questions']}\")\n",
        "print(f\"  Exact Match: {selfrag_metrics['exact_match']:.4f}\")\n",
        "print(f\"  Partial Match: {selfrag_metrics['partial_match']:.4f}\")\n",
        "print(f\"  ROUGE-1 F1: {selfrag_metrics['rouge1']:.4f}\")\n",
        "print(f\"  ROUGE-2 F1: {selfrag_metrics['rouge2']:.4f}\")\n",
        "print(f\"  ROUGE-L F1: {selfrag_metrics['rougeL']:.4f}\")"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "3NWodsOSdfnh",
        "outputId": "2513ed2e-c223-4638-c82b-fd05e3801851"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "================================================================================\n",
            "RELATIVE IMPROVEMENT (Self-RAG vs Baseline)\n",
            "================================================================================\n",
            "\n",
            "  exact_match         : +  0.00%\n",
            "  partial_match       : -25.00%\n",
            "  rouge1              : -15.62%\n",
            "  rouge2              : -33.56%\n",
            "  rougeL              : -26.81%\n",
            "\n",
            "================================================================================\n"
          ]
        }
      ],
      "source": [
        "# Calculate improvements\n",
        "print(\"\\n\" + \"=\"*80)\n",
        "print(\"RELATIVE IMPROVEMENT (Self-RAG vs Baseline)\")\n",
        "print(\"=\"*80 + \"\\n\")\n",
        "\n",
        "metrics_to_compare = ['exact_match', 'partial_match', 'rouge1', 'rouge2', 'rougeL']\n",
        "\n",
        "for metric in metrics_to_compare:\n",
        "    baseline_val = baseline_metrics[metric]\n",
        "    selfrag_val = selfrag_metrics[metric]\n",
        "\n",
        "    if baseline_val > 0:\n",
        "        improvement = ((selfrag_val - baseline_val) / baseline_val) * 100\n",
        "    else:\n",
        "        improvement = 0.0\n",
        "\n",
        "    sign = \"+\" if improvement >= 0 else \"\"\n",
        "    print(f\"  {metric:20s}: {sign}{improvement:6.2f}%\")\n",
        "\n",
        "print(\"\\n\" + \"=\"*80)"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "uLulAvG9dfnh"
      },
      "source": [
        "## 9. Detailed Example Comparison"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "5kWb3dMSdfnh",
        "outputId": "6b0c642b-184f-40a4-8a67-202a81fda1bf"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\u001b[1;30;43mStreaming output truncated to the last 5000 lines.\u001b[0m\n",
            "\n",
            "📝 Question: Which anticancer drugs target human topoisomerase II?\n",
            "\n",
            "🎯 Gold Answer: Etoposide (VP-16) and Teniposide (VM-26) are effective as an anti-tumour drug by inhibiting eukaryotic DNA topoisomerase II via establishing a covalent complex with DNA. Doxorubicin, Daunorubicin and Aclarubicin are anthracyclins that act as DNA topoisomerase II inhibitors and may be used in combination. Benzoxazoles, benzimidazoles and related fused heterocyclic compounds, which exhibited significant eukaryotic DNA topoisomerase II inhibitory activity. F14512 is a polyamine-containing epipodophyllotoxin derivative that acts as an inhibitor of DNA topoisomerase II. Bisdioxopiperazine drugs such as ICRF-187 are catalytic inhibitors of DNA topoisomerase II. \n",
            "Among topoisomerase II inhibitors, the cytostatic potency was by decreasing order: mitoxantrone; doxorubicin, which was slightly greater than DuP 941, azatoxin; DuP 937; and amsacrine, which was much greater than VP-16\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Etoposide (VP-16) and teniposide (VM-26) are anticancer drugs that target human topoisomerase II.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Etoposide (VP-16) and teniposide (VM-26) are anticancer drugs that target human topoisomerase II.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies etoposide (VP-16) and teniposide (VM-26) as anticancer drugs that target human topoisomerase II.\n",
            "2. The evidence from PubMed articles supports the claim that these drugs target topoisomerase II.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it only mentions etoposide and teniposide. There are other anticancer drugs that also target human topoisomerase II, such as doxorubicin and daunorubicin, which are not mentioned.\n",
            "2. The grounding could be improved by referencing specific details from the PubMed articles, such as the mechanisms by which etoposide and teniposide target topoisomerase II.\n",
            "3. There are no hallucinations or unsupported claims in the initial answer.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and could benefit from more specific references to the evidence provided.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Etoposide (VP-16), teniposide (VM-26), doxorubicin, and daunorubicin are anticancer drugs that target human topoisomerase II. These drugs have been shown to interact with topoisomerase II, as supported by evidence from PubMed articles. Further details on the specific mechanisms by which these drugs target topoisomerase II can be found in the literature.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1739\n",
            "   Self-RAG: 0.2159\n",
            "   Improvement: +24.15% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 172\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the synonyms of prostate-specific antigen?\n",
            "\n",
            "🎯 Gold Answer: Prostate-specific antigen (PSA) is a 33 kDa single chain glycoprotein belonging to the kallikrein family of serine proteases which is produced by epithelial cells of both normal and malignant prostate tissue. PSA is an important marker for the diagnosis of prostate cancer. PSA is also known as human kallikrein-related peptidase 3 (hK3).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The synonyms of prostate-specific antigen are human kallikrein-related peptidase 3 (hK3).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "hK3\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies \"hK3\" as a synonym for prostate-specific antigen (PSA) based on the evidence provided in the PubMed articles.\n",
            "2. The answer is grounded in specific evidence from multiple sources, supporting the claim that hK3 is indeed another name for PSA.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more explicit in stating that \"hK3\" is a synonym for PSA, as it might not be immediately clear to all readers.\n",
            "2. The answer could benefit from providing a more direct link between the evidence and the conclusion, explicitly stating that the evidence supports the synonym relationship between hK3 and PSA.\n",
            "3. The answer does not explicitly address the question of \"which are the synonyms of prostate-specific antigen,\" as it only provides one synonym (hK3). It could be more complete by mentioning other known synonyms, if applicable.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in evidence, but it could be improved by being more explicit, complete, and directly addressing all parts of the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Prostate-specific antigen (PSA) is also known as human kallikrein-related peptidase 3 (hK3). This synonym relationship is supported by evidence from PubMed articles, which confirm the interchangeability of the terms. Additional synonyms for PSA may include other terms used in scientific literature, such as kallikrein-related peptidase 3.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2687\n",
            "   Self-RAG: 0.3048\n",
            "   Improvement: +13.44% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 173\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the treatment of interferon-induced thyroiditis?\n",
            "\n",
            "🎯 Gold Answer: An altered thyroid function is frequently observed during interferon treatment with a pattern similar to Hashimoto Thyroiditis or Graves disease.\n",
            "Very frequently the alterations of thyroid hormones related to interferon-induced thyroiditis spontaneosly diseapper in  a few months\n",
            "Treatment when necessary is propanolol and  antithyroid drugs for the Graves like form and thyroxine for chronic hypothyroidism indiced by interferon\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The treatment of interferon-induced thyroiditis can consist of a high dose of anti-thyroid drugs and steroids, either in isolation or in combination. Additionally, propranolol may be prescribed for symptom management. Long-term outcomes of interferon-induced thyroiditis are generally benign with no long-term risk of hypothyroidism.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The treatment of interferon-induced thyroiditis may include propranolol for symptom management, high doses of anti-thyroid drugs, and steroids either alone or in combination. Long-term outcomes suggest a benign course with no increased risk of hypothyroidism.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer accurately mentions propranolol, anti-thyroid drugs, and steroids as potential treatments for interferon-induced thyroiditis, which is supported by the evidence provided.\n",
            "2. The answer acknowledges the benign long-term outcomes of interferon-induced thyroiditis, including the absence of an increased risk of hypothyroidism.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specific references to the evidence provided from PubMed articles. It would strengthen the response to directly cite the relevant studies.\n",
            "2. The answer could benefit from more detailed information on dosages, duration of treatment, and potential side effects associated with each treatment option.\n",
            "3. The claim that there is no increased risk of hypothyroidism in the long term is not directly supported by the evidence provided. While one document mentions benign outcomes, it does not explicitly state the absence of hypothyroidism risk.\n",
            "4. The answer does not address other potential treatment options or considerations for interferon-induced thyroiditis, such as monitoring thyroid function or the role of endocrinology consultation.\n",
            "\n",
            "Overall, the initial answer provides a general overview of treatment options for interferon-induced thyroiditis but could be improved by directly referencing the specific evidence provided and offering a more comprehensive discussion of treatment strategies and outcomes.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The treatment of interferon-induced thyroiditis may involve propranolol for symptom management, high doses of anti-thyroid drugs, and steroids either alone or in combination. Specific dosages and duration of treatment should be determined based on individual patient factors and response to therapy. Evidence suggests a generally benign long-term outcome with a low risk of hypothyroidism, although ongoing monitoring of thyroid function is recommended. Consultation with an endocrinologist may be beneficial for comprehensive management. (References: Document 1, Document 2, Document 3)\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1852\n",
            "   Self-RAG: 0.1277\n",
            "   Improvement: -31.06% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 174\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are viruses involved in the etiology of human subacute thyroiditis?\n",
            "\n",
            "🎯 Gold Answer: Subacute thyroiditis (SAT) is an inflammatory disorder of the thyroid caused probably by viruses\n",
            "The principal classes of viruses involed  in SAT include Epstein Barr and Retroviridae\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, viruses are involved in the etiology of human subacute thyroiditis, with examples including Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus. Influenza immunization or infection may also cause subacute thyroiditis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, viruses are involved in the etiology of human subacute thyroiditis.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that viruses are involved in the etiology of human subacute thyroiditis.\n",
            "2. The answer is supported by evidence from multiple PubMed articles, which strengthens its credibility.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of which viruses are specifically implicated in causing subacute thyroiditis. While it mentions Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus, it could benefit from more detailed information on the role of each virus.\n",
            "2. The answer could be improved by providing a more comprehensive overview of the role of viruses in subacute thyroiditis, including potential mechanisms of viral involvement.\n",
            "3. The answer does not address the potential role of other factors besides viruses in the etiology of subacute thyroiditis, which could provide a more well-rounded perspective on the condition.\n",
            "\n",
            "Overall, the initial answer is generally accurate but could be enhanced by providing more specific details and considering a broader range of factors influencing subacute thyroiditis.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Viruses such as Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus have been implicated in the etiology of human subacute thyroiditis. In addition, factors like influenza immunization or infection may also contribute to the development of subacute thyroiditis. The inflammatory disorder of subacute thyroiditis is likely triggered by these viral infections, leading to thyroid inflammation and associated symptoms. Further research is needed to fully understand the mechanisms by which these viruses induce thyroid inflammation in subacute thyroiditis.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2456\n",
            "   Self-RAG: 0.1942\n",
            "   Improvement: -20.94% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 175\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which enzyme is deficient in Krabbe disease?\n",
            "\n",
            "🎯 Gold Answer: galactocerebrosidase\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The enzyme deficient in Krabbe disease is galactocerebrosidase (GALC).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Galactocerebrosidase (GALC)\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the enzyme deficient in Krabbe disease as galactocerebrosidase (GALC), which is supported by evidence from Document 1 and Document 3.\n",
            "2. The answer provides specific references to PubMed articles to support the claim, demonstrating grounding in scientific literature.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not address the information from Document 2, which mentions deficient activity of the lysosomal hydrolase galactosylceramide beta-galactosidase in Krabbe disease. This omission affects the completeness of the answer.\n",
            "2. The answer could benefit from explicitly stating that while galactocerebrosidase deficiency is the primary enzymatic defect in Krabbe disease, other lysosomal enzymes like galactosylceramide beta-galactosidase may also be involved in the pathogenesis, as suggested by Document 2.\n",
            "3. There are no unsupported claims or hallucinations in the initial answer.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-grounded in scientific evidence but lacks completeness by not addressing all aspects of the question and considering additional enzymes involved in Krabbe disease pathogenesis.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "In Krabbe disease, the primary enzymatic defect involves a deficiency of galactocerebrosidase (GALC), leading to the accumulation of psychosine. Additionally, deficient activity of the lysosomal hydrolase galactosylceramide beta-galactosidase has been implicated in the pathogenesis of Krabbe disease. While GALC deficiency is the main enzyme affected, the involvement of other lysosomal enzymes like galactosylceramide beta-galactosidase should also be considered in the disease mechanism.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2000\n",
            "   Self-RAG: 0.0308\n",
            "   Improvement: -84.62% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 176\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Can PLN mutations lead to dilated cardiomyopathy?\n",
            "\n",
            "🎯 Gold Answer: Yes, PLN mutations can lead to dilated cardiomyopathy.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, PLN mutations can lead to dilated cardiomyopathy based on the information provided in the context from PubMed articles.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, PLN mutations can lead to dilated cardiomyopathy.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer correctly states that PLN mutations can lead to dilated cardiomyopathy, which is supported by the evidence provided from PubMed articles.\n",
            "2. Grounding: The answer references specific evidence from multiple PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: The initial answer could be more comprehensive by discussing the variability in the severity of dilated cardiomyopathy associated with PLN mutations, as mentioned in Document 1.\n",
            "2. Hallucinations: The initial answer does not include any unsupported claims.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence. However, it could be improved by providing a more comprehensive overview of the relationship between PLN mutations and dilated cardiomyopathy, including the variability in disease severity.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Yes, PLN mutations can lead to dilated cardiomyopathy. The severity of dilated cardiomyopathy associated with PLN mutations can vary, with cases ranging from mild to severe forms. Evidence suggests that identical PLN mutations can result in different disease severities. Additionally, mutations in the PLN gene have been linked to both late-onset and idiopathic dilated cardiomyopathy. This variability underscores the importance of considering PLN mutations in the evaluation of dilated cardiomyopathy cases.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5926\n",
            "   Self-RAG: 0.1951\n",
            "   Improvement: -67.07% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 177\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Give examples of next-generation sequencing applications in mutation screening?\n",
            "\n",
            "🎯 Gold Answer: Next generation sequencing data for a particular genomic region can be seen as the summation of all the individual sequences (reads) obtained for that region and no longer as the mean of this sum as it is the case for traditional Sanger sequencing. NGS is introduced to an increasing number of mutation screening applications. An NGS based mutation screening procedure allowing the detection of inherited Alu insertions within any predefined sequence was used for the case of c.1739_1740insAlu in BRCA1 and c.156_157insAlu in BRCA2. Another NGS study screened BRCA1 and BRCA2 resulting in  overall sensitivity for SOLiD and PGM of 97.8% (95% CI = 94.7 to 100.0) and 98.9% (95% CI = 96.8 to 100.0) respectively. The specificity for the SOLiD platform was high, at 100.0% (95% CI = 99.3 to 100.0). PGM correctly identified all 3 indels, but 68 false-positive indels were also called. Genes known to cause deafness were sequenced by the Illumina NGS platform. Results demonstrated that targeted exons captured by our approach achieved specificity, multiplexicity, uniformity, and depth of coverage suitable for accurate sequencing applications by the NGS systems. Reliable genotype calls for various homozygous and heterozygous mutations were achieved. In the context of von Willebrand disease 43 mutations, including 36 substitutions, 2 intronic splice site mutations, 2 indels, and 3 deletions were screened on the next-generation sequencing instrument. This demonstrated that at least 350 patients and relatives per run can be simultaneously analyzed in a fast, inexpensive manner. The Alport syndrome is caused by mutations in three key genes namely COL4A3, COL4A4 and COL4A5, each of which consists of approximately 50 exons, thus rendering mutations screening a highly time consuming and expensive endeavor. NGS is now being established for the simultaneous, fast and cost-effective detection of all possible variants in these three genes. NGS has also been used screening EGFR, KRAS and BRAF for mutations associated with cancer diagnosis and/or response to several anticancer therapies. NGS has also been used in mutation screening for hereditary spastic paraplegias, X linked leucoencephalopathy, retinitis pigmentosa,  inherited urea cycle disorders, as well as the Marfan (MFS), Loeys-Dietz (LDS) and Meckel syndromes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Examples of next-generation sequencing applications in mutation screening include using multiplex PCR followed by NGS for cost-effective and reliable mutation discovery, analyzing at least 350 patients and relatives per run in a fast and inexpensive manner, and designing NGS protocols enabling simultaneous detection of all possible variants in specific genes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Next-generation sequencing applications in mutation screening include tailored mutation discovery strategies using multiplex PCR followed by NGS, simultaneous analysis of multiple patients and relatives in a cost-effective manner, and a protocol enabling simultaneous detection of all possible variants in specific genes using selective amplification coupled to a DNA sequencing platform.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately describes tailored mutation discovery strategies using multiplex PCR followed by NGS, simultaneous analysis of multiple patients and relatives, and a protocol enabling simultaneous detection of variants in specific genes using selective amplification coupled to a DNA sequencing platform. The evidence from the provided PubMed articles supports these claims.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses different aspects of next-generation sequencing applications in mutation screening, such as tailored mutation discovery strategies, simultaneous analysis of multiple samples, and specific gene variant detection. It covers various important applications of NGS in mutation screening.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claims made about the applications of next-generation sequencing in mutation screening. Each claim is tied back to a relevant document, enhancing the credibility of the response.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. Each claim is backed by evidence from the provided PubMed articles, ensuring that the information presented is based on scientific research.\n",
            "\n",
            "Overall, the initial answer provides a well-supported and comprehensive overview of next-generation sequencing applications in mutation screening. It effectively ties each claim back to specific evidence, ensuring factual accuracy and credibility.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Next-generation sequencing applications in mutation screening encompass tailored mutation discovery strategies utilizing multiplex PCR followed by NGS, simultaneous analysis of over 350 patients and relatives per run for efficient and cost-effective screening, and a protocol enabling comprehensive detection of all potential variants in specific genes through selective amplification linked to a DNA sequencing platform, as supported by documented evidence.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1718\n",
            "   Self-RAG: 0.1308\n",
            "   Improvement: -23.86% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 178\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is nimodipine recommended for prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients?\n",
            "\n",
            "🎯 Gold Answer: Yes, nimodipine is recommended and FDA approved for prevention of vasospasm after aneurysmal subarachnoid hemorrhage. Multiple studies have demonstrated that nimodipine (administered orally or intravenously) is safe and effective for prevention of vasospasm, and reduce frequency of ischemic complications, lowered mortality and improved overall outcomes. Other preventive medication can be also effective for vasomotor prevention in aneurysmal subarachnoid hemorrhage patients.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, nimodipine is recommended for the prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients based on the available evidence from the provided context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, nimodipine is recommended for the prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients based on the available level-1 evidence and multiple studies showing significant benefits.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that nimodipine is recommended for the prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients based on level-1 evidence and multiple studies. The evidence provided from PubMed articles supports this claim.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main question regarding the recommendation of nimodipine for vasospasm prevention in aneurysmal subarachnoid hemorrhage patients. It also mentions the need for further multicenter randomized controlled trials (RCTs) to confirm the benefits of other treatment options.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the recommendation of nimodipine for vasospasm prevention in aneurysmal subarachnoid hemorrhage patients. The evidence provided includes information on the benefits of nimodipine compared to other treatments.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claims made are supported by the evidence provided from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is well-supported by specific evidence and accurately addresses the question regarding the use of nimodipine for vasospasm prevention in aneurysmal subarachnoid hemorrhage patients. The mention of the need for further RCTs to confirm the benefits of other treatment options adds depth to the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Nimodipine is recommended for the prevention of vasospasm in aneurysmal subarachnoid hemorrhage patients based on level-1 evidence and multiple studies. While nimodipine has shown significant benefits in preventing vasospasm, further multicenter randomized controlled trials are needed to confirm the efficacy of other treatment options. Additionally, other treatments such as HMG Co-A reductase inhibitors (statins) and enoxaparin have level-1 evidence supporting their use in vasospasm prevention. Advances in diagnosis and treatment, including nimodipine, intensive care management, hemodynamic manipulations, and endovascular neuroradiology procedures, have improved outcomes for these patients, although challenges persist.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3133\n",
            "   Self-RAG: 0.2876\n",
            "   Improvement: -8.20% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 179\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which depression rating scales were shown to have acceptable psychometric properties for screening of poststroke depression?\n",
            "\n",
            "🎯 Gold Answer: The Center of Epidemiological Studies-Depression Scale, Hamilton Depression Rating Scale, and the Patient Health Questionnaire, The Beck Depression Inventory, Hospital Anxiety and Depression Scale-depression subscale, Montgomery-Asberg Depression Rating Scale, Poststroke Depression Rating Scale and Clinical Global Impression scale appeared to have acceptable psychometric properties for identifying depression in patients after stroke. Therefore, these scales can be used for screening of post-stroke depression. Signs of Depression Scale and Visual Analogue Mood Scale showed inferior psychometric properties and therefore should not be used for screening for post-stroke depression.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The Hamilton Depression Rating Scale (HDRS) and the Patient Health Questionnaire (PHQ)-9 were shown to have acceptable psychometric properties for screening of poststroke depression.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The Hamilton Depression Rating Scale (HDRS), the Center of Epidemiological Studies-Depression Scale (CESD), and the Patient Health Questionnaire (PHQ)-9 were shown to have acceptable psychometric properties for screening poststroke depression.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies the Hamilton Depression Rating Scale (HDRS), the Center of Epidemiological Studies-Depression Scale (CESD), and the Patient Health Questionnaire (PHQ)-9 as scales with acceptable psychometric properties for screening poststroke depression. However, it fails to mention the Poststroke Depression Rating Scale (PSDRS) which was specifically designed for assessing depression after stroke, as evidenced in Document 1.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the question by listing three depression rating scales with acceptable psychometric properties for screening poststroke depression. However, it could be more comprehensive by including the PSDRS as another relevant scale based on the evidence provided.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that the HDRS, CESD, and PHQ-9 have acceptable psychometric properties for screening poststroke depression. This grounding in scientific literature strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. However, it could be improved by incorporating the evidence related to the PSDRS to provide a more comprehensive and accurate response.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in evidence but lacks completeness by omitting the PSDRS as a relevant scale for screening poststroke depression. Incorporating this additional information would enhance the overall quality of the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The Hamilton Depression Rating Scale (HDRS), the Center of Epidemiological Studies-Depression Scale (CESD), the Patient Health Questionnaire (PHQ)-9, and the Poststroke Depression Rating Scale (PSDRS) have demonstrated acceptable psychometric properties for screening poststroke depression. Studies have shown that the CESD, HDRS, and PHQ-9 are optimal measures for screening, while the PSDRS is specifically designed to assess depression after stroke, providing a comprehensive approach to screening for poststroke depression.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3276\n",
            "   Self-RAG: 0.3457\n",
            "   Improvement: +5.52% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 180\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the computational methods for the prediction of beta-barrel transmembrane proteins?\n",
            "\n",
            "🎯 Gold Answer: Computational tools have been developed for beta-barrel transmembrane protein discrimination, topology prediction and prediction of their structural features.\n",
            "Initial methods developed for the prediction of the transmembrane beta strands were based on hydrophobicity analysis, using sliding windows along the sequence, in order to capture the alternating patterns of hydrophobic-hydrophilic residues of the transmembrane strands, or using generalized secondary structure prediction methods. Other approaches included the construction of special empirical rules using amino-acid propensities and prior knowledge of the structural nature of the proteins, and the development of Neural Network-based predictors to predict the location of alpha-carbon atoms with respect to the membrane. During the last few years, other more refined methods, appeared, including: Neural Networks, Hidden Markov Models, Support Vector Machines, k-Nearest Neighbors, Radial Basis Functions, Bayesian Networks, Genetic Algorithms, Mahalanobis Discriminant Functions, Cellular Automata, N-to-1 Extreme Learning Machines. Hidden Markov Model-based methods are among the most successful in topology prediction, being able to capture the unique architecture of beta-barrel transmembrane proteins. Consensus methods, as well as pipelines of several related tools (e.g. subcellular localization prediciton, alpha-helical transmembrane protein prediction, signal-peptide/lipoprotein prediction) have also used for discriminating beta-barrel transmembrane proteins. Recently, a number of methods for predicting more detailed structural features (e.g. surface accessibility, residue contacts, even detailed atomic 3D models) tailored to beta-barrel transmembrane proteins have been developed, based on knowledge-based potential functions, graph theoretic models, physical models and multi-tape S-attribute grammars. Methods/tools falling in the aforementioned classes are (listed in alphabetical order): BBF (beta-barrel finder), BETAWARE, BOCTOPUS, BOMP, BTMX (Beta barrel TransMembrane eXposure), HHomp, HMM-B2TMR, OMBBpred, PROFtmb, PRED-TMBB, TMB-Hunt, TBBPred, TMBETAPRED-RBF, TMBHMM, TransFold, TMBpro, TMBKNN, Wimley\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The computational methods for predicting beta-barrel transmembrane proteins include ANN- and SVM-based methods, HMM-based methods, and searching for restricted domains.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The computational methods for predicting beta-barrel transmembrane proteins include ANN- and SVM-based methods, HMM-based methods, and searching for restricted domains.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer accurately mentions the computational methods for predicting beta-barrel transmembrane proteins as ANN- and SVM-based methods, HMM-based methods, and searching for restricted domains.\n",
            "2. Grounding: The evidence from PubMed articles supports the claims made in the initial answer, providing specific references to ANN- and SVM-based methods, HMM-based methods, and searching for restricted domains.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the initial answer mentions three computational methods, it could benefit from further elaboration on each method's specific techniques and how they are applied in predicting beta-barrel transmembrane proteins.\n",
            "2. Hallucinations: The initial answer does not include any unsupported claims, which is a strength in terms of accuracy.\n",
            "\n",
            "Overall, the initial answer provides a good overview of the computational methods for predicting beta-barrel transmembrane proteins, but it could be improved by providing more detailed explanations of each method's processes and applications.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The computational methods for predicting beta-barrel transmembrane proteins involve several approaches. These include Artificial Neural Network (ANN) and Support Vector Machine (SVM) based methods, which utilize machine learning algorithms to predict transmembrane regions. Additionally, Hidden Markov Model (HMM) based methods are employed to identify transmembrane regions in beta-barrel membrane proteins. Another strategy involves searching for specific restricted domains that are characteristic of beta-barrel membrane proteins. Each of these methods plays a crucial role in accurately predicting the structure and localization of beta-barrel transmembrane proteins.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0820\n",
            "   Self-RAG: 0.1937\n",
            "   Improvement: +136.19% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 181\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the available biomedical text mining tools for the detection of protein-protein interactions?\n",
            "\n",
            "🎯 Gold Answer: Several tools have been developed to detect protein-protein interactions (PPIs) by text mining the biomedical literature. Two main computational approaches used for this task are co-occurrence-based methods and Natural Language Processing methods. Biomedical text mining tools for PPI identification are the following (in alphabetical order): BioCreative Meta Server, BioMap, eFIP, Extracting Functional Impact of Phosphorylation, GeneView, HAPPI, Hidden Vector State model, iHop, LAITOR, OntoGene, OpenDMAP, PIE (Protein interaction information extraction system), PPI finder (Paired-PPI Finder), PPInterFinder, PPIs, PolySearch, PreBind and Textomy, Protopia, STRING, TafTalent.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the available biomedical text mining tools for the detection of protein-protein interactions are not explicitly mentioned.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Some available biomedical text mining tools for the detection of protein-protein interactions include those focused on automated extraction of PPIs from biomedical literature.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies that there are text mining tools available for the detection of protein-protein interactions.\n",
            "2. The answer is grounded in evidence from multiple PubMed articles that discuss the importance of automated extraction of protein-protein interactions from biomedical literature.\n",
            "\n",
            "Weaknesses:\n",
            "1. The answer lacks specific mention of the actual names or specific examples of text mining tools for detecting protein-protein interactions. It would be more informative to provide specific tool names for the reader.\n",
            "2. While the evidence supports the importance of automated extraction of protein-protein interactions, it does not directly list or discuss specific tools available for this purpose. More direct references to tools would enhance the completeness of the answer.\n",
            "3. The answer could benefit from a more detailed explanation of how these text mining tools work and their specific capabilities in detecting protein-protein interactions.\n",
            "\n",
            "Overall, the initial answer provides a good foundation by acknowledging the existence of text mining tools for detecting protein-protein interactions and is supported by relevant evidence. However, it could be strengthened by including specific examples of these tools and providing more detailed information on their functionalities.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Some specific biomedical text mining tools for detecting protein-protein interactions include STRING, BioGRID, and APID. These tools are designed to automatically extract PPIs from biomedical literature. For example, STRING integrates and scores protein-protein interactions from various sources, while BioGRID focuses on curating protein interaction data. APID offers a platform for the analysis and visualization of protein interactions. These tools play a crucial role in extracting and analyzing PPI data from the vast biomedical literature, aiding in the understanding of complex biological processes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1818\n",
            "   Self-RAG: 0.1977\n",
            "   Improvement: +8.72% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 182\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the state-of-the-art computational tools for the prediction of gene fusion events?\n",
            "\n",
            "🎯 Gold Answer: Gene fusion detection - also known as the 'Rosetta Stone' method - involves the identification of fused composite genes in a set of reference genomes, which indicates potential interactions between its un-fused counterpart genes in query genomes. A few methods/tools and computational pipelines for the detection of gene fusion events have been introduced. The basic steps followed in these approaches consist of (i) all-against-all sequence comparison, (ii) detection of non-overlapping similarities of two genes/proteins (components) to a single gene/protein (composite), and optionally (iii) elimination of putative spurious hits (e.g. due to promiscuous domains) achieves via clustering based on sequence similarity and examining dense regions of the resulting graph or by querying the PFAM database. An advantage of gene fusion analysis is that functional associations can be predicted even in cases of genes of unknown function. Due to the computationally intense nature of these approaches, precompiled data of this type are often organized in specialized databases. Tools and databases developed for this purpose include (in alphabetical order): fdfBLAST, FusionDB, InPrePPI, (Integrated method for Prediction of Protein-Protein Interactions), MosaicFinder, Phydbac2, PLEX, Predictome, Rosetta Stone method, STRING.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the state-of-the-art computational tools for the prediction of gene fusion events are not explicitly mentioned. Additional information beyond the provided context would be needed to identify specific tools.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Some state-of-the-art computational tools for predicting gene fusion events include FusionDB.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "- The initial answer correctly mentions FusionDB as a computational tool for predicting gene fusion events.\n",
            "- The evidence from PubMed articles supports the claim that gene fusion events can be used for predicting functional associations of proteins.\n",
            "\n",
            "Weaknesses:\n",
            "- The initial answer lacks diversity in mentioning other state-of-the-art computational tools for predicting gene fusion events. It would be more comprehensive to include a broader range of tools.\n",
            "- While FusionDB is mentioned, the answer could benefit from providing more specific details about its features and how it stands out compared to other tools.\n",
            "- The evidence provided from PubMed articles does not directly support the claim that FusionDB is a state-of-the-art tool. It would be beneficial to include specific references or studies that highlight FusionDB's effectiveness and accuracy in predicting gene fusion events.\n",
            "\n",
            "Overall, the initial answer is somewhat accurate but lacks depth and specificity in discussing state-of-the-art computational tools for predicting gene fusion events. It would be improved by providing more detailed information and referencing specific studies that support the effectiveness of FusionDB.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "State-of-the-art computational tools for predicting gene fusion events include FusionDB, which offers a characterization of numerous gene fusion events through multiple sequence alignments. While FusionDB is a notable tool in this field, it is essential to consider other tools such as FusionCatcher and STAR-Fusion for a comprehensive analysis. Further research and specific references are needed to establish the effectiveness and accuracy of these tools in predicting gene fusion events.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1233\n",
            "   Self-RAG: 0.1591\n",
            "   Improvement: +28.98% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 183\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How many genes are in the gene signature screened by MammaPrint?\n",
            "\n",
            "🎯 Gold Answer: Mammaprint has a 70 gene signature.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The gene signature screened by MammaPrint consists of 70 genes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "There are 70 genes in the gene signature screened by MammaPrint.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer correctly states that there are 70 genes in the gene signature screened by MammaPrint, which is supported by the evidence provided from multiple PubMed articles.\n",
            "2. Grounding: The answer references specific evidence from multiple documents that mention the 70 genes in the MammaPrint signature.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the answer accurately states the number of genes in the MammaPrint signature, it could benefit from providing additional context or information about the significance or function of these genes.\n",
            "2. Hallucinations: There are no unsupported claims in the initial answer.\n",
            "\n",
            "Overall, the initial answer is factually accurate and well-grounded in specific evidence. However, it could be improved by providing more context or information about the genes in the MammaPrint signature.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "There are 70 genes in the gene signature screened by MammaPrint. These genes have been shown to play a significant role in capturing specific biological functions related to breast cancer prognosis. Studies have examined the functions of each of these 70 genes to understand their implications in predicting outcomes for breast cancer patients.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3750\n",
            "   Self-RAG: 0.1356\n",
            "   Improvement: -63.84% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 184\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is there a pharmacogenetic test for trastuzumab?\n",
            "\n",
            "🎯 Gold Answer: Yes. HER2 testing is performed in breast cancer patients to determine suitability for trastuzumab (Herceptin therapy).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, there is a pharmacogenetic test for trastuzumab based on the analysis of HER2 amplification in breast cancer.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, there is a pharmacogenetic test for trastuzumab based on the analysis of HER2 amplification in breast cancer.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the use of pharmacogenetic testing for trastuzumab based on HER2 amplification in breast cancer.\n",
            "2. The answer references specific evidence from PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in explaining the process of pharmacogenetic testing for trastuzumab based on HER2 amplification.\n",
            "2. The evidence provided does not directly state that there is a specific pharmacogenetic test for trastuzumab, but rather mentions the analysis of HER2 amplification for trastuzumab selection.\n",
            "3. The answer could benefit from additional evidence or clarification to support the claim that there is a specific pharmacogenetic test for trastuzumab.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Yes, there is no specific pharmacogenetic test for trastuzumab; however, the analysis of HER2 amplification is crucial for selecting patients who may benefit from trastuzumab treatment in breast cancer. Biotin-labeled trastuzumab (BiotHER) can be utilized for HER2 testing by immunohistochemistry. Further research is needed to establish a direct pharmacogenetic test for trastuzumab efficacy.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2941\n",
            "   Self-RAG: 0.2571\n",
            "   Improvement: -12.57% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 185\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is paroxetine effective for treatment of premenstrual dysphoric disorder?\n",
            "\n",
            "🎯 Gold Answer: Yes, paroxetine is effective and FDA approved treatment of women with  premenstrual dysphoric disorder. A number of well designed clinical trials have confirmed efficacy and safety of both continuous or intermittent regiments of paroxetine for treatment of premenstrual dysphoric disorder. A number of other antidepressants and hormaonal therapies were also shown to be effective and are FDA approved for treatment of women with premenstrual dysphoric disorder.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, paroxetine is effective for the treatment of premenstrual dysphoric disorder as it has been approved by regulatory agencies and has shown significant reduction in premenstrual symptoms with a high response rate of 85%.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, based on the provided context, paroxetine is effective for the treatment of premenstrual dysphoric disorder as it has been approved by the US Food and Drug Administration and Health Canada, and has shown a response rate of 85% in reducing premenstrual symptoms.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that paroxetine has been approved by the US Food and Drug Administration and Health Canada for the treatment of premenstrual dysphoric disorder. The claim about a response rate of 85% is supported by the evidence provided in Document 2.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the effectiveness of paroxetine for the treatment of premenstrual dysphoric disorder and provides evidence to support this claim. However, it could be more comprehensive by discussing potential side effects, limitations of the studies, or comparing paroxetine to other treatment options.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claims made about paroxetine's effectiveness in treating premenstrual dysphoric disorder. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All statements are backed up by evidence from reputable sources.\n",
            "\n",
            "Overall, the initial answer is well-supported by evidence and accurately conveys the effectiveness of paroxetine for the treatment of premenstrual dysphoric disorder. It could be strengthened by providing a more comprehensive discussion of the topic, including potential limitations and side effects of paroxetine treatment.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on recent approvals by the US Food and Drug Administration and Health Canada, paroxetine has shown effectiveness in treating premenstrual dysphoric disorder, with a response rate of 85% in reducing premenstrual symptoms (Document 2). However, it is important to note that potential side effects and limitations of paroxetine treatment should be considered. Further research could explore comparisons with other treatment options to provide a more comprehensive understanding of its efficacy in managing premenstrual dysphoric disorder.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2476\n",
            "   Self-RAG: 0.2394\n",
            "   Improvement: -3.30% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 186\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Does cortical spreading depression appear in ischemic penumbra following ischemic stroke?\n",
            "\n",
            "🎯 Gold Answer: Yes, cortical spreading depression appears in ischemic penumbra following ischemic stroke and is associated with expansion of ischemic injury. This has been shown in humans and in animal models.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, cortical spreading depression appears in the ischemic penumbra following ischemic stroke, and it contributes to secondary lesion growth.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, cortical spreading depression appears in the ischemic penumbra following ischemic stroke.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that cortical spreading depression appears in the ischemic penumbra following ischemic stroke, which is supported by the evidence provided from PubMed articles.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main aspect of the question by confirming the presence of cortical spreading depression in the ischemic penumbra following ischemic stroke.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim, demonstrating a strong grounding in scientific literature.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The statements made align with the evidence presented from reputable sources.\n",
            "\n",
            "Overall, the initial answer is well-supported by scientific evidence and accurately addresses the question regarding the presence of cortical spreading depression in the ischemic penumbra following ischemic stroke. The inclusion of specific references adds credibility to the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Cortical spreading depression, specifically spreading depression-like peri-infarct depolarizations, has been observed in the ischemic penumbra following ischemic stroke. This phenomenon worsens penumbra conditions in cortical border zones of experimental focal ischemia, potentially contributing to secondary lesion growth in the penumbra. Multiple studies, including those referenced in PubMed articles, support the presence and impact of cortical spreading depression in the ischemic penumbra post-ischemic stroke.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5000\n",
            "   Self-RAG: 0.2680\n",
            "   Improvement: -46.39% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 187\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is there an association between c-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients? \n",
            "\n",
            "🎯 Gold Answer: Yes. Higher concentrations of C-reactive protein are associated with worse outcomes of subarachnoid hemorrhage patients.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, there is an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients. The document mentions that all inflammatory parameters measured, including C-reactive protein levels, were higher in patients with unfavorable outcomes after subarachnoid hemorrhage.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, there is an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients, as higher levels of C-reactive protein were observed in patients with unfavorable outcomes.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that there is an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients, as higher levels of C-reactive protein were observed in patients with unfavorable outcomes. This claim is supported by evidence from Document 1, which shows that inflammatory parameters, including C-reactive protein levels, were higher in patients with unfavorable outcomes.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main aspect of the question by stating that there is an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients. However, it could have provided more context on the conflicting results mentioned in Document 3 regarding the value of C-reactive protein as a prognostic factor after subarachnoid hemorrhage.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 1 to support the claim of an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence provided in the PubMed articles.\n",
            "\n",
            "Overall, the initial answer is mostly accurate, supported by specific evidence, and does not include any unsupported claims. It could be improved by providing more context on the conflicting results regarding the prognostic value of C-reactive protein after subarachnoid hemorrhage.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "There is an association between C-reactive protein concentrations and outcomes of subarachnoid hemorrhage patients, supported by evidence showing higher levels of C-reactive protein in patients with unfavorable outcomes (Document 1). However, conflicting results exist regarding the prognostic value of C-reactive protein after subarachnoid hemorrhage (Document 3). Additional studies are needed to clarify this aspect.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3333\n",
            "   Self-RAG: 0.2667\n",
            "   Improvement: -20.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 188\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is depression associated with poor prognosis of brain tumor patients?\n",
            "\n",
            "🎯 Gold Answer: Yes. In brain tumor patients depression is associated with shorter survival and worse functional outcomes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, preoperative depression is associated with worse survival in low-grade glioma patients. The adverse impact of depression on survival among cancer patients, including brain tumor patients, is a subject of interest in research.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, preoperative depression is associated with a worse prognosis for low-grade glioma patients.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that preoperative depression is associated with a worse prognosis for low-grade glioma patients.\n",
            "2. The answer is supported by evidence from multiple PubMed articles, which adds credibility to the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not address the broader question of whether depression is associated with poor prognosis in brain tumor patients in general, focusing only on low-grade glioma patients. This limits the completeness of the response.\n",
            "2. While the evidence from PubMed articles supports the claim, the answer could be strengthened by providing more specific details or findings from the studies cited.\n",
            "3. The answer does not mention any potential limitations or conflicting evidence that may exist in the literature regarding the association between depression and prognosis in brain tumor patients.\n",
            "4. The answer could benefit from a more comprehensive review of the literature to provide a more nuanced understanding of the relationship between depression and prognosis in brain tumor patients beyond low-grade gliomas.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Preoperative depression has been identified as a significant prognostic factor for worse survival in low-grade glioma patients, as supported by multiple studies (Document 1, Document 2). While the association between depression and prognosis in brain tumor patients beyond low-grade gliomas is less well-defined, the adverse impact of depression on survival among cancer patients is an active area of research (Document 3). Further investigation is needed to fully understand the relationship between depression and prognosis in brain tumor patients across different tumor types and stages.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2449\n",
            "   Self-RAG: 0.1346\n",
            "   Improvement: -45.03% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 189\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the role of anhedonia in coronary disease patients?\n",
            "\n",
            "🎯 Gold Answer: Anhedonia is associated with poor prognosis in patients with coronary disease. Namely, in patients with coronary disease, anhedonia was associated with increased mortality, greater risk for major cardiac event, impaired physical health status, more cardiac symptoms, more feelings of disability. These associations were independent from clinical and demographic factors.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Anhedonia has been shown to independently predict major clinical adverse events and all-cause mortality in coronary disease patients following implantation of coronary-artery stents and in post-MI patients. It is considered a risk factor for adverse clinical events in these populations, even after controlling for clinical depression and severity of depressive symptoms.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Anhedonia has been shown to independently predict major clinical adverse events and all-cause mortality in coronary disease patients, both following implantation of coronary-artery stents and after an acute coronary syndrome.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that anhedonia has been shown to independently predict major clinical adverse events and all-cause mortality in coronary disease patients, both following implantation of coronary-artery stents and after an acute coronary syndrome. The evidence provided from the PubMed articles supports these claims.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the role of anhedonia in predicting major clinical adverse events and all-cause mortality in coronary disease patients, both after stent implantation and acute coronary syndrome. However, it could be more comprehensive by discussing potential mechanisms or pathways through which anhedonia may impact coronary disease outcomes.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claims made about the role of anhedonia in coronary disease patients. This grounding in scientific literature enhances the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All statements are backed by evidence from the provided PubMed articles.\n",
            "\n",
            "Overall, the initial answer is well-supported by evidence and accurately conveys the role of anhedonia in predicting adverse outcomes in coronary disease patients. It could be strengthened by providing a more comprehensive discussion of potential mechanisms underlying this relationship.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Anhedonia, the lack of positive affect, has been demonstrated as an independent predictor of major clinical adverse events and all-cause mortality in coronary disease patients. This relationship has been observed following implantation of coronary-artery stents and after an acute coronary syndrome. While the evidence supports the predictive role of anhedonia, further research is needed to elucidate the underlying mechanisms through which anhedonia influences outcomes in coronary disease patients.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2330\n",
            "   Self-RAG: 0.1176\n",
            "   Improvement: -49.51% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 190\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the generic versions of Viagra\n",
            "\n",
            "🎯 Gold Answer: Sildenafil Citrate and Elonza in Thailand are the generic versions of Viagra\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The generic versions of Viagra mentioned in the provided context are:\n",
            "1. Zenegra-100 by Mepro Pharm in Mumbai, Maharashtra, India\n",
            "2. Suhagra-100 by Okasa Ltd in Pune, Maharashtra, India\n",
            "3. Vega by an unspecified manufacturer in Manila, Philippines\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The generic versions of Viagra containing sildenafil citrate mentioned in the provided context are Caverta, Zenegra-100, Suhagra-100, and Vega.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies Caverta, Zenegra-100, Suhagra-100, and Vega as generic versions of Viagra containing sildenafil citrate.\n",
            "2. The answer is supported by evidence from PubMed articles, specifically mentioning the generic versions and their manufacturers.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of providing detailed information about each generic version, such as dosage strengths, formulations, and potential side effects.\n",
            "2. The evidence provided from the PubMed articles does not directly link the mentioned generic versions to being alternatives to Viagra. It mentions generic sildenafil products but does not explicitly state their equivalence to Viagra.\n",
            "3. The answer could benefit from additional information on the regulatory approval status of these generic versions and their availability in different markets.\n",
            "4. The answer does not address potential interactions or contraindications of these generic versions with other medications, which are crucial considerations in biomedical contexts.\n",
            "\n",
            "Overall, while the initial answer correctly identifies some generic versions of Viagra containing sildenafil citrate, it lacks depth and specificity in providing comprehensive information. Further clarification and additional evidence would strengthen the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The generic versions of Viagra containing sildenafil citrate are Caverta, Zenegra-100, Suhagra-100, and Vega. These generic versions have been mentioned in the context of containing sildenafil citrate. However, detailed information regarding dosage strengths, formulations, potential side effects, regulatory approval status, and market availability is lacking. While evidence from PubMed articles supports the existence of generic sildenafil products, direct equivalence to Viagra is not explicitly stated. Additionally, information on potential interactions or contraindications with other medications is missing. Further research and clarification are needed to provide a more comprehensive understanding of these generic versions.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1923\n",
            "   Self-RAG: 0.1308\n",
            "   Improvement: -31.96% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 191\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the influence of patent expiry on  ACE inhibitor prescribing.\n",
            "\n",
            "🎯 Gold Answer: Patent expiry has different effects on prescribing in different systems. It leads to decreased cost but no decreased refill compliance in countries like Sweden, Germany etc. In countries like Taiwan, where doctors profit directly from dispensing, patients are switched to ARBs which are more costly.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The influence of patent expiry on ACE inhibitor prescribing includes cost savings for off-patent ACE inhibitors, possible switching from ACE inhibitors to ARBs, and decreased costs per Defined Daily Dose (DDD) after patent expiry. However, the influence on pharmacy refill compliance after generic switch post-patent expiry is not associated with a decrease. The context suggests that patent expiry can impact prescribing decisions and cost-effectiveness of ACE inhibitors.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Patent expiry of ACE inhibitors leads to decreased costs per Defined Daily Dose (DDD) and may result in increased prescribing of off-patent ACE inhibitors. However, the influence on prescribing behavior may vary depending on the specific drug and country's pricing strategies.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that patent expiry of ACE inhibitors can lead to decreased costs per Defined Daily Dose (DDD) and may result in increased prescribing of off-patent ACE inhibitors. This is supported by evidence from Document 2, which shows that costs per DDD decreased for all three drugs after patent expiry.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the influence of patent expiry on ACE inhibitor prescribing, mentioning the potential impact on costs and prescribing behavior. However, it could be more comprehensive by discussing potential factors influencing prescribing decisions beyond just cost, such as clinical efficacy, side effects, and physician preferences.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support its claims. It cites Document 1, which highlights the impact of pricing strategies on prescribing behavior in Taiwan, and Document 3, which discusses pharmacy refill compliance after generic switch following patent expiry.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence presented in the provided documents.\n",
            "\n",
            "Overall, the initial answer provides a solid evaluation of the influence of patent expiry on ACE inhibitor prescribing, supported by specific evidence from PubMed articles. It could be strengthened by considering additional factors influencing prescribing decisions and providing a more comprehensive analysis of the topic.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Patent expiry of ACE inhibitors can lead to decreased costs per Defined Daily Dose (DDD) and potentially increased prescribing of off-patent ACE inhibitors. Factors influencing prescribing decisions extend beyond cost and may include considerations of clinical efficacy, side effects, and physician preferences. Evidence suggests that pricing strategies, such as Taiwan's stepwise price adjustments, impact prescribing behavior by affecting profit margins for physicians. Additionally, pharmacy refill compliance following generic switch after patent expiry, as seen with ramipril, may not decrease. The influence of patent expiry on ACE inhibitor prescribing is multifaceted and involves various factors beyond cost alone.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1739\n",
            "   Self-RAG: 0.1233\n",
            "   Improvement: -29.11% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 192\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How many clinical trials for off-label drugs in neonates are cited in the literature.\n",
            "\n",
            "🎯 Gold Answer: There are no reports on clinical trials of off-label drugs in neonates. An analysis of Pediatric Investigation Plans submitted between 2007 and 2010 shows that neonates were included in the study of 4 products, but it is unknown if the trial drugs are off-label and if the trials are being conducted at all.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The context provided does not specify the exact number of clinical trials for off-label drugs in neonates.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "There were 15 clinical trials cited in the literature for off-label drugs in neonates.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer states that there were 15 clinical trials cited in the literature for off-label drugs in neonates. However, the evidence provided from the PubMed articles only mentions 15 clinical trials in total, not specifically for off-label drugs in neonates. The evidence does mention neonates being included in four of the products, but it does not specify the number of clinical trials related to off-label drug use in neonates.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not fully address all parts of the question. It provides a specific number of clinical trials but does not specify if these trials are specifically for off-label drugs in neonates. More information is needed to determine the exact number of clinical trials for off-label drugs in neonates.\n",
            "\n",
            "3. GROUNDING: The initial answer does reference specific evidence from PubMed articles, which is a strength. However, the evidence provided does not directly support the claim of 15 clinical trials for off-label drugs in neonates.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer includes an unsupported claim that there were 15 clinical trials specifically for off-label drugs in neonates. This claim is not directly supported by the evidence provided.\n",
            "\n",
            "Overall, the initial answer lacks specificity and direct evidence to support the claim of 15 clinical trials for off-label drugs in neonates. More detailed information and specific references to trials related to off-label drug use in neonates are needed to accurately answer the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on the evidence provided from PubMed articles, there were 15 clinical trials cited in the literature, with at least 1,282 children to be recruited into studies across five different products. Neonates were included in four of the products, but the specific number of clinical trials for off-label drugs in neonates is not specified. Further research is needed to determine the exact number of clinical trials specifically focused on off-label drug use in neonates.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1918\n",
            "   Self-RAG: 0.2576\n",
            "   Improvement: +34.31% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 193\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the generic versions of Viagra?\n",
            "\n",
            "🎯 Gold Answer: Generic versions of sildenafil are Elonza, Caverta, Zenegra-100, Vega Asia, Suhagra-100, Vega, Revatio.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The generic versions of Viagra mentioned in the provided context are Zenegra-100, Suhagra-100, and Vega.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The generic versions of Viagra containing sildenafil citrate mentioned in the provided context are Caverta, Zenegra-100, Suhagra-100, and Vega.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the generic versions of Viagra containing sildenafil citrate as Caverta, Zenegra-100, Suhagra-100, and Vega.\n",
            "2. The answer is supported by evidence from PubMed articles, specifically mentioning the generic versions and their manufacturers.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of providing detailed information about each generic version, such as dosage strengths, formulations, or specific differences compared to Viagra.\n",
            "2. The evidence provided from PubMed articles does not directly link the generic versions mentioned to Viagra or sildenafil citrate, making the connection somewhat indirect.\n",
            "3. The answer could benefit from additional information on the availability, pricing, and regulatory approval status of these generic versions to provide a more comprehensive overview.\n",
            "4. The answer does not address potential side effects, contraindications, or other important considerations related to using generic versions of Viagra.\n",
            "\n",
            "Overall, while the initial answer correctly identifies some generic versions of Viagra containing sildenafil citrate and is supported by evidence, it could be improved by providing more detailed and direct information, as well as addressing additional aspects related to the topic.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "The generic versions of Viagra containing sildenafil citrate are Caverta, Zenegra-100, Suhagra-100, and Vega. Caverta is manufactured by San Diego, California, United States. Zenegra-100 is produced by Mepro Pharm in Mumbai, Maharashtra, India. Suhagra-100 is made by Okasa Ltd in Pune, Maharashtra, India. Vega is manufactured in Delhi, India. These generic versions have been shown to have bioequivalence to the original formula in studies like the one conducted on generic sildenafil by Unison Laboratories in Thailand. Additional information on dosage strengths, formulations, pricing, availability, regulatory approval status, and potential side effects should be considered before use.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5625\n",
            "   Self-RAG: 0.2051\n",
            "   Improvement: -63.53% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 194\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is physical performance influenced by thyroid hormone metabolism?\n",
            "\n",
            "🎯 Gold Answer: Yes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, there is evidence suggesting that thyroid hormone metabolism can influence physical performance, particularly in adults and elderly individuals. The impact of strenuous exercise on thyroid hormone metabolism in children and adolescents is less clear due to limited data.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, physical performance can be influenced by thyroid hormone metabolism, as indicated by the relationship between thyroid hormone concentrations and physical function in adults and elderly individuals.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly acknowledges the influence of thyroid hormone metabolism on physical performance.\n",
            "2. The answer references specific evidence from PubMed articles to support the relationship between thyroid hormone concentrations and physical function in adults and elderly individuals.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not fully address the question's scope, as it focuses primarily on adults and elderly individuals. It fails to mention the potential impact on physical performance in children and adolescents.\n",
            "2. While the evidence provided supports the influence of thyroid hormone concentrations on physical function, it does not directly establish a causal relationship between thyroid hormone metabolism and physical performance in athletes or other populations.\n",
            "3. The answer could benefit from a more comprehensive review of the available literature to provide a more balanced perspective on the topic.\n",
            "4. The initial answer does not mention any potential limitations or conflicting findings in the evidence presented, which could provide a more nuanced understanding of the relationship between thyroid hormone metabolism and physical performance.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Physical performance can be influenced by thyroid hormone metabolism, with evidence suggesting a relationship between thyroid hormone concentrations and physical function in adults and elderly individuals. However, the impact of strenuous exercise on thyroid hormone metabolism in children and adolescents remains understudied, with conflicting results in adult athletes. While changes in thyroid hormone concentrations may be related to overall physical function in the elderly, the causal relationship between thyroid hormone metabolism and physical performance in athletes or other populations is not definitively established. Further research is needed to fully understand the implications of thyroid hormone metabolism on physical performance across different age groups and activity levels.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0444\n",
            "   Self-RAG: 0.0000\n",
            "   Improvement: -100.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 195\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which gene test can be used for the X-linked myotubular myopathy?\n",
            "\n",
            "🎯 Gold Answer: Genetic testing of the MTM1 gene can be used for the X-linked myotubular myopathy.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The gene test that can be used for X-linked myotubular myopathy is the MTM1 gene test.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The gene test that can be used for X-linked myotubular myopathy is the MTM1 gene test.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the MTM1 gene as the gene associated with X-linked myotubular myopathy.\n",
            "2. The answer is supported by evidence from multiple PubMed articles that specifically mention the MTM1 gene in relation to X-linked myotubular myopathy.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have provided more context or explanation about the role of the MTM1 gene in X-linked myotubular myopathy.\n",
            "2. While the evidence supports the association between the MTM1 gene and X-linked myotubular myopathy, the answer could have included more details about the specific gene test methods used for detecting mutations in the MTM1 gene.\n",
            "3. The answer could have addressed the potential limitations or challenges associated with gene testing for X-linked myotubular myopathy.\n",
            "4. The answer does not mention any alternative gene tests or considerations for X-linked myotubular myopathy, which could provide a more comprehensive overview of diagnostic options.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in specific evidence linking the MTM1 gene to X-linked myotubular myopathy. However, it could be improved by providing more detailed information on gene testing methods, potential limitations, and alternative diagnostic approaches.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The gene test commonly used for X-linked myotubular myopathy, associated with mutations in the MTM1 gene located on Xq28, involves screening for mutations in the MTM1 gene through methods such as exon amplification, single-strand conformation polymorphism, and sequencing analysis. These methods have been utilized to identify mutations in affected individuals. While the MTM1 gene test is a primary diagnostic tool, it is important to consider potential limitations such as the need for comprehensive genetic counseling and the possibility of variants of uncertain significance. Alternative gene tests or diagnostic approaches may be considered in cases where the MTM1 gene test does not yield conclusive results.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.6250\n",
            "   Self-RAG: 0.1322\n",
            "   Improvement: -78.84% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 196\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the symptoms of abacavir hypersensitivity?\n",
            "\n",
            "🎯 Gold Answer: Patients receiving abacavir develop an idiosyncratic hypersensitivity reaction that can include a wide range of symptoms. The most common are: fever, enathema, skin rash, nausea, vomiting, diarrhoea, cough, gastrointestinal disorders, anaphylactic shock, respiratory symptoms.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The symptoms of abacavir hypersensitivity include rash, fever, gastrointestinal disorders, respiratory symptoms, enanthema, and multisystemic involvement.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The symptoms of abacavir hypersensitivity include rash, fever, gastrointestinal disorders, respiratory symptoms, enanthema, and multisystemic involvement.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies some of the common symptoms of abacavir hypersensitivity, such as rash, fever, gastrointestinal disorders, and respiratory symptoms.\n",
            "2. The answer references specific evidence from PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not mention enanthema as a symptom of abacavir hypersensitivity, which is supported by evidence from Document 2.\n",
            "2. The claim of \"multisystemic involvement\" is not explicitly supported by the evidence provided. While Document 1 mentions multisystemic involvement, it is not clear if this is a common symptom or a rare occurrence.\n",
            "3. The initial answer could be more comprehensive by providing a more detailed description of each symptom and their prevalence in abacavir hypersensitivity reactions.\n",
            "4. The initial answer does not address the potential seriousness of the hypersensitivity reaction associated with abacavir, as mentioned in Document 3.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in evidence but could benefit from addressing the additional symptom of enanthema and providing a more comprehensive overview of the symptoms and seriousness of abacavir hypersensitivity reactions.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The symptoms of abacavir hypersensitivity include rash, fever, gastrointestinal disorders, respiratory symptoms, and enanthema. While multisystemic involvement has been reported in some cases, it is not consistently observed. Abacavir hypersensitivity reactions can be serious, with a wide range of signs and symptoms.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3200\n",
            "   Self-RAG: 0.2368\n",
            "   Improvement: -25.99% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 197\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the role of the histidine rich calcium binding protein (HRC) in cardiomyopathy?\n",
            "\n",
            "🎯 Gold Answer: The histidine-rich Ca-binding protein (HRC), a 165 kDa sarcoplasmic reticulum (SR) protein, regulates SR Ca cycling during excitation–contraction coupling.  HRC mutations or polymorphisms lead to cardiac dysfunction.  The Ser96Ala genetic variant of HRC is associated with life-threatening ventricular arrhythmias and sudden death in idiopathic dilated cardiomyopathy (DCM).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The histidine-rich calcium binding protein (HRC) may play a role in cardiomyopathy by potentially influencing ventricular arrhythmias, sudden death in dilated cardiomyopathy patients, inhibiting maximal rates of sarcoplasmic reticulum Ca-transport leading to cardiac dysfunction, and regulating sarcoplasmic reticulum Ca cycling during excitation-contraction coupling.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The histidine-rich calcium binding protein (HRC) may play a role in regulating sarcoplasmic reticulum calcium cycling during excitation-contraction coupling in cardiomyopathy. The Ser96Ala polymorphism of HRC has been associated with ventricular arrhythmias and sudden death in dilated cardiomyopathy patients. Additionally, HRC has been shown to inhibit maximal rates of sarcoplasmic reticulum calcium transport, potentially leading to cardiac dysfunction.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions the role of the histidine-rich calcium binding protein (HRC) in regulating sarcoplasmic reticulum calcium cycling during excitation-contraction coupling in cardiomyopathy.\n",
            "2. The answer accurately states that the Ser96Ala polymorphism of HRC has been associated with ventricular arrhythmias and sudden death in dilated cardiomyopathy patients.\n",
            "3. The answer references specific evidence from PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more comprehensive by providing additional details on how HRC specifically influences cardiomyopathy beyond inhibiting maximal rates of sarcoplasmic reticulum calcium transport.\n",
            "2. The answer does not explicitly mention the potential role of HRC in myocardial ischemia/reperfusion injury, as suggested by one of the provided documents.\n",
            "3. The answer could benefit from a more detailed explanation of how HRC regulates sarcoplasmic reticulum calcium cycling during excitation-contraction coupling in cardiomyopathy.\n",
            "4. The answer does not address the broader context of HRC's function in cardiomyopathy beyond the specific associations with ventricular arrhythmias and sudden death in dilated cardiomyopathy patients.\n",
            "\n",
            "Overall, the initial answer provides a good foundation but could be strengthened by expanding on the role of HRC in cardiomyopathy and incorporating additional relevant information from the provided evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The histidine-rich calcium binding protein (HRC) plays a crucial role in cardiomyopathy by regulating sarcoplasmic reticulum calcium cycling during excitation-contraction coupling. Specifically, the Ser96Ala polymorphism of HRC has been linked to ventricular arrhythmias and sudden death in dilated cardiomyopathy patients. HRC inhibits maximal rates of sarcoplasmic reticulum calcium transport, potentially contributing to cardiac dysfunction. Moreover, HRC's involvement in myocardial ischemia/reperfusion injury warrants further investigation to understand its impact on cardiac function. Studies suggest that HRC, a 165 kDa sarcoplasmic reticulum protein, modulates SR calcium cycling during excitation-contraction coupling in cardiomyopathy.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3299\n",
            "   Self-RAG: 0.3562\n",
            "   Improvement: +7.96% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 198\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Mutations in which gene determine response to both erlotinib and gefitinib?\n",
            "\n",
            "🎯 Gold Answer: Patients who carry somatic activating mutations in the tyrosine kinase domain of the epidermal growth factor receptor (EGFR) gene, respond well to erlotinib and gefitinib.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "EGFR (Epidermal Growth Factor Receptor) gene mutations determine response to both erlotinib and gefitinib.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "EGFR (Epidermal Growth Factor Receptor)\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies EGFR (Epidermal Growth Factor Receptor) as the gene associated with determining response to both erlotinib and gefitinib.\n",
            "2. The evidence provided from PubMed articles supports the claim that mutations in EGFR are associated with sensitivity to both drugs.\n",
            "3. The answer is grounded in specific evidence from multiple sources, indicating a strong factual basis.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more explicit in stating that mutations in the EGFR gene specifically within the TK domain are responsible for determining response to erlotinib and gefitinib. This specificity could enhance the completeness of the answer.\n",
            "2. While the evidence supports the relationship between EGFR mutations and drug sensitivity, it would strengthen the answer to directly quote or reference specific findings from the documents to provide a more detailed grounding.\n",
            "3. The initial answer does not mention the specific correlation between EGFR gene copy number, mutations, and drug sensitivity, which could provide a more comprehensive understanding of the topic.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence but could benefit from more specificity and completeness in addressing all aspects of the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Mutations within the TK domain of the EGFR (Epidermal Growth Factor Receptor) gene determine response to both erlotinib and gefitinib. Evidence from PubMed articles indicates that these mutations are associated with sensitivity to both drugs. Additionally, there is a significant correlation between EGFR gene copy number, EGFR gene mutations, and gefitinib sensitivity.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4615\n",
            "   Self-RAG: 0.3636\n",
            "   Improvement: -21.21% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 199\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which population has a high frequency of the HLA-B*1502 allele?\n",
            "\n",
            "🎯 Gold Answer: HLA-B*1502 has a high frequency in Han Chinese and other Asian populations, except Japanese. (There is a strong association between human leucocyte antigen (HLA)-B*1502 and carbamazepine-induced Stevens-Johnson syndrome (SJS)).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The HLA-B*1502 allele is seen in high frequency in many Asian populations other than Han Chinese.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The HLA-B*1502 allele is seen in high frequency in many Asian populations other than Han Chinese.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that the HLA-B*1502 allele is seen in high frequency in many Asian populations other than Han Chinese, which is supported by the evidence from Document 3. However, the claim that the allele is seen in high frequency in many Asian populations other than Han Chinese is not directly supported by the evidence provided.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not fully address the question of which population has a high frequency of the HLA-B*1502 allele. It mentions that the allele is seen in many Asian populations other than Han Chinese but does not specify which populations have a high frequency.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that the HLA-B*1502 allele is seen in high frequency in many Asian populations other than Han Chinese. However, it could benefit from more direct evidence supporting the claim about the high frequency in other Asian populations.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. However, it could be more specific in its claims about the frequency of the HLA-B*1502 allele in different populations.\n",
            "\n",
            "Overall, the initial answer provides some support for the claim that the HLA-B*1502 allele is seen in high frequency in many Asian populations other than Han Chinese, but it could be strengthened by providing more specific evidence and addressing the question more directly.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The HLA-B*1502 allele is observed in high frequency in the Han Chinese population. While there is limited data on the frequency of this allele in other Asian populations, studies have shown increased prevalence in certain groups, such as in patients with OXC-induced MPE in the Chinese Han population. Further research is needed to determine the prevalence of this allele in other Asian populations.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3019\n",
            "   Self-RAG: 0.2376\n",
            "   Improvement: -21.29% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 200\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is imatinib an antidepressant drug?\n",
            "\n",
            "🎯 Gold Answer: No. Imatinib is a tyrosine-kinase inhibitor used in the treatment of multiple cancers, most notably Chronic myelogenous leukemia (CML) and Gastrointestinal stromal tumor (GIST).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, imatinib is not an antidepressant drug.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "No, imatinib is not an antidepressant drug. It is a kinase inhibitor approved for conditions such as chronic myeloid leukemia and gastrointestinal stromal tumors.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer correctly states that imatinib is not an antidepressant drug and provides accurate information about its approved uses for chronic myeloid leukemia and gastrointestinal stromal tumors.\n",
            "2. Grounding: The answer references specific evidence from PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the initial answer addresses the main question about imatinib not being an antidepressant drug, it could have provided additional context or explanation about why imatinib is not used for treating depression.\n",
            "2. Hallucinations: There are no unsupported claims in the initial answer.\n",
            "\n",
            "Overall, the initial answer is factually accurate and well-grounded in evidence. It could be strengthened by providing more comprehensive information about why imatinib is not used as an antidepressant drug.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Imatinib is not an antidepressant drug; it is a kinase inhibitor primarily used for chronic myeloid leukemia and gastrointestinal stromal tumors. Imatinib targets the Kit (CD117) protein and is approved for multiple indications, including the treatment of these specific conditions. Unlike antidepressants, imatinib is not indicated for the treatment of depression.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1111\n",
            "   Self-RAG: 0.3158\n",
            "   Improvement: +184.21% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 201\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What gene test is recommended for clopidogrel?\n",
            "\n",
            "🎯 Gold Answer: The genetic test recommended for clopidogrel is CYP2C19 genotyping.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "CYP2C19 gene test is recommended for clopidogrel.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "CYP2C19 gene test is recommended for clopidogrel.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies the CYP2C19 gene test as recommended for clopidogrel based on the evidence provided from PubMed articles. This claim is supported by the information that CYP2C19 is a significant determinant of clopidogrel response.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main part of the question by specifying the gene test recommended for clopidogrel, which is the CYP2C19 gene test. However, it could be more comprehensive by providing additional context or information about why this specific gene test is recommended.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the recommendation of the CYP2C19 gene test for clopidogrel. The information provided from the articles confirms the importance of CYP2C19 in determining the pharmacodynamic effects of clopidogrel.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The recommendation of the CYP2C19 gene test is grounded in scientific evidence.\n",
            "\n",
            "Overall, the initial answer is factually accurate, grounded in specific evidence, and does not include unsupported claims. It could be strengthened by providing more context or explanation for why the CYP2C19 gene test is recommended for clopidogrel.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The CYP2C19 gene test is recommended for clopidogrel to identify gene variants that influence clopidogrel response, as supported by evidence indicating that CYP2C19 is a significant determinant of the pharmacodynamic effects of clopidogrel. This recommendation is based on studies such as the Genotype Information and Functional Testing Study (GIFT; NCT00992420) which found that CYP2C19 genotype plays a crucial role in determining clopidogrel response, particularly in patients with high on-treatment platelet reactivity.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5000\n",
            "   Self-RAG: 0.1975\n",
            "   Improvement: -60.49% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 202\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What disease is mirtazapine predominantly used for?\n",
            "\n",
            "🎯 Gold Answer: Mirtazapine is predominantly used in the treatment of major depression.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Mirtazapine is predominantly used for the treatment of depression.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Mirtazapine is predominantly used for the treatment of depression.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "The initial answer stating that mirtazapine is predominantly used for the treatment of depression is supported by the evidence provided. The PubMed articles clearly mention mirtazapine as an antidepressant and its use in treating depression. The answer is factually accurate, addresses the main aspect of the question, and is grounded in specific evidence from reputable sources.\n",
            "\n",
            "However, the answer could be strengthened by providing more comprehensive information about other potential uses of mirtazapine, such as its off-label use for conditions like anxiety, insomnia, and nausea. Including this additional information would enhance the completeness of the response. Additionally, the answer could benefit from discussing the efficacy and safety profile of mirtazapine compared to other antidepressants mentioned in the evidence.\n",
            "\n",
            "Overall, the initial answer is well-supported by evidence but could be improved by providing a more comprehensive overview of mirtazapine's uses and comparing it to other treatment options.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Mirtazapine is predominantly used for the treatment of depression, as supported by evidence from PubMed articles. In addition to its antidepressant properties, mirtazapine is also utilized off-label for conditions such as anxiety, insomnia, and nausea. Comparisons of mirtazapine with other antidepressants in terms of efficacy and safety could provide further insights into its clinical utility.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.8421\n",
            "   Self-RAG: 0.2424\n",
            "   Improvement: -71.21% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 203\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is the microRNA 132 (miR-132) involved in brain pathologies?\n",
            "\n",
            "🎯 Gold Answer: Yes. MicroRNA 132 (miR-132), is involved in brain pathologies.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, microRNA 132 (miR-132) is involved in brain pathologies, specifically in neurodevelopmental and neuromorphological pathologies present in schizophrenia.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, miR-132 is involved in brain pathologies, as its dysregulation contributes to neurodevelopmental and neuromorphological abnormalities in conditions such as schizophrenia.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that miR-132 is involved in brain pathologies.\n",
            "2. The answer provides specific evidence from PubMed articles to support the claim.\n",
            "3. The answer mentions that dysregulation of miR-132 contributes to neurodevelopmental and neuromorphological abnormalities in schizophrenia, which is supported by the evidence provided.\n",
            "\n",
            "Weaknesses:\n",
            "1. The answer could be more explicit in stating that miR-132 dysregulation specifically contributes to brain pathologies, rather than just mentioning its involvement.\n",
            "2. The evidence provided does not directly link miR-132 dysregulation to brain pathologies in general, beyond the specific example of schizophrenia. More comprehensive evidence linking miR-132 to a broader range of brain pathologies would strengthen the answer.\n",
            "3. The answer could benefit from discussing potential limitations or conflicting evidence regarding the role of miR-132 in brain pathologies to provide a more balanced perspective.\n",
            "\n",
            "Overall, the initial answer is on the right track but could be improved by providing a more comprehensive and nuanced evaluation of miR-132's involvement in brain pathologies based on the available evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Yes, miR-132 dysregulation is specifically implicated in various brain pathologies, as evidenced by its altered expression in conditions like schizophrenia and Huntington's disease (HD). Studies have shown that miR-132, along with other key neuronal microRNAs, is downregulated in the brains of individuals with HD, suggesting a broader role in neurodegenerative disorders. Additionally, dysregulation of miR-132 has been linked to neurodevelopmental and neuromorphological abnormalities observed in schizophrenia. While these findings support the involvement of miR-132 in brain pathologies, further research is needed to explore its role across a wider spectrum of neurological conditions and to address potential conflicting evidence.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.6897\n",
            "   Self-RAG: 0.1565\n",
            "   Improvement: -77.30% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 204\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which diseases is microRNA 132 (miR-132) implicated in?\n",
            "\n",
            "🎯 Gold Answer: Several targets for for miR-132 have been described and it is implicated in many diseases such as:\n",
            "neurodegenerative disease, \n",
            "epilepsy,\n",
            "schizophrenia,\n",
            "Huntington's disease (HD),\n",
            "Alzheimer's disease (AD),\n",
            "neuroinflammation,\n",
            "osteosarcoma,\n",
            "chronic lymphocytic leukemia (CLL),\n",
            "angiogenesis,\n",
            "eye disease,\n",
            "alcoholic liver disease,\n",
            "progressive supranuclear palsy (PSP taupathy),\n",
            "mild cognitive impairment.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, microRNA 132 (miR-132) is implicated in human neurodegenerative diseases.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "miR-132 is implicated in human neurodegenerative diseases.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies miR-132 as being implicated in human neurodegenerative diseases.\n",
            "2. The evidence provided from Document 3 supports the claim that miR-132 is a key regulator of neurite outgrowth and may serve as a potential therapeutic target for neurodegenerative diseases.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not mention other diseases beyond neurodegenerative diseases that miR-132 may be implicated in, such as cancer or cardiovascular diseases, which could provide a more comprehensive understanding of its role.\n",
            "2. The evidence provided from Document 1 and Document 2 does not directly support the claim that miR-132 is implicated in neurodegenerative diseases. While Document 1 discusses the role of miR-132 in angiogenesis, and Document 2 mentions its regulation by neuronal activity, these do not directly link miR-132 to neurodegenerative diseases.\n",
            "3. The initial answer could benefit from referencing more specific evidence related to miR-132's involvement in neurodegenerative diseases to strengthen the claim further.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and specific grounding in the evidence provided. It would be strengthened by incorporating additional evidence directly linking miR-132 to neurodegenerative diseases and addressing other potential disease implications.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "miR-132 is implicated in human neurodegenerative diseases, particularly as a key regulator of neurite outgrowth. While Document 3 supports its potential as a therapeutic target, Document 1 discusses its role in angiogenesis, and Document 2 indicates its regulation by neuronal activity. Further research is needed to establish direct links between miR-132 and neurodegenerative diseases, as well as explore its potential implications in other diseases like cancer or cardiovascular conditions.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2154\n",
            "   Self-RAG: 0.1653\n",
            "   Improvement: -23.26% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 205\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Gene silencing can be achieved by RNA interference (RNAi) in eukaryotic organisms. What is the name of the analogous process in prokaryotic organisms?\n",
            "\n",
            "🎯 Gold Answer: Bacteria have developed several defense mechanisms against bacteriophages over evolutionary time, but the concept of prokaryotic RNA interference mediated defense mechanism against phages and other invading genetic elements has emerged only recently. Clustered regularly interspaced short palindromic repeats (CRISPR) together with closely associated genes (cas genes) constitute the CASS system that is believed to provide a RNAi-like defense mechanism against bacteriophages within the host bacterium.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The analogous process in prokaryotic organisms to gene silencing by RNA interference (RNAi) in eukaryotic organisms is mediated by the clustered regularly interspaced short palindromic repeat (CRISPR) system.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "CRISPR-Cas system\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the analogous process in prokaryotic organisms as the CRISPR-Cas system.\n",
            "2. The answer is supported by evidence from multiple PubMed articles that discuss the RNAi-like defense mechanism in prokaryotes mediated by the CRISPR-Cas system.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have provided a more direct link between the CRISPR-Cas system and gene silencing in prokaryotic organisms. While the evidence mentions the RNAi-like pathway in prokaryotes, it would have been stronger to explicitly state how the CRISPR-Cas system achieves gene silencing.\n",
            "2. The answer could have been more explicit in addressing the question's focus on gene silencing in prokaryotic organisms. While the CRISPR-Cas system is related to defense mechanisms against genetic invaders, the connection to gene silencing could have been emphasized more clearly.\n",
            "3. The evidence provided does support the claim that the CRISPR-Cas system functions analogously to RNAi in eukaryotic organisms, but the initial answer could have elaborated on this connection further for a more comprehensive response.\n",
            "\n",
            "Overall, the initial answer is on the right track but could benefit from more explicit connections and explanations to fully address the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The analogous process to gene silencing by RNA interference (RNAi) in eukaryotic organisms in prokaryotic organisms is mediated by the CRISPR-Cas system. The CRISPR-Cas system in prokaryotes functions similarly to RNAi in eukaryotes by providing a defense mechanism against genetic invaders, such as bacteriophages, through an RNAi-like pathway. This system involves noncoding RNAs derived from CRISPR loci that target and silence specific genes in the invading genetic material, thereby achieving gene silencing within the host bacterium.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2766\n",
            "   Self-RAG: 0.2621\n",
            "   Improvement: -5.25% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 206\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is it feasible to determine the complete proteome of yeast?\n",
            "\n",
            "🎯 Gold Answer: Yes, since the complete genome of yeast is known.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, it is feasible to determine the complete proteome of yeast using a strategy based on high-throughput peptide synthesis and mass spectrometry, achieving coverage of 97% of the genome-predicted proteins.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, it is feasible to determine the complete proteome of yeast, as demonstrated by the generation of an almost complete reference map covering 97% of the genome-predicted proteins of Saccharomyces cerevisiae using high-throughput peptide synthesis and mass spectrometry.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that it is feasible to determine the complete proteome of yeast.\n",
            "2. The answer provides specific evidence from PubMed articles to support the claim, showing a good grounding in scientific literature.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer may overstate the completeness of the proteome map generated, as it claims to cover 97% of the genome-predicted proteins of Saccharomyces cerevisiae. However, Document 3 mentions that attempts to generate complete proteome maps have not reached full coverage.\n",
            "2. The answer could benefit from acknowledging the limitations and challenges associated with determining a complete proteome, as indicated in Document 3.\n",
            "3. The answer could be improved by discussing the potential variability and dynamic nature of the proteome, which may affect the completeness of proteome maps.\n",
            "\n",
            "Overall, the initial answer provides a generally accurate assessment of the feasibility of determining the complete proteome of yeast but could benefit from a more nuanced discussion of the challenges and limitations involved in achieving complete coverage.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Determining the complete proteome of yeast presents challenges despite progress made in generating reference maps. While efforts have achieved coverage of a significant portion of the Saccharomyces cerevisiae proteome, full coverage remains elusive. The dynamic nature and variability of the proteome further complicate achieving comprehensive mapping. High-throughput peptide synthesis and mass spectrometry have enabled the generation of detailed proteome maps, but limitations persist in achieving complete coverage.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1778\n",
            "   Self-RAG: 0.1013\n",
            "   Improvement: -43.04% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 207\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Does physical activity influence gut hormones?\n",
            "\n",
            "🎯 Gold Answer: Yes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, physical activity can influence gut hormones, as indicated by the release of gut hormones such as gastrin, CCK, and PP immediately after exercise, as mentioned in Document 3.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, physical activity influences gut hormones as indicated by the release of gut hormones such as gastrin, CCK, and PP immediately after exercise in Document 3.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that physical activity influences gut hormones.\n",
            "2. The answer provides specific examples of gut hormones influenced by physical activity, such as gastrin, CCK, and PP.\n",
            "3. The answer references Document 3 as evidence to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in explaining the relationship between physical activity and gut hormones. It mentions the release of gut hormones immediately after exercise but does not delve into the mechanisms or long-term effects.\n",
            "2. The answer could benefit from including additional evidence beyond Document 3 to strengthen the argument.\n",
            "3. The initial answer does not address the potential complexities or nuances in how different types or intensities of physical activity may influence gut hormones differently.\n",
            "4. The answer does not mention any potential limitations or conflicting evidence regarding the influence of physical activity on gut hormones.\n",
            "\n",
            "Overall, while the initial answer provides a basic understanding of the relationship between physical activity and gut hormones, it could be improved by providing more in-depth analysis, additional evidence, and acknowledging potential limitations.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Physical activity influences gut hormones by triggering the release of hormones such as gastrin, CCK, and PP, as evidenced by Document 3. This release occurs immediately after exercise, indicating a direct impact on hormone levels. However, the specific mechanisms and long-term effects of this relationship require further investigation beyond the immediate post-exercise response. Additional research, such as that referenced in Document 1 and Document 2, suggests that the control of spontaneous physical activity by gut hormones plays a role in energy balance regulation. Different types and intensities of physical activity may have varying effects on gut hormones, highlighting the need for a nuanced understanding of this relationship. It is important to consider potential limitations and conflicting evidence when exploring the influence of physical activity on gut hormones.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0667\n",
            "   Self-RAG: 0.0000\n",
            "   Improvement: -100.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 208\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Carbapenemase-producing gram-negative bacteria is a major health concern because their resistance to antibiotics.\n",
            "List the most frequent carbapenemases found in Enterobacteriaceae.\n",
            "\n",
            "🎯 Gold Answer: The most frequent carbapenemases in Enterobacteriaceae  are OXA-48, KPC, VIM, NDM, IMP, SME, NMC, GES, IMI and MBL.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The most frequent carbapenemases found in Enterobacteriaceae are OXA-48, KPC, and VIM-1.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The most frequent carbapenemases found in Enterobacteriaceae are OXA-48, KPC, and VIM-1.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies OXA-48, KPC, and VIM-1 as frequent carbapenemases found in Enterobacteriaceae, which is supported by the evidence provided from Document 1 and Document 2.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main part of the question by listing the most frequent carbapenemases found in Enterobacteriaceae. However, it could be more comprehensive by mentioning other carbapenemases that are also important in this context, such as IMP and NDM.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 1 and Document 2) to support the claims made about the most frequent carbapenemases in Enterobacteriaceae.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claims made are supported by evidence from reputable sources.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence. It could be improved by providing a more comprehensive list of carbapenemases found in Enterobacteriaceae and mentioning other important carbapenemases like IMP and NDM.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The most frequent carbapenemases found in Enterobacteriaceae include OXA-48, KPC, VIM-1, IMP, and NDM. These carbapenemases contribute significantly to antibiotic resistance in these bacteria, posing a serious health concern.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.6667\n",
            "   Self-RAG: 0.4800\n",
            "   Improvement: -28.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 209\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is factor XI deficient in Hemophilia C?\n",
            "\n",
            "🎯 Gold Answer: Factor XI deficiency is associated with a bleeding tendency called Hemophilia C.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, factor XI is deficient in Hemophilia C.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, factor XI is deficient in Hemophilia C.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies factor XI deficiency as being associated with Hemophilia C.\n",
            "2. The evidence provided from PubMed articles supports the claim that factor XI deficiency is linked to Hemophilia C.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have provided more detailed information on the relationship between factor XI deficiency and Hemophilia C, such as the specific role of factor XI in the disease.\n",
            "2. While the evidence supports the claim, it would have been stronger if specific details or findings from the PubMed articles were included to enhance the grounding of the answer.\n",
            "3. The initial answer could have addressed the fact that Hemophilia C is also known as factor XI deficiency, to provide a more complete understanding for the reader.\n",
            "\n",
            "Overall, the initial answer is generally accurate and supported by evidence, but it could benefit from more detailed explanations and specific references to strengthen the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Factor XI deficiency, also known as Hemophilia C, is a rare hematologic disorder that affects both genders. It is characterized by a deficiency in factor XI, a clotting protein involved in the coagulation cascade. Hemophilia C is typically asymptomatic, but individuals with severe factor XI deficiency may experience bleeding tendencies. The condition is distinct from Hemophilia A and B, which involve deficiencies in factor VIII and factor IX, respectively. The association between factor XI deficiency and Hemophilia C is well-established in the literature, with factor XI being a key factor in the pathogenesis of the disease.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5000\n",
            "   Self-RAG: 0.1651\n",
            "   Improvement: -66.97% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 210\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is TREM2 associated with Alzheimer's disease in humans?\n",
            "\n",
            "🎯 Gold Answer: TREM2 variants have been found to be associated with early as well as with late onset Alzheimer's disease.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, TREM2 is associated with Alzheimer's disease in humans based on the provided context from PubMed articles.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, TREM2 is associated with Alzheimer's disease in humans based on the provided context from PubMed articles.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that TREM2 is associated with Alzheimer's disease in humans.\n",
            "2. The evidence provided from PubMed articles supports the claim that TREM2 is linked to Alzheimer's disease risk.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in detailing the extent of the association between TREM2 and Alzheimer's disease. For example, it could mention the specific role of TREM2 in disease pathology.\n",
            "2. While the evidence from PubMed articles supports the claim, it would be stronger if the answer included more diverse sources or a meta-analysis to provide a broader perspective on the association.\n",
            "3. The initial answer could benefit from mentioning any conflicting evidence or limitations in the studies cited to provide a more balanced view of the association between TREM2 and Alzheimer's disease.\n",
            "4. The initial answer does not address the mechanism by which TREM2 may be associated with Alzheimer's disease, which could enhance the completeness of the response.\n",
            "\n",
            "Overall, the initial answer is generally accurate and supported by evidence, but it could be strengthened by providing more specific details, considering a broader range of sources, addressing potential limitations, and discussing the underlying mechanisms of the association.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Yes, TREM2 is associated with Alzheimer's disease in humans. Specifically, TREM2 has been identified as a rare risk factor for late-onset Alzheimer's disease (AD) in various populations, including the Spanish population. Studies have reported the association of specific variants in the TREM2 gene with the risk for AD. While the evidence supports this association, further research is needed to elucidate the precise role of TREM2 in Alzheimer's disease pathology.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3243\n",
            "   Self-RAG: 0.1957\n",
            "   Improvement: -39.67% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 211\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Proteomic analyses need prior knowledge of the organism complete genome. Is the complete genome of the bacteria of the genus Arthrobacter available?\n",
            "\n",
            "🎯 Gold Answer: Yes, the complete genome sequence of Arthrobacter (two strains) is deposited in GenBank.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, the complete genome sequences of bacteria from the genus Arthrobacter are available based on the information provided in the context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, the complete genome sequences of bacteria from the genus Arthrobacter are available based on the information provided in the context from PubMed articles.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that the complete genome sequences of bacteria from the genus Arthrobacter are available. The evidence provided from PubMed articles supports this claim by referencing specific studies that have sequenced the genomes of Arthrobacter species.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main question by confirming the availability of complete genome sequences for Arthrobacter bacteria. However, it could be more comprehensive by mentioning the number of Arthrobacter species with sequenced genomes and the accessibility of these sequences in public databases.\n",
            "\n",
            "3. GROUNDING: The answer references specific evidence from PubMed articles, which adds credibility to the claim of the availability of Arthrobacter genome sequences. This strengthens the argument and provides a basis for the statement.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The evidence provided aligns with the claim made regarding the availability of Arthrobacter genome sequences.\n",
            "\n",
            "Overall, the initial answer is factually accurate, grounded in specific evidence from PubMed articles, and does not contain unsupported claims. However, it could be improved by providing more comprehensive information on the number of sequenced Arthrobacter genomes and where these sequences can be accessed.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on the evidence from PubMed articles, multiple complete genome sequences of Arthrobacter bacteria have been successfully obtained and documented. Specific studies have sequenced the genomes of Arthrobacter species such as Arthrobacter phenanthrenivorans (Sphe3) and Arthrobacter sp. Rue61a. These genome sequences are accessible in public databases, providing valuable resources for proteomic analyses.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4706\n",
            "   Self-RAG: 0.2154\n",
            "   Improvement: -54.23% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 212\n",
            "================================================================================\n",
            "\n",
            "📝 Question: The secreted frizzled-related protein 3 (sFPR3) is altered in human cancers.\n",
            "Are its level found to increase or to decrease?\n",
            "\n",
            "🎯 Gold Answer: Secreted frizzled-related protein 3 is potentially acting as a tumor suppressor gene, thus it is down-regulated (decreased) in some cancers.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The secreted frizzled-related protein 3 (sFRP3) is found to be down-regulated in some cancers.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The secreted frizzled-related protein 3 (sFRP3) is found to be down-regulated in human cancers.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that secreted frizzled-related protein 3 (sFRP3) is down-regulated in human cancers, which is supported by the evidence provided in Document 1 and Document 2. Both documents mention the down-regulation of sFRP3 in cancer contexts.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main aspect of the question by stating that sFRP3 is down-regulated in human cancers. However, it could have provided more context on the potential implications of this down-regulation in cancer development or progression.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 1 and Document 2) to support the claim that sFRP3 is down-regulated in human cancers. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the information provided in the evidence from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate, grounded in specific evidence, and does not include unsupported claims. It effectively addresses the question by stating that sFRP3 is down-regulated in human cancers. However, it could be strengthened by providing more context or implications of this down-regulation in the context of cancer biology.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "The secreted frizzled-related protein 3 (sFRP3) is down-regulated in human cancers, as supported by evidence from Document 1 and Document 2. This down-regulation of sFRP3 may indicate its role as a potential tumor suppressor gene. Additionally, altered Wnt signaling and down-regulation of frizzled-related proteins, including sFRP3, have been observed in various human cancers, suggesting a potential impact on cancer susceptibility and progression.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5789\n",
            "   Self-RAG: 0.3297\n",
            "   Improvement: -43.06% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 213\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Proteomic analyses have revealed proteins associated with the triple-negative breast cancers. List some proposed proteins.\n",
            "\n",
            "🎯 Gold Answer: Selected proteins of interest proposed from triple-negative cancer proteomic studies are CD44, PARP1, Mage-A4, LSR, RAB25, S100A14, MUC1, Hsp90, Actin, 14-3-3, vimentin, HSP70, CK18, moesin, IDH2, CRABP2, SEC14L2, beta-catenin, MUC18, Stat1 and CD74.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, some proposed proteins associated with triple-negative breast cancers include Mage-A4, lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14, mucin 1 (MUC1), and a 31-gene signature capable of predicting distant metastasis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Mage-A4, lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14, mucin 1 (MUC1)\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer provides a list of proteins associated with triple-negative breast cancers.\n",
            "2. The evidence from PubMed articles supports the presence of these proteins in the context of triple-negative breast cancer.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not mention Mage-A4 in the evidence provided, which may raise concerns about its inclusion in the list of proposed proteins.\n",
            "2. The evidence provided does not specifically mention the association of S100A14 with triple-negative breast cancers, which may weaken the claim.\n",
            "3. The initial answer could benefit from more direct references to the specific studies or experiments that identified these proteins in the context of triple-negative breast cancer.\n",
            "4. The initial answer does not address the potential roles or implications of these proteins in triple-negative breast cancers, which could provide a more comprehensive understanding of their significance in this context.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Mage-A4, lipolysis-stimulated lipoprotein receptor (LSR), RAB25, S100A14, mucin 1 (MUC1) have been proposed as proteins associated with triple-negative breast cancers. Evidence from PubMed articles supports the presence of LSR, RAB25, and MUC1 in this context. Specifically, a study identified Mage-A4 as a potential therapeutic target in estrogen receptor-negative breast cancer. Additionally, comparative proteomic and gene array analyses revealed LSR, RAB25, S100A14, and MUC1 as potential markers of breast cancer cells with tumor-initiating features. Further research is needed to fully elucidate the roles and implications of these proteins in triple-negative breast cancers.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2933\n",
            "   Self-RAG: 0.1765\n",
            "   Improvement: -39.84% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 214\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Where in the cell do we find the protein Cep135?\n",
            "\n",
            "🎯 Gold Answer: centrosome\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the protein Cep135 is found in the centrosome within the cell.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Cep135 is found in the centrosome within the cell.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the location of the protein Cep135 within the cell as the centrosome.\n",
            "2. The evidence from PubMed articles supports the claim that Cep135 is a component of the centrosome in various organisms.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of the evidence provided. It would be stronger if it directly referenced specific findings from the PubMed articles.\n",
            "2. The answer could be improved by providing more context on the role of Cep135 within the centrosome and its functions.\n",
            "3. The answer does not address any potential alternative locations or functions of Cep135 within the cell, which could provide a more comprehensive understanding of the protein.\n",
            "\n",
            "Overall, the initial answer is generally accurate but could benefit from more specific references to the evidence and additional information on the role of Cep135 within the centrosome.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Cep135 is a protein that is consistently found in the centrosome across various organisms, as supported by multiple PubMed articles. Specifically, research suggests that Cep135 serves as a structural component of the centrosome. Further investigation into the specific functions and interactions of Cep135 within the centrosome could provide a deeper understanding of its role in cellular processes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1176\n",
            "   Self-RAG: 0.0345\n",
            "   Improvement: -70.69% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 215\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Does strenuous physical activity affect thyroid hormone metabolism?\n",
            "\n",
            "🎯 Gold Answer: YES\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, there are controversial results regarding the impact of strenuous physical activity on thyroid hormone metabolism in adults. Limited data is available on the effects of strenuous exercise on thyroid hormone metabolism in children and adolescents. The relationship between physical activity and thyroid hormone metabolism appears to be complex and may vary depending on age and other factors.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Strenuous physical activity may impact thyroid hormone metabolism, with controversial results in adult athletes and limited data in children and adolescents. Additionally, even a modest excess of thyroid hormones has been associated with reduced physical function in elderly men, suggesting a potential relationship between thyroid hormone levels and physical activity.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions the controversial results in adult athletes and limited data in children and adolescents regarding the impact of strenuous physical activity on thyroid hormone metabolism.\n",
            "2. The answer references specific evidence from PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in detailing the nature of the controversial results in adult athletes and the limited data in children and adolescents. It lacks a clear synthesis of the evidence presented in the PubMed articles.\n",
            "2. The answer could benefit from a more direct connection between the evidence provided and the potential impact of strenuous physical activity on thyroid hormone metabolism.\n",
            "3. The mention of a potential relationship between thyroid hormone levels and physical activity in elderly men is somewhat speculative and not directly supported by the evidence presented in the PubMed articles.\n",
            "4. The answer could be improved by providing a more cohesive and structured analysis of the evidence presented, linking it more explicitly to the question at hand.\n",
            "\n",
            "Overall, the initial answer provides a good starting point but could be strengthened by providing a more detailed and focused analysis of the evidence presented in the PubMed articles to address the question more comprehensively.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Strenuous physical activity has been shown to have varying effects on thyroid hormone metabolism, with conflicting results observed in adult athletes and limited research available for children and adolescents. Studies suggest that even a slight increase in thyroid hormone levels may be linked to decreased physical function in elderly men. However, the direct relationship between thyroid hormone levels and physical activity remains complex and requires further investigation to fully understand the impact of strenuous exercise on thyroid hormone metabolism across different age groups.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0000\n",
            "   Self-RAG: 0.0000\n",
            "   Improvement: N/A (Both ROUGE-L scores are 0)\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 216\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which compounds exist that are thyroid hormone analogs?\n",
            "\n",
            "🎯 Gold Answer: Compoounds such as 3,5-diiodo-L-thyronine, T2, GC-24, CO23, DITPA, 3,5-diiodothyropropionic acid, GC-1, Tetrac, 3,3',5,5'-tetraiodo-thyroacetic acid, KB- 2115, KB - 141, thyronamines, T4-agarose, CGS 23425, D-T3, 3,3',5-triiodo-D-thyronine, 3,5-T2, 3,5-diiodo-L-thyronine, DIT, 3,5-diiodo-L-tyrosine, MIT, 3-monoiodo-L-tyrosine, triac, 3, 3',5-triiodo-thyroacetic acid, 3,5-Diiodo-4-hydroxyphenylpropionic acid, DIHPA, 3,5-Dimethyl-3'-isopropyl-L-thyronine, DIMIT, 3,5-diiodo-3'-isopropylthyroacetic acid and IpTA2 are compounds that are thyroid hormone analogs.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, some compounds that exist as thyroid hormone analogs include thyronamines, T4, rT3, D-T3, 3,5-T2, DIT, MIT, tetrac, triac, 3,5,3'-L-triiodothyronine, 3,5,3'-D-triiodothyronine, 3,3',5'-L-triiodothyronine, 3,5,3'-L-triiodothyroacetic acid, and 3,5-L-diiodothyronine.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Thyronamines, T4, rT3, D-T3, 3,5-T2, DIT, MIT, tetrac, triac, 3,5,3'-L-triiodothyronine, 3,5,3'-D-triiodothyronine, 3,3',5'-L-triiodothyronine, 3,5,3'-L-triiodothyroacetic acid, and 3,5-L-diiodothyronine are compounds that exist as thyroid hormone analogs.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer provides a comprehensive list of compounds that are described as thyroid hormone analogs.\n",
            "2. The answer references specific evidence from multiple PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not explicitly mention the compound 3,3',5'-L-triiodothyronine, which is mentioned in one of the provided PubMed articles.\n",
            "2. The answer could benefit from a clearer organization to distinguish between the different classes of compounds mentioned.\n",
            "3. The initial answer does not explicitly address the evidence from Document 1, which mentions thyronamines as thyroid hormone analogs.\n",
            "4. The answer could be improved by providing a brief explanation or context for each compound listed to enhance understanding for readers who may not be familiar with these compounds.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Thyronamines, T4, rT3, D-T3, 3,5-T2, DIT, MIT, tetrac, triac, 3,5,3'-L-triiodothyronine, 3,5,3'-D-triiodothyronine, 3,3',5'-L-triiodothyronine, 3,5,3'-L-triiodothyroacetic acid, and 3,5-L-diiodothyronine are compounds recognized as thyroid hormone analogs. Additionally, 3,3',5'-L-triiodothyronine is another compound mentioned in the provided evidence. These compounds have been identified in various studies as analogs of thyroid hormones, with thyronamines also being classified within this group. Further clarification on the distinctions between these compounds and their specific roles in thyroid hormone analogs can enhance understanding for readers.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3158\n",
            "   Self-RAG: 0.2786\n",
            "   Improvement: -11.77% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 217\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How does thyroid  hormone  regulate  SR-Ca2+ ATPase  (SERCA) protein in the heart?\n",
            "\n",
            "🎯 Gold Answer: The thyroid hormone (TH) induced regulation of  SERCA is mediated both by non-genomic and genomic actions.\n",
            "Genomic actions are mediated by the binding of T(3) receptors (TRs) to the thyroid response elements in the SERCA promotor and result in increased gene expression. \n",
            "Thyroid hormone  increases the transcription of  SERCA 2  through three thyroid hormone response elements. \n",
            "Data show that the regulation of  cardiac SERCA by thyroid hormone is made at the  pretranslational and possibly transcriptional level \n",
            "TRβ1 is shown to be coupled to the expression of SERCA in the heart\n",
            "An  increase of TR expression in the hypertrophied heart has been show to result in  increased SERCA expression.\n",
            "Inhibition of TRα1 by dronedarone does not change the expression of SERCA in the heart\n",
            "Findings show that  SERCA 2 gene expression  is regulated  by TR  isoform-specific interactions with transcription factor (MEF-2) \n",
            "Hypothyroidism is accompanied by decreased expression of SERCA in the heart.   T3 increases expression of the cardiac SERCA\n",
            "TH treatment can reverse the reduction in the ratio of SERCA to phospholamban expression which is found in postinfarcted hearts\n",
            "TH treatment  results in increased expression of SERCA in hearts from banded rats\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Thyroid hormone regulates SR-Ca2+ ATPase (SERCA) protein in the heart by influencing the mRNA encoding the protein, potentially at a pretranslational and transcriptional level. The responsiveness of SR-Ca2+ ATPase mRNA to thyroid hormone has been established.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Thyroid hormone regulates SR-Ca2+ ATPase (SERCA) protein in the heart by influencing the mRNA encoding the protein, potentially at the pretranslational and transcriptional levels.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions that thyroid hormone influences the mRNA encoding the SERCA protein in the heart.\n",
            "2. The answer is supported by evidence from PubMed articles, specifically mentioning the influence of thyroid hormone on the mRNA encoding the SR-Ca2+ ATPase.\n",
            "\n",
            "Weaknesses:\n",
            "1. The answer could be more specific in detailing the mechanisms through which thyroid hormone regulates the SERCA protein. While it mentions potential effects at the pretranslational and transcriptional levels, it could provide more in-depth information on these processes.\n",
            "2. The answer does not fully address how thyroid hormone specifically regulates the SR-Ca2+ ATPase protein function or activity in the heart.\n",
            "3. The evidence provided from the PubMed articles supports the influence of thyroid hormone on the mRNA encoding the SERCA protein but does not directly confirm the regulation of the protein's function or activity by thyroid hormone.\n",
            "4. The answer could benefit from including more detailed information on the specific pathways or signaling mechanisms involved in the regulation of SERCA by thyroid hormone.\n",
            "\n",
            "Overall, the initial answer provides a basic understanding of the relationship between thyroid hormone and SERCA regulation but lacks specificity and depth in explaining the mechanisms involved. More detailed information and specific references to the regulation of SERCA function by thyroid hormone would enhance the answer's accuracy and completeness.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Thyroid hormone regulates SR-Ca2+ ATPase (SERCA) protein in the heart by primarily influencing the mRNA encoding the protein at pretranslational and transcriptional levels. Specifically, thyroid hormone has been shown to affect the expression of the SERCA 2 gene in cardiac tissue. While the exact mechanisms through which thyroid hormone modulates SERCA protein function or activity are not fully elucidated, evidence suggests a pretranslational and potentially transcriptional level effect on the cardiac SR Ca2+ pump gene. Further research is needed to fully understand the specific pathways and signaling mechanisms involved in the regulation of SERCA by thyroid hormone.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1447\n",
            "   Self-RAG: 0.2169\n",
            "   Improvement: +49.95% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 218\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is cocaine use associated with increased risk for intracerebral hemorrhage?\n",
            "\n",
            "🎯 Gold Answer: Cocaine use is associated with increased incidence of intracranial hemorrhages most likely due to pressure increases.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context from PubMed articles, it is evident that there is an association between cocaine use and an increased risk for intracerebral hemorrhage.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, based on the provided context from PubMed articles, cocaine use is associated with an increased risk for intracerebral hemorrhage.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that there is an association between cocaine use and intracerebral hemorrhage.\n",
            "2. The answer provides specific evidence from PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The answer lacks specificity in terms of the strength of the association between cocaine use and intracerebral hemorrhage. It would be beneficial to mention if the association is strong or weak.\n",
            "2. The answer does not mention any potential limitations or conflicting evidence from the PubMed articles cited. It is important to acknowledge any nuances in the research findings.\n",
            "3. The answer could benefit from a more detailed explanation of the mechanisms through which cocaine use may increase the risk of intracerebral hemorrhage.\n",
            "4. The answer does not explicitly state the sample size or quality of the studies cited, which is crucial for evaluating the reliability of the evidence presented.\n",
            "\n",
            "Overall, the initial answer provides a basic overview of the association between cocaine use and intracerebral hemorrhage but lacks depth in terms of discussing the strength of the association, potential limitations, mechanisms involved, and details about the quality of the evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on the evidence from PubMed articles, there is a documented association between cocaine use and an increased risk for intracerebral hemorrhage. However, the strength of this association varies across studies and may be influenced by individual predisposing factors. Mechanisms contributing to cocaine-induced intracerebral hemorrhage include alterations in blood pressure, vascular integrity, and coagulation pathways. It is important to note that the quality and sample size of the studies cited may impact the reliability of these findings. Further research is needed to fully elucidate the complex relationship between cocaine use and intracerebral hemorrhage.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1905\n",
            "   Self-RAG: 0.1091\n",
            "   Improvement: -42.73% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 219\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How does exercise affect thyroid hormone receptors expression in the heart?\n",
            "\n",
            "🎯 Gold Answer: Exercise has been shown to increase  TRβ1 receptor expression in young rats.  Exercise has been shown to increase both TRα1 and  TRβ1 receptor expression in aged rats.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, there is no direct information regarding how exercise affects thyroid hormone receptor expression in the heart.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Exercise can potentially influence the expression of thyroid hormone receptors in the heart, as indicated by the documented correlation between thyroid hormone levels and myocardial functional status in patients with heart failure. Additionally, the effect of thyroid hormone on the expression of cardiac SR Ca2+ pump is dependent on thyroid hormone receptors, suggesting a potential role for exercise-induced changes in thyroid hormone levels on receptor expression in the heart.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that there is a correlation between thyroid hormone levels and myocardial functional status in heart failure patients, as supported by Document 1. It also correctly mentions that the effect of thyroid hormone on the expression of the cardiac SR Ca2+ pump is dependent on thyroid hormone receptors, as evidenced by Document 2.\n",
            "\n",
            "2. COMPLETENESS: The initial answer partially addresses the question by discussing the potential influence of exercise on thyroid hormone receptor expression in the heart. However, it could be improved by directly linking exercise to changes in thyroid hormone levels and receptor expression in the heart.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 1 and Document 2 to support the claims made about the correlation between thyroid hormone levels and myocardial functional status in heart failure patients, as well as the role of thyroid hormone receptors in the expression of the cardiac SR Ca2+ pump.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. \n",
            "\n",
            "Overall, the initial answer provides a reasonable explanation of how exercise may affect thyroid hormone receptor expression in the heart based on the available evidence. However, it could be strengthened by directly addressing the impact of exercise on thyroid hormone levels and receptor expression in the heart, as well as incorporating additional evidence to support these claims.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Exercise can impact thyroid hormone receptor expression in the heart by potentially modulating thyroid hormone levels. Studies have shown a correlation between changes in thyroid hormone levels and myocardial functional status in heart failure patients. Additionally, thyroid hormone receptors play a crucial role in regulating the expression of the cardiac SR Ca2+ pump. Research indicates that thyroid hormone (T3) can increase the expression of the cardiac SR Ca2+ pump, with this effect being dependent on thyroid hormone receptors. Therefore, exercise-induced changes in thyroid hormone levels may influence the expression of thyroid hormone receptors in the heart, potentially affecting cardiac function.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1569\n",
            "   Self-RAG: 0.1374\n",
            "   Improvement: -12.40% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 220\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the effects of depleting protein  km23-1 (DYNLRB1)  in a cell?\n",
            "\n",
            "🎯 Gold Answer: The knockdown of km23-1 results in numerous effects at the cellular level, such as decreased cell migration. Additionaly, km23-1 is involved in signalling pathways and its knockdown results in decreased RhoA activation, inhibition of TGFβ-mediated activation of ERK and JNK, phosphorylation of c-Jun, transactivation of the c-Jun promoter and decreased TGFbeta responses.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, depleting protein km23-1 (DYNLRB1) in a cell leads to decreased RhoA activation in Mv1Lu epithelial cells and is required for Smad2-dependent TGFbeta signaling.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Depleting protein km23-1 (DYNLRB1) in a cell decreases RhoA activation and is required for Smad2-dependent TGFbeta signaling.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer accurately mentions that depleting protein km23-1 (DYNLRB1) decreases RhoA activation, which is supported by evidence from Document 2.\n",
            "2. The answer also correctly states that km23-1 is required for Smad2-dependent TGFbeta signaling, which is backed by evidence from Document 3.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in directly linking the effects of depleting km23-1 to the mentioned cellular responses. While it mentions the effects on RhoA activation and TGFbeta signaling, it could benefit from more explicit connections to these outcomes.\n",
            "2. The answer could be more complete by providing additional context or details on the specific mechanisms through which km23-1 depletion affects RhoA activation and TGFbeta signaling.\n",
            "3. The answer does not address the broader implications or potential consequences of depleting km23-1 in a cell beyond the immediate effects on RhoA activation and TGFbeta signaling.\n",
            "\n",
            "Overall, the initial answer is partially accurate in its claims but could be strengthened by providing more detailed and specific explanations supported by the evidence provided.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Depleting protein km23-1 (DYNLRB1) in a cell has been shown to decrease RhoA activation, as evidenced by knockdown studies in Mv1Lu epithelial cells. Additionally, km23-1 is essential for Smad2-dependent TGFbeta signaling, highlighting its role in this pathway. The specific mechanisms through which km23-1 depletion affects RhoA activation and TGFbeta signaling require further investigation for a comprehensive understanding of its cellular impact. Further research is needed to elucidate the broader implications and potential consequences of depleting km23-1 beyond its immediate effects on these pathways.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2299\n",
            "   Self-RAG: 0.2313\n",
            "   Improvement: +0.61% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 221\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Albumin depletion is a common first step for proteomic analysis of CSF fluid. What is the advantage and disadvantage of this procedure?\n",
            "\n",
            "🎯 Gold Answer: Depletion of the high abundant protein Albumin from CSF samples is improving the detection of lower abundant proteins but may also lead to the potential loss of non-target proteins.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Advantage: Albumin depletion in CSF can improve protein profiling pattern and reproducibility in proteomic analysis.\n",
            "\n",
            "Disadvantage: Insufficient information provided to determine specific disadvantages of albumin depletion in CSF.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Advantage: Albumin depletion in CSF can improve protein profiling pattern and reproducibility in proteomic analysis, allowing for better detection of lower-abundance components of clinical interest.\n",
            "\n",
            "Disadvantage: There is no mention of a specific disadvantage in the provided context.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that albumin depletion in CSF can improve protein profiling pattern and reproducibility in proteomic analysis, allowing for better detection of lower-abundance components of clinical interest. This claim is supported by the evidence provided in Document 1 and Document 3.\n",
            "\n",
            "2. COMPLETENESS: The initial answer only addresses the advantage of albumin depletion in CSF for proteomic analysis and does not mention any specific disadvantage. This is a weakness as it does not provide a balanced view of the procedure.\n",
            "\n",
            "3. GROUNDING: The initial answer does not reference specific evidence to support the advantage of albumin depletion in CSF for proteomic analysis. It would be stronger if it directly cited the studies mentioned in the evidence provided.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims.\n",
            "\n",
            "Overall, the initial answer accurately highlights the advantage of albumin depletion in CSF for proteomic analysis, but it lacks completeness by not addressing any specific disadvantages. It would benefit from referencing specific evidence to strengthen its grounding in scientific literature.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "\n",
            "Advantage: Albumin depletion in CSF can improve protein profiling pattern and reproducibility in proteomic analysis, allowing for better detection of lower-abundance components of clinical interest. This procedure has been shown to enhance the specificity and sensitivity of detecting biomarkers in CSF samples, leading to more accurate diagnostic and prognostic assessments.\n",
            "\n",
            "Disadvantage: One potential disadvantage of albumin depletion in CSF is the risk of unintentional removal of non-albumin proteins that may be of interest in the proteomic analysis. Careful consideration and validation of the depletion method are necessary to ensure that important biomarkers are not lost during the process.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2069\n",
            "   Self-RAG: 0.1970\n",
            "   Improvement: -4.80% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 222\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Does thyroid hormone regulate calcium transient in the myocardium? \n",
            "\n",
            "🎯 Gold Answer: YES\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, thyroid hormone influences the calcium transient in the myocardium by affecting the duration of contraction and increasing the expression of the cardiac SR Ca2+ pump.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, thyroid hormone influences the calcium transient in the myocardium by affecting the expression of the cardiac SR Ca2+ pump and modulating the duration of contraction.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that thyroid hormone influences the calcium transient in the myocardium.\n",
            "2. The answer is supported by evidence from PubMed articles, which adds credibility to the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in detailing how thyroid hormone influences the calcium transient in the myocardium. It mentions the effects on the expression of the cardiac SR Ca2+ pump and the duration of contraction but could elaborate on the mechanisms involved.\n",
            "2. The answer does not directly address whether thyroid hormone regulates calcium transient in the myocardium but rather focuses on its influence on specific components involved in calcium handling.\n",
            "3. The evidence provided from the PubMed articles supports the influence of thyroid hormone on calcium handling components but does not directly confirm the regulation of calcium transient in the myocardium by thyroid hormone.\n",
            "4. The initial answer could benefit from a more explicit connection between the evidence presented and the specific question being asked.\n",
            "\n",
            "Overall, the initial answer provides some relevant information supported by evidence but could be improved by providing a more detailed and direct explanation of how thyroid hormone regulates calcium transient in the myocardium.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Thyroid hormone influences calcium handling in the myocardium by affecting the expression of the cardiac SR Ca2+ pump and modulating the duration of contraction. While evidence suggests that thyroid hormone can impact the time course of the calcium transient and increase the expression of the cardiac SR Ca2+ pump, direct confirmation of thyroid hormone's regulation of calcium transient in the myocardium is still under investigation. Further research is needed to elucidate the specific mechanisms through which thyroid hormone may regulate calcium transient in the myocardium.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0625\n",
            "   Self-RAG: 0.0000\n",
            "   Improvement: -100.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 223\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the advantage of using long nano columns in proteomics?\n",
            "\n",
            "🎯 Gold Answer: The longer the columns, the longer gradients are applied and finally more proteins (increased peak capacity) are identified in a complex  proteomic experiment\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The advantage of using long nano columns in proteomics is that they facilitate deep, sensitive, and reproducible proteome analysis by allowing for deep sampling of the proteome, providing high resolution separations, and enabling rapid equilibration and loading of samples.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The advantage of using long nano columns in proteomics is to facilitate deep sampling of the proteome, leading to rapid, sensitive, and reproducible proteome analysis with very high resolutions when required.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that using long nano columns in proteomics can facilitate deep sampling of the proteome, leading to rapid, sensitive, and reproducible proteome analysis with high resolutions when required. This claim is supported by evidence from Document 1, Document 2, and Document 3.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main advantage of using long nano columns in proteomics, which is deep sampling of the proteome. However, it could be more comprehensive by mentioning other potential advantages or discussing any limitations associated with using long nano columns.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 1, Document 2, and Document 3) to support the claims made about the advantages of using long nano columns in proteomics. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. All statements made are backed up by evidence from scientific articles.\n",
            "\n",
            "Overall, the initial answer provides a solid explanation of the advantages of using long nano columns in proteomics, supported by specific evidence from scientific literature. It could be further improved by discussing potential limitations or other advantages of this approach.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Using long nano columns in proteomics offers the advantage of facilitating deep sampling of the proteome, enabling rapid, sensitive, and reproducible proteome analysis with high resolutions when needed. This approach, supported by evidence from Document 1, Document 2, and Document 3, allows for comprehensive proteome coverage and efficient sample loading and equilibration. While the primary benefit is deep proteome sampling, other advantages include rapid analysis, sensitivity, and reproducibility. It is important to note that long nano columns may be particularly beneficial in research requiring very high resolutions, such as certain proteomics studies.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1290\n",
            "   Self-RAG: 0.1043\n",
            "   Improvement: -19.13% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 224\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Where can we find the protein lacritin?\n",
            "\n",
            "🎯 Gold Answer: The protein lacritin can be found in lacrimal and salivary glands as well as in tear fluid and in the thyroid.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Lacritin protein can be found in human lacrimal gland, major and minor salivary glands, and slightly in the thyroid gland. No lacritin protein is detected in other human tissues examined.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Lacritin protein can be found in human lacrimal gland, major and minor salivary glands, and slightly in the thyroid.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions that lacritin protein can be found in the human lacrimal gland, major and minor salivary glands, and slightly in the thyroid.\n",
            "2. The answer is grounded in evidence from PubMed articles, specifically mentioning lacritin being secreted from lacrimal acinar cells and its expression in different glands.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not fully address the question as it does not explicitly state that lacritin is highly expressed in the lacrimal gland, moderately in major and minor salivary glands, and slightly in the thyroid.\n",
            "2. The answer could be more precise in stating that lacritin mRNA and protein are highly expressed in the lacrimal gland, moderately in major and minor salivary glands, and slightly in the thyroid, as supported by the evidence from PubMed articles.\n",
            "3. The initial answer could benefit from directly quoting or paraphrasing the specific evidence from the PubMed articles to strengthen its grounding and credibility.\n",
            "4. The initial answer does not include any unsupported claims or hallucinations.\n",
            "\n",
            "Overall, the initial answer is mostly accurate but could be improved by providing a more detailed and precise explanation based on the specific evidence from the PubMed articles.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Lacritin mRNA and protein are highly expressed in the human lacrimal gland, moderately in major and minor salivary glands, and slightly in the thyroid. This information is supported by evidence from PubMed articles indicating lacritin secretion from lacrimal acinar cells and its specific expression in these glands. No lacritin message or protein has been detected in other human tissues among over 50 examined.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5098\n",
            "   Self-RAG: 0.2381\n",
            "   Improvement: -53.30% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 225\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is known about Vancomycin dosing in neonates?\n",
            "\n",
            "🎯 Gold Answer: Staphylococcus epidermis, including methicillin-resistant strains, are inhibited by vancomycin concentrations of 1-4 µg/ml. \n",
            "Staphylococcus pyogenes, Streptococcus pneumonia, and Streptococcus viridans are susceptible to 2 µg/ml vancomycin. \n",
            "Bacillus spp. are inhibited by 2 µg/ml, Corynebacterium spp. by 0.04-3.1 µg/ml and Clostridium spp. by 0.39-6 µg/ml vancomycin. \n",
            "Peak and trough concentrations of vancomycin should be 40 μg/ml and 10 μg/ml, respectively, to both be effective and avoid oto- or nephrotoxicity in adults. There is no ideal pattern of vancomycin dosing; vancomycin dosages must be individualized. Because vancomycin activity is primarily time-dependent, the 24-h area under the curve (AUC0-24h) divided by the minimum inhibitor concentration (MIC) value (AUC0-24h/MIC) is a better predictor of efficacy. In adults with MIC values less than 1 μg/ml, trough concentrations greater than 10 µg/ml result in AUC0-24h/MIC values 400\n",
            "Compared with adults, neonates have a higher extracellular fluid volume and a limited renal elimination capacity resulting in different pharmacokinetics subject to maturation stage.  Infants weighing less than 1,000 gm had significantly larger volumes of drug distribution and consequently longer drug half-lives than larger premature infants, regardless of postconceptual or actual age. These differences alter the vancomycin dosing recommendations in these two groups of premature infants.\n",
            "Vancomycin-associated nephrotoxicity is rare in neonates, even with serum peak concentrations 40 microg/mL. Vancomycin is associated with ototoxicity.\n",
            "There is no consensus on vancomycin dosing in newborns and young infants, which leads to significant variation in vancomycin dosing regimens and TDM guidance across neonatal units. The development of standardized, evidence-based protocols should be prioritized.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Vancomycin dosing in neonates is variable, with differences in dosing recommendations based on weight categories. Infants weighing less than 1,000 gm may require higher initial doses compared to larger premature infants. Monitoring of serum vancomycin concentrations is recommended for optimal therapy. Standardized, evidence-based protocols for vancomycin dosing in neonates are needed.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Vancomycin dosing in neonates varies based on weight, with infants weighing less than 1,000 gm requiring a loading dose of 25 mg/kg followed by 15 mg/kg every 12 hours, while infants over 1,000 gm should receive 10 mg/kg every 12 hours with a loading dose of 12.5 mg/kg. Serum vancomycin concentration monitoring is recommended for therapy optimization.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that vancomycin dosing in neonates varies based on weight, with specific dosing recommendations provided for infants under 1,000 gm and over 1,000 gm. This information is supported by Document 2, which outlines the dosing regimens based on weight categories.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the dosing recommendations for vancomycin in neonates based on weight categories, including loading doses and maintenance doses. However, it could have further elaborated on the importance of serum vancomycin concentration monitoring for therapy optimization, which is briefly mentioned but not fully explained.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 2 to support the dosing recommendations provided for vancomycin in neonates. This strengthens the credibility of the information presented.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The dosing recommendations and the need for serum vancomycin concentration monitoring are all supported by evidence from Document 2.\n",
            "\n",
            "Overall, the initial answer provides accurate information on vancomycin dosing in neonates based on weight categories, supported by specific evidence from Document 2. It could be improved by further elaborating on the importance of serum vancomycin concentration monitoring for therapy optimization.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Vancomycin dosing in neonates varies based on weight, with infants weighing less than 1,000 gm requiring a loading dose of 25 mg/kg followed by 15 mg/kg every 12 hours, while infants over 1,000 gm should receive 10 mg/kg every 12 hours with a loading dose of 12.5 mg/kg. These dosing recommendations are supported by Document 2, which highlights the differences in drug distribution and half-lives between the weight categories. It is crucial to monitor serum vancomycin concentrations for therapy optimization, as recommended in Document 2. Standardized, evidence-based protocols for dosing and therapeutic drug monitoring (TDM) in neonatal units are essential, as emphasized in Document 3.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1386\n",
            "   Self-RAG: 0.1418\n",
            "   Improvement: +2.32% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 226\n",
            "================================================================================\n",
            "\n",
            "📝 Question: A common problem in proteomics is the contamination of samples with exogenous proteins (often from other species). These proteins can be found in specific databases. List some contaminants.\n",
            "\n",
            "🎯 Gold Answer: Some common contaminants in proteomics are proteases (used for the digestion of the proteins), keratins (usually from the skin),  proteins originated from the serum of the culture media and antibodies if used in the experiment.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the contaminants that can be found in proteomics samples include exogenous proteins from other species.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Common contaminants in proteomics samples can include proteins from species such as bovine, porcine, and yeast.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies bovine, porcine, and yeast as common contaminants in proteomics samples.\n",
            "2. The evidence provided from PubMed articles supports the general idea of studying proteins in proteomics.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in listing contaminants beyond bovine, porcine, and yeast. The evidence does not directly support these specific contaminants.\n",
            "2. The evidence provided does not directly address the issue of sample contamination with exogenous proteins from other species.\n",
            "3. The initial answer could benefit from referencing specific studies or databases that list common contaminants in proteomics samples.\n",
            "4. The initial answer does not provide a comprehensive list of potential contaminants, which could limit the reader's understanding of the topic.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks specificity and direct evidence to fully support the claims made. It would be improved by providing a more detailed and evidence-based list of common contaminants in proteomics samples.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "\n",
            "Common contaminants in proteomics samples can include proteins from species such as bovine, porcine, yeast, E. coli, and mouse. Studies have shown that these contaminants can impact the accuracy of proteomic analyses (Document 1). The Chromosome-centric Human Proteome Project (C-HPP) and the Human Proteome Project (HPP) aim to identify and characterize proteins, emphasizing the importance of understanding and mitigating sample contamination in proteomics research (Document 2, Document 3). Researchers can refer to databases like the Contaminant Repository for Affinity Purification (CRAPome) for a comprehensive list of potential contaminants in proteomics samples.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1818\n",
            "   Self-RAG: 0.2154\n",
            "   Improvement: +18.46% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 227\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are there randomised controlled trials on sevoflurane?\n",
            "\n",
            "🎯 Gold Answer: Yes. There are < 10 studies reported, answering questions like : how to improve speed of recovery, relationship to dreaming and anesthetic experience, effect on cardiac troponin release, effect on myocardial injury, postoperative delirium,  haemodynamics & emergence and recovery characteristics of total intravenous anaesthesia,  costs of postoperative nausea and vomiting, pediatric conscious sedation for dental procedures\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, there is a randomised controlled trial on sevoflurane mentioned in Document 1.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, there is a randomised controlled trial on sevoflurane mentioned in the provided context.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies the presence of a randomised controlled trial on sevoflurane.\n",
            "2. The evidence provided from PubMed articles supports the claim that there are studies involving sevoflurane.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not specify which particular randomised controlled trial on sevoflurane is being referred to. It would be more informative to provide details such as the title, authors, and publication date of the trial.\n",
            "2. The evidence provided includes information on various studies involving sevoflurane but does not directly link to a specific randomised controlled trial. It would be more beneficial to directly reference a specific trial to strengthen the argument.\n",
            "3. The initial answer could benefit from a more detailed analysis of the methodology and results of the randomised controlled trial to provide a more comprehensive evaluation.\n",
            "\n",
            "Overall, while the initial answer correctly identifies the presence of randomised controlled trials on sevoflurane, it could be improved by providing more specific details and directly referencing a particular trial to enhance the credibility of the claim.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "There are several randomised controlled trials involving sevoflurane. One example is a multicentre trial that included 98 adult patients who received intravenous propofol for induction followed by sevoflurane maintenance anaesthesia. Additionally, studies have explored the prophylactic use of clonidine against sevoflurane-induced agitation and the safe and effective use of sevoflurane for short-term sedation in ICU patients with stable hemodynamic conditions. Further details on specific trials, including titles, authors, and publication dates, can provide a more comprehensive understanding of the research landscape surrounding sevoflurane.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0909\n",
            "   Self-RAG: 0.1304\n",
            "   Improvement: +43.48% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 228\n",
            "================================================================================\n",
            "\n",
            "📝 Question: List all clinical trials of the polypill.\n",
            "\n",
            "🎯 Gold Answer: 'Use of a Multidrug Pill In Reducing cardiovascular Events' (UMPIRE) trial, European Clinical Trials database, as EudraCT: 2009-016278-34 and the Clinical Trials Registry, India as CTRI/2010/091/000250.\n",
            "'IMProving Adherence using Combination Therapy (IMPACT)', Australian New Zealand Clinical Trial Registry (ACTRN12606000067572).\n",
            "'Kanyini Guidelines Adherence with the Polypill (Kanyini-GAP)'\n",
            "Phase II study of the Polycap, double-blind, randomised trial, registered with ClinicalTrials.gov, number NCT00443794\n",
            "Second Indian Polycap Study, TIPS-2\n",
            "Cluster Randomized Usual Care vs Caduet Investigation Assessing Long-term-risk (CRUCIAL trial)\n",
            "GEMINI trial, 14-week, open-label trial conducted in 1220 patients from the USA\n",
            "GEMINI-Australia, Asia, Latin America, Africa/Middle East (AALA) study \n",
            "JEWEL study program, with JEWEL 1 conducted among 1138 patients from the UK and Canada and JEWEL 2 conducted in 1107 patients from Europe\n",
            "CAPABLE54, the Clinical Utility of Caduet in Simultaneously Achieving Blood Pressure and Lipid End Points , in the USA\n",
            "CUSP (The Caduet® in an Untreated Subject Population trial)\n",
            "TOGETHER trial\n",
            "A randomised controlled trial in seven countries – Australia, Brazil, India, Netherlands , New Zealand , United Kingdom  and United States.   Australian New Zealand Clinical Trials Registry (ACTRN 12607000099426)\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "1. Indian Polycap Study (TIPS)\n",
            "2. Second Indian Polycap Study (TIPS-2)\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "1. The double-blinded Indian Polycap Study (TIPS)\n",
            "2. The Second Indian Polycap Study (TIPS-2)\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately lists two clinical trials of the polypill, the Indian Polycap Study (TIPS) and the Second Indian Polycap Study (TIPS-2). The evidence from the provided PubMed articles supports the existence of these trials.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the question by listing two specific clinical trials of the polypill. However, it could be more comprehensive by providing additional details such as the objectives, outcomes, and key findings of these trials.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the existence of the listed clinical trials. This grounding strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claims made about the existence of the Indian Polycap Study (TIPS) and the Second Indian Polycap Study (TIPS-2) are supported by evidence from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate and well-grounded in specific evidence from PubMed articles. However, it could be improved by providing more comprehensive information about the listed clinical trials, including their objectives, outcomes, and key findings.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "1. The double-blinded Indian Polycap Study (TIPS) was a primary prevention trial of a Polypill, indicating an overall benefit closer to 60%.\n",
            "2. The Second Indian Polycap Study (TIPS-2) compared risk factor reduction and tolerability of a full-dose polypill with potassium versus a low-dose polypill (polycap) in individuals at high risk of cardiovascular diseases.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0693\n",
            "   Self-RAG: 0.1200\n",
            "   Improvement: +73.14% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 229\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the reported adverse effects of gabapentin used in children?\n",
            "\n",
            "🎯 Gold Answer: Limited literature data, suggest that gabapentin may cause rash that is severe enough to necessitate discontinuation in a small percentage of children.\n",
            "In a large survey of all age groups: The commonest adverse effects seen were somnolence, fainting, ataxia, nystagmus, tremor and headache, fatigue. However, their incidence was low and intensity mild. In a pediatric group only somnolence and dizziness were reported in 2 out of 33 patients.\n",
            "Behavioural adverse effects are more common  in children with intellectual disability and attention deficit, worse in <10yo :  hyperactivity, defiance, irritability, agitation, aggression, explosive outbursts, oppositional behavior, often  warranting discontinuation of the medication.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The reported adverse effects of gabapentin used in children include skin reactions and fewer adverse effects compared to conventional anticholinergics.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The reported adverse effects of gabapentin used in children include skin reactions and fewer adverse effects compared to conventional anticholinergics.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately mentions skin reactions as an adverse effect of gabapentin in children, which is supported by Document 3. However, the claim about fewer adverse effects compared to conventional anticholinergics is not explicitly supported by the evidence provided.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses some reported adverse effects of gabapentin in children, specifically skin reactions. However, it does not mention other potential adverse effects that may have been reported in the literature.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claims made about the adverse effects of gabapentin in children. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims, which is a strength.\n",
            "\n",
            "Overall, the initial answer provides some accurate information about the reported adverse effects of gabapentin in children, specifically mentioning skin reactions. However, it could be improved by providing a more comprehensive list of potential adverse effects and ensuring that all claims are directly supported by the evidence provided.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The reported adverse effects of gabapentin used in children include skin reactions, as documented in Document 3. While Document 2 suggests that gabapentin is generally well tolerated with fewer adverse effects compared to conventional anticholinergics in children with OAB, a comprehensive list of potential adverse effects beyond skin reactions is not provided in the evidence. Further research may be needed to fully understand the spectrum of adverse effects associated with gabapentin use in children.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1167\n",
            "   Self-RAG: 0.1954\n",
            "   Improvement: +67.49% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 230\n",
            "================================================================================\n",
            "\n",
            "📝 Question: In what proportion of children with heart failure has Enalapril been shown to be safe and effective?\n",
            "\n",
            "🎯 Gold Answer: In children with heart failure evidence of the effect of enalapril is empirical. Enalapril was clinically safe and effective in 50% to 80% of for children with cardiac failure secondary to congenital heart malformations before and after cardiac surgery,  impaired ventricular function , valvar regurgitation,  congestive cardiomyopathy,  , arterial hypertension, life-threatening arrhythmias coexisting with circulatory insufficiency.   \n",
            "ACE inhibitors have shown a transient beneficial effect on heart failure due to anticancer drugs and possibly a beneficial effect in muscular dystrophy-associated cardiomyopathy, which deserves further studies.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "In the provided context, Enalapril was found to be safe and effective in 82% of children with heart failure.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "In 82% of children with heart failure, Enalapril has been shown to be safe and effective.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer claims that Enalapril has been shown to be safe and effective in 82% of children with heart failure. However, the evidence provided from the PubMed articles does support this claim. The evidence mentions that in 82% of children, the beneficial influence of angiotensin convertase inhibitor use was found, which indicates improvement compared to the state before the introduction of the inhibitor. However, it also states that in 10% of subjects, Enalapril did not show any significant therapeutic effect. Therefore, the claim that Enalapril is safe and effective in 82% of children is not entirely accurate.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not fully address all aspects of the question. It mentions the proportion of children in which Enalapril was found to be safe and effective but does not provide information on the safety and effectiveness separately. Additionally, it does not mention the specific subgroups of children with heart failure in which Enalapril was studied.\n",
            "\n",
            "3. GROUNDING: The initial answer does reference specific evidence from PubMed articles to support the claim, which is a strength. However, the interpretation of the evidence could be more accurate and nuanced.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence provided from the PubMed articles.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and nuanced interpretation of the evidence\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "In children with heart failure, Enalapril has been shown to have a beneficial influence in 82% of cases, leading to improvement compared to the state before its introduction. However, it is important to note that in 10% of subjects, Enalapril did not show significant therapeutic effects. Additionally, 12% of patients experienced side effects requiring discontinuation of Enalapril. The evidence suggests that Enalapril is clinically safe and effective for children with heart failure secondary to ventricular impairment, valvar regurgitation, or after cardiac surgery. Renal failure was noted as a concern in young infants with left-to-right shunts.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2524\n",
            "   Self-RAG: 0.2983\n",
            "   Improvement: +18.19% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 231\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the percentage of responders to tetrabenazine treatment for dystonia in children?\n",
            "\n",
            "🎯 Gold Answer: Tetrabenazine is used empirically in the treatment of dystonia in children with variable success. Observational studies report improvement of up to > 60% of the patients.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The provided context does not contain specific information on the percentage of responders to tetrabenazine treatment for dystonia in children.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Based on the provided context, the percentage of responders to tetrabenazine treatment for dystonia in children is 50% (1 out of 2 children).\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Critique:\n",
            "\n",
            "1. FACTUAL ACCURACY: The initial answer states that the percentage of responders to tetrabenazine treatment for dystonia in children is 50% based on 1 out of 2 children responding. However, the evidence provided does not specifically mention the percentage of responders in children or provide a clear numerical representation of the response rate in children. Therefore, the claim of 50% responders is not directly supported by the evidence.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not fully address all parts of the question. It focuses on the response to tetrabenazine treatment in children with dystonia but does not provide a comprehensive overview of the response rates in children based on the evidence provided.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim of responders to tetrabenazine treatment for dystonia in children. However, the evidence cited does not directly quantify the percentage of responders in children, leading to a lack of clarity in supporting the claim.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include unsupported claims or hallucinations. However, it extrapolates the response rate in children based on limited evidence, which may lead to an overgeneralization of the findings.\n",
            "\n",
            "Overall, the initial answer lacks direct evidence to support the claim of a 50% response rate to tetrabenazine treatment for dystonia in children. It would benefit from a more comprehensive analysis of the available evidence to provide a\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on the available evidence, the response rate to tetrabenazine treatment for dystonia in children is not explicitly stated. The evidence mentions cases of children with dystonia being treated with tetrabenazine, along with other medications, but does not provide a clear percentage of responders. Therefore, the specific percentage of responders to tetrabenazine treatment in children with dystonia remains uncertain based on the provided information.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2222\n",
            "   Self-RAG: 0.2022\n",
            "   Improvement: -8.99% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 232\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the known families of deadenylases?\n",
            "\n",
            "🎯 Gold Answer: All known deadenylases belong to either the DEDD or the exonuclease–endonuclease–phosphatase (EEP) superfamily. Members of DEDD include the POP2, CAF1Z, PARN and PAN2 families. Members of EEP include the CCR4, Nocturnin, ANGEL and 2'-PDE families.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The known families of deadenylases include PARN, Nocturnin, and Angel.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The known families of deadenylases include PARN, Nocturnin, and Angel.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies PARN, Nocturnin, and Angel as known families of deadenylases.\n",
            "2. The evidence from PubMed articles supports the claim that these three deadenylases are part of the multiple deadenylases described in eukaryotic cells.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of providing additional known families of deadenylases beyond PARN, Nocturnin, and Angel. The evidence suggests there are multiple deadenylases, but the answer does not elaborate on them.\n",
            "2. The answer could benefit from referencing specific details or characteristics of each known family of deadenylases to enhance the grounding of the response.\n",
            "3. The answer does not address the full scope of known families of deadenylases, as indicated by the evidence mentioning a set of multiple poly(A)-specific deadenylases beyond just PARN, Nocturnin, and Angel.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and specificity in addressing the full range of known families of deadenylases. It would be strengthened by providing more comprehensive information supported by specific evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The known families of deadenylases include PARN, Nocturnin, Angel, and a set of multiple poly(A)-specific deadenylases identified in eukaryotic cells. These deadenylases play a crucial role in the regulated shortening of the poly(A) tail during mRNA turnover. Further characterization and specific details of each known family of deadenylases can provide a more comprehensive understanding of their functions and mechanisms in cellular processes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2500\n",
            "   Self-RAG: 0.1748\n",
            "   Improvement: -30.10% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 233\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the relationship between nucleosomes and exons?\n",
            "\n",
            "🎯 Gold Answer: Nucleosomes are preferentially located within exons compared to nearby intronic sequences. Preferential positioning within the exons is indepedent of gene expression levels, stronger in exons with weak splice sites and conserved through metazoan evolution.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The relationship between nucleosomes and exons is that nucleosome occupation potential is significantly stronger in exons compared to their adjacent intron regions. Nucleosomes are well positioned in exons and carry characteristic histone modifications, marking the exon-intron structure.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Nucleosomes are more strongly positioned in exons compared to adjacent intron regions, suggesting a relationship between nucleosomes and gene exon architecture.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that nucleosomes are more strongly positioned in exons compared to adjacent intron regions, which is supported by evidence from multiple PubMed articles.\n",
            "2. The answer acknowledges the relationship between nucleosomes and gene exon architecture, which is consistent with the evidence provided.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from providing more specific details on the nature of the relationship between nucleosomes and exons. While it mentions that nucleosomes are more strongly positioned in exons, it does not delve into the functional implications or mechanisms behind this relationship.\n",
            "2. The answer could be strengthened by directly quoting or summarizing specific findings from the referenced PubMed articles to provide more concrete evidence for the claims made.\n",
            "3. The answer does not address potential limitations or conflicting evidence in the literature regarding the relationship between nucleosomes and exons. It would be beneficial to acknowledge any nuances or controversies in this area of research.\n",
            "\n",
            "Overall, the initial answer provides a generally accurate overview of the relationship between nucleosomes and exons, but it could be improved by providing more specific evidence and addressing potential limitations in the existing literature.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Nucleosomes exhibit stronger positioning within exons compared to adjacent intron regions, as supported by studies showing increased nucleosome occupation potential in exons. This relationship between nucleosomes and exons is further highlighted by the presence of characteristic histone modifications within exons, indicating a role in gene exon-intron architecture. Previous research has suggested a link between nucleosome positioning and the chromatin organization of the exon-intron structure. However, further investigation is needed to elucidate the functional implications and underlying mechanisms of this relationship, as well as to address any potential limitations or conflicting evidence in the literature.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2500\n",
            "   Self-RAG: 0.1846\n",
            "   Improvement: -26.15% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 234\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the treatment of triiodothyronine toxicosis?\n",
            "\n",
            "🎯 Gold Answer: Treatment of T3 toxicosis is a complex medical problem because not well responsive to the various options. Usual treatment includes antithyroid drugs such as propyltiouracil, radioactive iodine or beta blockers like propanol; surgery may be also necessary in some cases.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The treatment of triiodothyronine toxicosis in the provided context is propranolol at a dose of 160 mg/day, which led to a significant and sustained decrease in serum total T3 concentrations.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The treatment of triiodothyronine toxicosis is propranolol at a dose of 160 mg/day for 6 months, leading to a significant and sustained decrease in serum total T3 concentrations.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Critique:\n",
            "\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that the treatment of triiodothyronine toxicosis involves propranolol at a dose of 160 mg/day for 6 months, leading to a significant and sustained decrease in serum total T3 concentrations. This claim is supported by evidence from Document 1, which shows a significant and sustained fall in serum total T3 concentrations with this treatment regimen.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not address other potential treatment options for triiodothyronine toxicosis, such as Trihexyphenidyl, tetrabenazine, or verapamil, as mentioned in Documents 2 and 3. It would be more comprehensive to discuss these alternative treatments and their efficacy in managing the condition.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 1 to support the claim about the effectiveness of propranolol in reducing serum total T3 concentrations in patients with triiodothyronine toxicosis. However, it could benefit from incorporating evidence from Documents 2 and 3 to provide a more well-rounded evaluation of treatment options.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence presented in Document 1 regarding the use of propranolol in treating triiodothyronine toxicosis.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in specific evidence from Document 1. However\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The treatment of triiodothyronine toxicosis can involve various options. Propranolol at a dose of 160 mg/day for 6 months has been shown to lead to a significant and sustained decrease in serum total T3 concentrations (Document 1). Additionally, alternative treatments such as Trihexyphenidyl, tetrabenazine, and verapamil have been reported to be effective in managing the condition (Documents 2 and 3). It is important to consider individual patient responses and potential side effects when selecting the most appropriate treatment approach.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1972\n",
            "   Self-RAG: 0.1667\n",
            "   Improvement: -15.48% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 235\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How could we infer functional associations from gene fusion events?\n",
            "\n",
            "🎯 Gold Answer: The detection of gene fusion events across genomes can be used for the prediction of functional associations of proteins, based on the observation that related proteins in one organism (including physically interacting proteins/members of complexes, proteins involved in the same pathway) tend to be found in other species as a fused composite gene encoding a single multifunctional protein. For this purpose, gene fusion events may be used as the sole evidence or as independent information combined with other 'genome-aware' or similarity-based methods, and functional association may be predicted at different levels. An advantage of this approach is that it is not necessary to know the function of the composite/components to infer association.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, we can infer functional associations from gene fusion events by detecting gene fusion events across genomes, which can be used for predicting physical interactions or complex formation among proteins.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Functional associations can be inferred from gene fusion events by predicting physical interactions or complex formation among proteins within genomes.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Critique:\n",
            "\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that functional associations can be inferred from gene fusion events by predicting physical interactions or complex formation among proteins. This claim is supported by evidence from PubMed articles, specifically Document 1 and Document 2, which both mention the use of gene fusion events for predicting functional associations.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main aspect of inferring functional associations from gene fusion events by focusing on predicting physical interactions or complex formation among proteins. However, it could be more comprehensive by mentioning other potential ways to infer functional associations from gene fusion events, such as shared regulatory elements or pathway analysis.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 1 and Document 2) to support the claim that gene fusion events can be used for predicting functional associations of proteins. This grounding strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the information provided in the referenced PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate and well-grounded in evidence from PubMed articles. However, it could be more comprehensive by addressing other potential ways to infer functional associations from gene fusion events.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "\n",
            "Functional associations can be inferred from gene fusion events through various methods. In addition to predicting physical interactions or complex formation among proteins, other approaches include analyzing shared regulatory elements and conducting pathway analysis. These strategies leverage gene fusion events to elucidate functional associations of proteins within genomes. This information is supported by evidence from PubMed articles, specifically Document 1, Document 2, and Document 3, which highlight the diverse ways in which gene fusion events can be utilized to predict functional associations.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2133\n",
            "   Self-RAG: 0.2000\n",
            "   Improvement: -6.25% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 236\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is it possible to determine the proteome of a formalin fixed and paraffin embedded  (FFPE) tissue?\n",
            "\n",
            "🎯 Gold Answer: Yes, advances in sample preparation has enabled the proteomic analysis of formalin-fixed and paraffin-embedded tissues.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, it is possible to determine the proteome of formalin-fixed paraffin-embedded (FFPE) tissues based on the information provided in the context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, it is possible to determine the proteome of formalin-fixed paraffin-embedded (FFPE) tissues based on the information provided in the context.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that it is possible to determine the proteome of formalin-fixed paraffin-embedded (FFPE) tissues.\n",
            "2. The answer is supported by evidence from PubMed articles that specifically mention the ability to investigate the proteome of FFPE tissues.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specific details on the methods or challenges involved in determining the proteome of FFPE tissues. It would be beneficial to provide more information on the techniques used or limitations faced in this process.\n",
            "2. While the evidence from PubMed articles supports the general idea that proteome analysis of FFPE tissues is possible, the answer could be strengthened by referencing specific studies or findings that demonstrate successful proteome profiling from FFPE samples.\n",
            "3. The answer could benefit from addressing the potential impact of formalin fixation and paraffin embedding on the quality and integrity of proteins in FFPE tissues, as this is a critical aspect to consider when analyzing the proteome from such samples.\n",
            "\n",
            "Overall, the initial answer is generally accurate but could be improved by providing more detailed and specific information supported by relevant research studies in the field.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Yes, it is possible to determine the proteome of formalin-fixed paraffin-embedded (FFPE) tissues. Proteome analysis of FFPE tissues involves challenges such as protein cross-linking due to formalin fixation and protein degradation. Techniques like mass spectrometry have been utilized to identify and quantify proteins in FFPE samples. Recent advancements in clinical proteomics have enabled qualitative proteome profiling of FFPE tissues, contributing to the field's progress. Studies have shown successful proteome investigation in FFPE samples, highlighting the importance of considering the impact of fixation and embedding on protein quality and integrity during analysis.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4500\n",
            "   Self-RAG: 0.1607\n",
            "   Improvement: -64.29% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 237\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the most widely reported side-effects in the treatment of Crohn's disease?\n",
            "\n",
            "🎯 Gold Answer: Leukopenia, paresthesia, psoriasis, alopecia and hemolysis are the most commonly reported side effects depending on the treatment. Severe adverse effects include myelosuppression, liver toxicity and hyperplasia, pancreatitis and pericarditis. The most severe but rare side-effects reported are progressive multifocal leukoencephalopathy (PML), serious infections, and lymphoma.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The most widely reported side-effects in the treatment of Crohn's disease include acute pancreatitis, nodular regenerative hyperplasia, and a number of important adverse effects.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The most widely reported side-effects in the treatment of Crohn's disease are acute pancreatitis and nodular regenerative hyperplasia.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies acute pancreatitis and nodular regenerative hyperplasia as reported side effects in the treatment of Crohn's disease.\n",
            "2. The evidence provided from PubMed articles supports the claims made in the initial answer.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it only mentions two specific side effects (acute pancreatitis and nodular regenerative hyperplasia) without considering other widely reported side effects in the treatment of Crohn's disease.\n",
            "2. The grounding of the initial answer is limited to specific evidence from PubMed articles, which may not provide a comprehensive overview of all widely reported side effects.\n",
            "3. The initial answer does not address the full scope of the question, as it focuses solely on two specific side effects without considering other potential side effects that may be widely reported in the treatment of Crohn's disease.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "In addition to acute pancreatitis and nodular regenerative hyperplasia, other widely reported side effects in the treatment of Crohn's disease include but are not limited to liver toxicity, infections, and gastrointestinal disturbances. These adverse effects have been documented in various studies and clinical reports.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3056\n",
            "   Self-RAG: 0.2637\n",
            "   Improvement: -13.69% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 238\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How many tissue kallikrein genes are present in the human genome?\n",
            "\n",
            "🎯 Gold Answer: Tissue kallikreins (KLKs) are a group of closely related serine proteinases that are represented by multigene families in the human genome. The human tissue kallikrein gene family consists of 15 genes, denoted KLK1–KLK15, tandemly arranged on chromosomal locus 19q13.4.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The human genome contains 15 tissue kallikrein genes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "There are 15 tissue kallikrein genes present in the human genome.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that there are 15 tissue kallikrein genes present in the human genome, which is supported by the evidence provided from PubMed articles.\n",
            "2. The answer references specific evidence from multiple documents to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have provided more context or explanation about the significance of the tissue kallikrein gene family in the human genome.\n",
            "2. The answer does not explicitly address the fact that the tissue kallikrein genes are tandemly arranged on human chromosome 19q13.4, which could provide additional relevant information.\n",
            "3. The answer could have included a brief mention of the evolutionary conservation of kallikrein gene families in other species, as mentioned in Document 2, to provide a broader perspective.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in specific evidence but could benefit from additional context and completeness in addressing the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "There are 15 tissue kallikrein genes present in the human genome, all of which are tandemly arranged on human chromosome 19q13.4. The tissue kallikrein gene family is the largest contiguous family of proteases in the human genome. Additionally, kallikrein gene families have been identified in various species, including humans, mice, rats, and other organisms, indicating evolutionary conservation across species.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2449\n",
            "   Self-RAG: 0.2574\n",
            "   Improvement: +5.12% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 239\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the plant DNA (cytosine-5) methyltransferase families?\n",
            "\n",
            "🎯 Gold Answer: The plant DNA (cytosine-5)methyltransferases are classified into the families: MET, CMT, and the de novo DRM.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the plant DNA (cytosine-5) methyltransferase families mentioned are:\n",
            "1. Plant proteins with a novel arrangement of motifs required for DNA methyltransferase catalytic activity.\n",
            "2. Arabidopsis methylase with eight conserved sequence motifs found in prokaryote cytosine-5 methyltransferases.\n",
            "3. Zea methyltransferase2 (Zmet2) with a chromodomain, similar to Arabidopsis chromomethylases CMT1 and CMT3, containing C-terminal motifs characteristic of eukaryotic and prokaryotic DNA methyltransferases.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The plant DNA (cytosine-5) methyltransferase families mentioned in the provided context are:\n",
            "1. Novel arrangement of motifs required for DNA methyltransferase catalytic activity\n",
            "2. Arabidopsis methylase with conserved sequence motifs similar to prokaryote cytosine-5 methyltransferases\n",
            "3. Zea methyltransferase2 (Zmet2) with a chromodomain and sequence similarity to Arabidopsis chromomethylases CMT1 and CMT3\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer provides specific examples of plant DNA (cytosine-5) methyltransferase families, supported by evidence from PubMed articles.\n",
            "2. The answer references specific motifs and sequences related to DNA methyltransferase catalytic activity in plants.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not comprehensively cover all known plant DNA (cytosine-5) methyltransferase families. It only mentions specific examples like Arabidopsis methylase and Zea methyltransferase2.\n",
            "2. The answer could benefit from providing a broader overview of plant DNA methyltransferase families beyond the mentioned examples.\n",
            "3. While the evidence supports the claims made, the answer could be strengthened by including additional references or studies to further validate the information presented.\n",
            "4. The answer does not address the diversity and complexity of plant DNA methyltransferase families, which could enhance the completeness of the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Plant DNA (cytosine-5) methyltransferase families include diverse groups with unique characteristics. Some examples are:\n",
            "1. Proteins with a novel arrangement of motifs crucial for DNA methyltransferase catalytic activity.\n",
            "2. Arabidopsis methylase, which shares conserved sequence motifs with prokaryotic cytosine-5 methyltransferases.\n",
            "3. Zea methyltransferase2 (Zmet2) containing a chromodomain and sharing sequence similarity with Arabidopsis chromomethylases CMT1 and CMT3.\n",
            "\n",
            "These examples highlight the complexity and diversity of plant DNA methyltransferase families, as supported by evidence from PubMed articles. Further exploration of additional plant DNA methyltransferase families beyond these examples would provide a more comprehensive understanding of this field.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1860\n",
            "   Self-RAG: 0.1379\n",
            "   Improvement: -25.86% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 240\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is miR-21 related to carcinogenesis?\n",
            "\n",
            "🎯 Gold Answer: Yes. It has been demonstrated in several experimental studies that miR-21 has oncogenic potential,  and is significantly dysregulated in numerous types of cancer. Therefore, miR-21 is closely related to carcinogenesis.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, miR-21 is related to carcinogenesis based on the information provided in the context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, miR-21 is related to carcinogenesis based on the information provided in the context.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that miR-21 is related to carcinogenesis, which is supported by evidence from the provided PubMed articles.\n",
            "2. The answer acknowledges that miR-21 is implicated in various aspects of carcinogenesis, showing an understanding of the complexity of its role in cancer development.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in explaining the exact role of miR-21 in carcinogenesis. It would be beneficial to provide more detailed information on how miR-21 contributes to cancer development.\n",
            "2. The answer does not address the conflicting information presented in the evidence from Document 2, which states that the functions and molecular mechanisms of miR-21 in carcinogen-induced tumorigenesis are unclear. This omission weakens the overall argument for the relationship between miR-21 and carcinogenesis.\n",
            "3. The answer does not mention the uncertainty highlighted in Document 3 regarding the target gene of miR-21 in radiation-induced carcinogenesis. This omission raises questions about the completeness of the answer and the certainty of the relationship between miR-21 and carcinogenesis.\n",
            "4. The initial answer could benefit from providing a more balanced view by acknowledging the uncertainties and gaps in knowledge regarding miR-21's role in carcinogenesis, as indicated in the evidence from the provided PubMed articles.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "miR-21 has been associated with carcinogenesis, playing a role in various aspects of cancer development. However, the exact functions and molecular mechanisms of miR-21 in carcinogen-induced tumorigenesis remain unclear, as indicated in Document 2. Additionally, the specific target gene of miR-21 in radiation-induced carcinogenesis has not been definitively identified, as highlighted in Document 3. While miR-21's involvement in cancer is recognized, uncertainties persist regarding its precise contributions and mechanisms in different cancer contexts.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2979\n",
            "   Self-RAG: 0.1754\n",
            "   Improvement: -41.10% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 241\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the function of the viral KP4 protein?\n",
            "\n",
            "🎯 Gold Answer: The virally encoded fungal toxin KP4  specifically blocks L-type voltage-gated calcium channels.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The function of the viral KP4 protein is to exhibit an antifungal effect and potentially inhibit cell growth and division by blocking calcium-regulated signal transduction pathways.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The function of the viral KP4 protein is to exhibit antifungal activity and potentially inhibit cell growth and division by blocking calcium-regulated signal transduction pathways.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions the antifungal activity of the viral KP4 protein, which is supported by the evidence from PubMed articles.\n",
            "2. The statement about potentially inhibiting cell growth and division by blocking calcium-regulated signal transduction pathways is also supported by the evidence provided.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in detailing the mechanisms by which the viral KP4 protein exhibits antifungal activity and inhibits cell growth and division. It lacks a detailed explanation of how these functions are carried out.\n",
            "2. While the evidence from PubMed articles supports the claims made in the initial answer, the answer could be strengthened by directly quoting or referencing specific findings from these documents to provide a more grounded response.\n",
            "3. The initial answer does not explicitly mention the source of the information provided, which could weaken the credibility of the claims made.\n",
            "4. The initial answer does not address potential limitations or conflicting evidence regarding the function of the viral KP4 protein, which could provide a more balanced perspective on the topic.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The viral KP4 protein exhibits antifungal activity by targeting fungal cell membranes and disrupting their integrity. Additionally, KP4 may inhibit cell growth and division by interfering with calcium-regulated signal transduction pathways. This mechanism suggests a potential dual role in combating fungal infections and modulating cellular processes. The antifungal effect of KP4 has been supported by studies exploring its impact on fungal pathogens. Further research is needed to elucidate the precise molecular mechanisms underlying these functions and to address any potential limitations or conflicting evidence.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2439\n",
            "   Self-RAG: 0.1010\n",
            "   Improvement: -58.59% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 242\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is the H3K4me3 histone mark related to transcriptional initiation or elongation?\n",
            "\n",
            "🎯 Gold Answer: H3K4me3 is associated with transcriptionally active genes, but its function in the transcription process is still unclear. It is well known to occur in the promoter region of genes for transcription activation but its levels correlate positively with the antisense expression levels of the associated sense genes implying that it may be also involved in the activation of antisense transcription. Although it is mostly associated with transcription initiation H3K4me3 levels determine the efficiency of transcription elongation.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The H3K4me3 histone mark is related to transcriptional initiation.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The H3K4me3 histone mark is related to transcriptional initiation.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that the H3K4me3 histone mark is related to transcriptional initiation, which is supported by the evidence provided from PubMed articles.\n",
            "2. The answer is grounded in specific evidence from multiple sources, which strengthens its credibility.\n",
            "\n",
            "Weaknesses:\n",
            "1. The answer could be more complete by also mentioning that the H3K4me3 mark is associated with both active and poised promoters, not just transcriptional initiation.\n",
            "2. The answer does not explicitly address the possibility of the H3K4me3 mark being related to transcriptional elongation, which could provide a more comprehensive understanding of its role in gene expression regulation.\n",
            "3. There are no unsupported claims or hallucinations in the initial answer.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence but could benefit from a more comprehensive discussion of the role of the H3K4me3 histone mark in gene expression regulation.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The H3K4me3 histone mark is primarily associated with transcriptional initiation, as it is commonly found in the promoter regions of genes and is a mark of active and poised promoters. While it plays a crucial role in the initiation of transcription, it is also involved in maintaining the readiness of genes for activation. The evidence suggests that H3K4me3 is enriched around transcription start sites, indicating its importance in the early stages of gene expression. While its direct involvement in transcriptional elongation is less clear, further research is needed to fully understand its role in gene expression regulation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1176\n",
            "   Self-RAG: 0.3237\n",
            "   Improvement: +175.14% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 243\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the main histone modifications associated with enhancers?\n",
            "\n",
            "🎯 Gold Answer: Histone 3 lysine 4 mono- (H3K4me1) and di-methylation (H3K4me2) are the main post-transcriptional histone modifications related to enhancer activity.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Hyperacetylation of histones H3 and H4 is the main histone modification associated with enhancers.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Hyperacetylation of histones H3 and H4 is the main histone modification associated with enhancers.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies hyperacetylation of histones H3 and H4 as a main histone modification associated with enhancers.\n",
            "2. The evidence from Document 2 supports the claim that hyperacetylation of histones H3 and H4 is associated with enhancers.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it does not mention other important histone modifications associated with enhancers, such as histone methylations like H3K4me1, H3K4me3, H3K27me3, and H3K9me1, as indicated in Document 3.\n",
            "2. The initial answer could benefit from referencing additional evidence to support the claim about histone modifications associated with enhancers.\n",
            "3. The initial answer makes an unsupported claim by stating that hyperacetylation of histones H3 and H4 is the \"main\" histone modification associated with enhancers, without considering the broader spectrum of histone modifications involved.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and grounding in specific evidence. It should be revised to include a more comprehensive list of histone modifications associated with enhancers and reference additional supporting evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Histone modifications associated with enhancers include hyperacetylation of histones H3 and H4, as well as histone methylations like H3K4me1, H3K4me3, H3K27me3, and H3K9me1, as indicated in Document 3. These modifications collectively contribute to chromatin remodeling and transcriptional regulation at enhancer sites. Hyperacetylation of histones H3 and H4 is a well-established mark of active chromatin at enhancers, while histone methylations also play crucial roles in enhancer function. Additional evidence from Document 2 supports the role of hyperacetylation in establishing active chromatin states at enhancer loci.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4000\n",
            "   Self-RAG: 0.1321\n",
            "   Improvement: -66.98% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 244\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the main causes of fetal echogenic bowel?\n",
            "\n",
            "🎯 Gold Answer: Fetal echogenic bowel is mainly associated to feto-maternal, intramniotic bleeding but in several cases it is linked to cystic fibrosis, cytomegalovirus (CMV), herpes simplex virus and other viral infections and fetal aneuploidy.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The main causes of fetal echogenic bowel include intrauterine growth restriction (IUGR), intrauterine fetal demise, cystic fibrosis (CF), and intra-amniotic bleeding.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The main causes of fetal echogenic bowel include intrauterine growth restriction (IUGR), intrauterine fetal demise, cystic fibrosis (CF), and intra-amniotic bleeding.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies IUGR, intrauterine fetal demise, cystic fibrosis (CF), and intra-amniotic bleeding as potential causes of fetal echogenic bowel. The evidence from the PubMed articles supports these claims, indicating that echogenic bowel is associated with IUGR, intrauterine fetal demise, CF, and intra-amniotic bleeding.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses all the main causes of fetal echogenic bowel as supported by the evidence provided. It covers a range of potential underlying conditions that can lead to this ultrasound finding.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support each of the mentioned causes of fetal echogenic bowel. This strengthens the credibility of the claims made.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. Each cause mentioned is backed by evidence from reputable sources.\n",
            "\n",
            "Overall, the initial answer is factually accurate, complete, well-grounded in specific evidence, and does not include any unsupported claims. It effectively addresses the main causes of fetal echogenic bowel based on the available scientific literature.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The main causes of fetal echogenic bowel include intrauterine growth restriction (IUGR), intrauterine fetal demise, cystic fibrosis (CF), and intra-amniotic bleeding. Echogenic bowel has been associated with an increased risk for adverse fetal outcomes, such as cystic fibrosis, and can also be a normal variant in the second trimester. Intra-amniotic bleeding is another potential cause of echogenic bowel. These associations are supported by evidence from PubMed articles.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2182\n",
            "   Self-RAG: 0.1373\n",
            "   Improvement: -37.09% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 245\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are CpG islands located close to housekeeping genes?\n",
            "\n",
            "🎯 Gold Answer: Yes, CpG islands are preferentially located at the start of transcription of housekeeping genes and are associated with tissue-specific genes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, CpG islands are located close to housekeeping genes, specifically at the 5'-end or start of transcription of these genes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, CpG islands are located close to housekeeping genes, particularly at the 5'-end or start of transcription sites.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that CpG islands are located close to housekeeping genes.\n",
            "2. The answer provides specific information about the location of CpG islands, particularly at the 5'-end or start of transcription sites.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it does not mention that CpG islands can also be associated with tissue-specific genes, as indicated in Document 2.\n",
            "2. The answer could benefit from referencing specific evidence more directly, such as citing the specific PubMed articles and their findings.\n",
            "3. The claim that CpG islands are \"found almost exclusively at the 5'-end of housekeeping genes\" may be an oversimplification as Document 3 mentions that CpG islands are often observed near the transcriptional start sites of housekeeping genes, which may not always be exclusively at the 5'-end.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "CpG islands are commonly found near the transcriptional start sites of genes, including both housekeeping genes and tissue-specific genes. While they are preferentially located at the start of transcription of housekeeping genes, CpG islands can also be associated with tissue-specific genes. This information is supported by various studies (Document 1, Document 2, Document 3).\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5714\n",
            "   Self-RAG: 0.4557\n",
            "   Improvement: -20.25% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 246\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are nucleosomes positioned at DNA replication origins?\n",
            "\n",
            "🎯 Gold Answer: No, origins of replication occur in nucleosome-free regions in both budding yeast and Drosophila. Open chromatin domains, characterized by nucleosome depletion, are preferentially permissive for replication.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, nucleosomes are positioned at DNA replication origins.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, nucleosomes are positioned at DNA replication origins, and the presence of a well-positioned nucleosome adjacent to the origin NFR is essential for ORC to nucleate pre-RC assembly and for origin activity.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that nucleosomes are positioned at DNA replication origins and that a well-positioned nucleosome adjacent to the origin NFR is essential for ORC to nucleate pre-RC assembly and for origin activity. This is supported by evidence from Document 2.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main aspect of the question regarding the presence of nucleosomes at DNA replication origins and their importance for pre-RC assembly and origin activity. However, it could be more comprehensive by discussing the role of open chromatin domains characterized by nucleosome depletion in replication, as shown in Document 3.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 2 to support the claim about the importance of well-positioned nucleosomes at DNA replication origins. However, it could strengthen its grounding by incorporating evidence from Document 3 regarding open chromatin domains and replication.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence presented in the provided documents.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in specific evidence. To improve, it could be more comprehensive by incorporating information from Document 3 about open chromatin domains and their role in replication.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Nucleosomes are indeed positioned at DNA replication origins, with a well-positioned nucleosome adjacent to the origin NFR being crucial for ORC to initiate pre-RC assembly and for origin activity, as supported by Document 2. Additionally, open chromatin domains characterized by nucleosome depletion are preferentially permissive for replication, as demonstrated in Document 3. This highlights the interplay between nucleosome positioning and chromatin accessibility in DNA replication processes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1714\n",
            "   Self-RAG: 0.3158\n",
            "   Improvement: +84.21% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 247\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which is the process that Conserved noncoding elements mostly regulate?\n",
            "\n",
            "🎯 Gold Answer: Conserved noncoding elements play a fundamental role in regulating animal development\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Conserved noncoding elements mostly regulate developmental processes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Developmental regulation.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer is supported by evidence from multiple PubMed articles, which consistently mention the association of conserved noncoding elements with genes involved in developmental regulation.\n",
            "2. Grounding: The answer references specific evidence from the PubMed articles, demonstrating a strong foundation for the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the answer correctly identifies developmental regulation as a process regulated by conserved noncoding elements, it could be more specific in mentioning other processes that these elements may also regulate. The evidence suggests that conserved noncoding elements are implicated in regulating other crucial processes beyond development.\n",
            "2. Hallucinations: The answer does not include any unsupported claims, which is a strength in this evaluation.\n",
            "\n",
            "Overall, the initial answer is factually accurate and well-grounded in the provided evidence. However, it could be improved by acknowledging the broader range of processes regulated by conserved noncoding elements, as suggested by the evidence presented.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Conserved noncoding elements primarily regulate developmental processes, as evidenced by their association with developmental regulatory genes. Additionally, these elements have been implicated in the regulation of other crucial processes beyond development, indicating a broader role in gene regulation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4444\n",
            "   Self-RAG: 0.2857\n",
            "   Improvement: -35.71% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 248\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which is the most widely used model for the study of multiple sclerosis (MS)?\n",
            "\n",
            "🎯 Gold Answer: Experimental autoimmune encephalomyelitis (EAE) is a classical, conventional and widely recognized animal model for studying multiple sclerosis (MS). EAE is the best available model for the inflammatory processes that occur in MS, and for the disease process. A less commonly used model is that of Theiler's murine encephalomyelitis virus (TMEV).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Experimental autoimmune encephalomyelitis (EAE) is the most widely used model for the study of multiple sclerosis (MS).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Experimental autoimmune encephalomyelitis (EAE) is the most widely used model for the study of multiple sclerosis (MS).\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies Experimental Autoimmune Encephalomyelitis (EAE) as a widely used model for studying multiple sclerosis (MS). The evidence from the provided PubMed articles supports this claim.\n",
            "\n",
            "2. COMPLETENESS: The initial answer directly addresses the question by stating that EAE is the most widely used model for the study of MS. It does not provide information on other potential models, but this was not explicitly required by the question.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that EAE is a commonly used model for studying MS. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claim that EAE is the most widely used model for studying MS is well-supported by the evidence provided.\n",
            "\n",
            "Overall, the initial answer is factually accurate, addresses the question directly, provides specific evidence to support the claim, and does not include any unsupported claims. It effectively conveys that EAE is a widely used model for the study of MS based on the evidence presented.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Experimental autoimmune encephalomyelitis (EAE) is a widely used model for studying multiple sclerosis (MS), supported by evidence indicating its effectiveness in assessing neurological impairments quantitatively and its relevance to the inflammatory processes observed in MS.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3529\n",
            "   Self-RAG: 0.4091\n",
            "   Improvement: +15.91% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 249\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Do Conserved noncoding elements act as enhancers?\n",
            "\n",
            "🎯 Gold Answer: An important percentage of noncoding elements conserved across distant species shows enhancer activity and other forms of regulatory functionality.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, Conserved noncoding elements (CNEs) in vertebrate genomes often act as developmental enhancers.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, Conserved noncoding elements (CNEs) in vertebrate genomes often act as developmental enhancers.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that Conserved noncoding elements (CNEs) in vertebrate genomes often act as developmental enhancers, which is supported by the evidence from Document 2.\n",
            "2. The answer references specific evidence from PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of the mechanism by which Conserved noncoding elements act as enhancers. While Document 1 mentions the mechanism of enhancer activity of highly conserved noncoding elements, it also states that there is no adequate explanation yet. This nuance should have been included in the answer.\n",
            "2. The answer could have been more comprehensive by addressing the lack of a complete understanding of how Conserved noncoding elements function as enhancers, as indicated in Document 1.\n",
            "3. The answer does not acknowledge the potential limitations or conflicting evidence in the field regarding the role of Conserved noncoding elements as enhancers. It would have been beneficial to provide a more balanced perspective by considering different viewpoints or studies that may present alternative interpretations.\n",
            "\n",
            "Overall, while the initial answer is generally accurate and grounded in evidence, it could benefit from a more nuanced and comprehensive evaluation of the role of Conserved noncoding elements as enhancers in vertebrate genomes.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Conserved noncoding elements (CNEs) in vertebrate genomes are often associated with developmental enhancer activity, as supported by evidence from Document 2. While the exact mechanism by which highly conserved noncoding elements act as enhancers remains unclear, Document 1 highlights the lack of a complete explanation. Additionally, Document 3 suggests a connection between highly conserved noncoding elements and developmental regulatory genes. It is important to note that there are ongoing debates and limitations in understanding the precise role and mechanisms of CNEs as enhancers in vertebrate genomes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1667\n",
            "   Self-RAG: 0.1143\n",
            "   Improvement: -31.43% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 250\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which human genes are more commonly related to craniosynostosis?\n",
            "\n",
            "🎯 Gold Answer: The genes that are most commonly linked to craniosynostoses are the members of the Fibroblast Growth Factor Receptor family FGFR3 and to a lesser extent FGFR1 and FGFR2. Some variants of the disease have been associated with the triplication of the MSX2 gene and mutations in NELL-1. NELL-1 is being regulated bu RUNX2, which has also been associated to cases of craniosynostosis. Other genes reported to have a role in the development of the disease are RECQL4, TWIST, SOX6 and GNAS.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The human genes commonly related to craniosynostosis based on the provided context are FGFR1, FGFR2, FGFR3, TWIST, and MSX2.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "FGFR2, FGFR3, FGFR1, TWIST, MSX2\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies FGFR2, FGFR3, TWIST, and MSX2 as genes commonly related to craniosynostosis.\n",
            "2. The evidence from PubMed articles supports the inclusion of FGFR2, FGFR3, TWIST, and MSX2 in the list of genes related to craniosynostosis.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer misses the inclusion of FGFR1 as a gene commonly related to craniosynostosis, which is supported by the evidence from Document 2.\n",
            "2. The evidence from Document 3 specifically mentions the MSX2 gene, but it does not provide direct support for the inclusion of FGFR1 in the list.\n",
            "3. The initial answer could be improved by including FGFR1 in the list of genes commonly related to craniosynostosis to align with the evidence provided in Document 2.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and supported by evidence but lacks completeness by not including FGFR1 as a gene commonly related to craniosynostosis.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "FGFR1, FGFR2, FGFR3, TWIST, MSX2\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1765\n",
            "   Self-RAG: 0.0682\n",
            "   Improvement: -61.36% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 251\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which is the most common disease attributed to malfunction or absence of primary cilia?\n",
            "\n",
            "🎯 Gold Answer: When ciliary function is perturbed, photoreceptors may die, kidney tubules develop cysts, limb digits multiply and brains form improperly. Mice display abnormalities very similar to those of patients with neonatal diabetes and hypothyroidism syndrome, including the development of diabetes and polycystic kidney disease. Malformation of primary cilia, and in the collecting ducts of kidney tubules this is accompanied by development of autosomal recessive polycystic kidney disease (PKD).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The most common disease attributed to malfunction or absence of primary cilia is autosomal dominant polycystic kidney disease (PKD).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Polycystic kidney disease (PKD) is the most common disease attributed to malfunction or absence of primary cilia.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies Polycystic Kidney Disease (PKD) as a disease associated with dysfunctional primary cilia. However, the evidence provided also mentions other diseases linked to primary cilia dysfunction, such as cancer, obesity, diabetes, and developmental defects. Therefore, the initial answer is not entirely accurate in stating that PKD is the most common disease attributed to malfunction or absence of primary cilia.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not address the fact that primary cilia dysfunction is associated with various other diseases beyond PKD. It focuses solely on PKD without acknowledging the broader implications of primary cilia malfunction.\n",
            "\n",
            "3. GROUNDING: The initial answer does reference specific evidence from PubMed articles, which support the association between primary cilia dysfunction and PKD. However, it fails to incorporate the broader context provided by the evidence, which highlights the involvement of primary cilia in other diseases as well.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include unsupported claims. However, it does oversimplify the relationship between primary cilia dysfunction and disease by focusing solely on PKD.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and fails to provide a comprehensive overview of the diseases associated with primary cilia dysfunction. It would benefit from acknowledging the broader spectrum of conditions linked to primary cilia malfunction based on the evidence provided.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Polycystic kidney disease (PKD) is one of the diseases associated with dysfunctional primary cilia, as evidenced by its early linkage. However, primary cilia dysfunction has also been linked to various other conditions, including cancer, obesity, diabetes, and developmental defects. While PKD is a well-known example, it is important to recognize the broader spectrum of diseases attributed to malfunction or absence of primary cilia based on current research findings.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2558\n",
            "   Self-RAG: 0.1594\n",
            "   Improvement: -37.68% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 252\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the biological role of expansins in fungi?\n",
            "\n",
            "🎯 Gold Answer: Expansins are extracellular proteins that increase plant cell-wall extensibility. These wall-loosening proteins are involved in cell wall extension and polysaccharide degradation. In fungi expansins and expansin-like proteins have been found to localize in the conidial cell wall and are probably involved in cell wall remodeling during germination.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The biological role of expansins in fungi is not explicitly mentioned in the provided context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The biological role of expansins in fungi is to increase plant cell-wall extensibility, facilitating the accommodation of the fungus by infected cortical cells.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions that expansins increase plant cell-wall extensibility, which is supported by evidence from Document 1.\n",
            "2. The answer also correctly states that expansins are involved in the accommodation of the fungus by infected cortical cells, supported by evidence from Document 2.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not provide a comprehensive explanation of the biological role of expansins in fungi. It focuses solely on their role in increasing plant cell-wall extensibility and accommodation by infected cortical cells, missing other potential roles.\n",
            "2. The answer lacks grounding in specific evidence related to expansins in fungi. While it references evidence about expansins in general and their role in plant cell walls, it does not directly link this information to fungi.\n",
            "3. The answer includes a statement about gene expression in fungi that is not directly related to expansins, introducing an unsupported claim and potentially confusing the reader.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and specific grounding in evidence related to expansins in fungi. It would benefit from a more focused and evidence-based explanation of expansins' biological role in fungi.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Expansins in fungi play a crucial role in modifying plant cell walls to increase extensibility, aiding in the penetration and colonization of host cells by the fungus. This process involves the action of alpha-expansins, which are extracellular proteins known to enhance plant cell-wall extensibility. Additionally, expansins are directly involved in facilitating the accommodation of the fungus by infected cortical cells. The regulation of expansin gene expression in fungi may involve chromatin-level control mechanisms, potentially impacting fungal secondary metabolism.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1538\n",
            "   Self-RAG: 0.2443\n",
            "   Improvement: +58.78% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 253\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is paramyxovirus involved in human subacute thyroiditis?\n",
            "\n",
            "🎯 Gold Answer: There is no evidence that paramyxovirus are involved in etiology of subacute thyroiditis.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The provided context does not mention paramyxovirus as being involved in human subacute thyroiditis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "No, based on the provided context, paramyxovirus is not mentioned as being involved in human subacute thyroiditis.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that paramyxovirus is not mentioned in the provided context of human subacute thyroiditis.\n",
            "2. The answer is concise and to the point.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specific evidence to support the claim that paramyxovirus is not involved in human subacute thyroiditis. It would be stronger if it referenced specific evidence to back up this assertion.\n",
            "2. The answer could benefit from providing more context on the viruses known to be associated with subacute thyroiditis, as this would enhance completeness.\n",
            "3. The initial answer does not address the possibility of paramyxovirus being involved in subacute thyroiditis beyond the provided context, which could be seen as a limitation in addressing the question comprehensively.\n",
            "\n",
            "Overall, the initial answer is accurate in its assessment based on the provided context but could be improved by providing more specific evidence and addressing the question more comprehensively.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Paramyxovirus is not commonly associated with human subacute thyroiditis. Subacute thyroiditis is primarily linked to viruses such as Coxsackie, cytomegalovirus, Epstein-Barr virus, and adenovirus. Influenza immunization or infection may also trigger subacute thyroiditis.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3704\n",
            "   Self-RAG: 0.1224\n",
            "   Improvement: -66.94% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 254\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Do proton pump inhibitors affect thyroxine absorption?\n",
            "\n",
            "🎯 Gold Answer: Proton-pump inhibitors, antacids and a long list of drugs may decrease thyroxine absorption.\n",
            "Patients with hypothyroidism and normal TSH values during LT4 replacement therapy may need additional thyroid function testing after treatment with PPIs and may need adjustment of their LT4 dose.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, proton pump inhibitors have been shown to interfere with the absorption of thyroxine.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, proton pump inhibitors have been shown to interfere with the absorption of thyroxine.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that proton pump inhibitors have been shown to interfere with the absorption of thyroxine.\n",
            "2. The answer is supported by multiple references from PubMed articles, providing specific evidence to back up the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more precise in its language by specifying that the absorption interference is related to levothyroxine specifically, rather than thyroxine in general.\n",
            "2. The answer could benefit from a more direct comparison between the effects of proton pump inhibitors on levothyroxine absorption compared to other drugs mentioned in the evidence.\n",
            "3. The answer does not explicitly address the mechanism by which proton pump inhibitors interfere with levothyroxine absorption, which could provide a more comprehensive understanding of the topic.\n",
            "4. The initial answer does not mention the potential clinical implications of this interaction, such as the need for dose adjustments or monitoring when using proton pump inhibitors in patients taking levothyroxine.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Proton pump inhibitors, such as omeprazole and esomeprazole, have been shown to interfere with the absorption of levothyroxine, a synthetic form of thyroxine. This interference is also observed with other drugs like bile acid sequestrants, ferrous sulfate, sucralfate, calcium carbonate, aluminum-containing antacids, phosphate binders, and raloxifene. The mechanism underlying this interaction involves impaired dissolution and solubility of levothyroxine in the acidic environment of the stomach. Clinically, this interaction may necessitate dose adjustments or monitoring when using proton pump inhibitors in patients taking levothyroxine to ensure optimal therapeutic outcomes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1754\n",
            "   Self-RAG: 0.1791\n",
            "   Improvement: +2.09% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 255\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which drugs may interfere thyroxine absorption?\n",
            "\n",
            "🎯 Gold Answer: bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, raloxifene and proton-pump inhibitors, have also been shown to interfere with the absorption of levothyroxine\n",
            "sevelamer hydrochloride or chromium picolinate should be advised to separate the time of ingestion of these drugs from their thyroid hormone preparation by several hours\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Proton-pump inhibitors, antacids, bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, and raloxifene may interfere with thyroxine absorption.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Proton-pump inhibitors, antacids, bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, and raloxifene may interfere with thyroxine absorption.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies several drugs that may interfere with thyroxine absorption.\n",
            "2. The answer is supported by evidence from multiple PubMed articles, indicating a thorough research effort.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in citing the exact evidence from each document to strengthen the grounding of the claims.\n",
            "2. The answer could benefit from clarifying that levothyroxine is the same as thyroxine, as some documents use the former term.\n",
            "3. The answer does not explicitly mention the potential interference of bile acid sequestrants with thyroxine absorption, despite evidence supporting this claim in the provided documents.\n",
            "4. The answer could be more concise and organized by grouping related drugs together for clarity.\n",
            "\n",
            "Overall, the initial answer provides a good foundation but could be improved by enhancing specificity in referencing evidence, addressing all relevant drugs, and improving clarity and organization.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Proton-pump inhibitors, antacids, bile acid sequestrants, ferrous sulphate, sucralfate, calcium carbonate, aluminium-containing antacids, phosphate binders, and raloxifene have been shown to interfere with the absorption of thyroxine (levothyroxine). Evidence from multiple PubMed articles supports the potential interference of these drugs with thyroxine absorption. It is important to note that bile acid sequestrants can also impact thyroxine absorption, as indicated in the provided documents. Grouping related drugs together can help clarify the potential interactions that may affect thyroxine absorption.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4359\n",
            "   Self-RAG: 0.4179\n",
            "   Improvement: -4.13% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 256\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is microRNA(miRNA) 29 involved in post-ischemic cardiac remodeling?\n",
            "\n",
            "🎯 Gold Answer: miRNA 29 is involved in post-ischemic myocardial remodeling in particular in the peri-infarctual zone.  miRNA 29 produces apoptosis and enhances fibrotic response.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, microRNA 29 (miR-29) is involved in post-ischemic cardiac remodeling based on the provided context from Document 3, which indicates that miR-29 family members are down-regulated in the region of the heart adjacent to the infarct and play a role in regulating cardiac fibrosis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, microRNA 29 (miR-29) is involved in post-ischemic cardiac remodeling as it is down-regulated in the region of the heart adjacent to the infarct and regulates myocardial fibrosis by targeting mRNAs encoding proteins involved in fibrosis.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that miR-29 is down-regulated in the region of the heart adjacent to the infarct.\n",
            "2. The answer accurately mentions that miR-29 regulates myocardial fibrosis by targeting mRNAs encoding proteins involved in fibrosis.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specific references to the evidence provided in the PubMed articles. It would be stronger if direct citations were included to support the claims made.\n",
            "2. The answer could benefit from mentioning the specific studies or experiments that have demonstrated the involvement of miR-29 in post-ischemic cardiac remodeling.\n",
            "3. The answer does not address the broader context of miR-29's role in ischemia-reperfusion injury and remodeling after myocardial infarction, as suggested in Document 1.\n",
            "4. The answer could be improved by discussing potential limitations or conflicting evidence regarding the role of miR-29 in post-ischemic cardiac remodeling.\n",
            "\n",
            "Overall, the initial answer provides a general overview of miR-29's involvement in post-ischemic cardiac remodeling but lacks specific references and depth in discussing the evidence supporting this claim.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "MicroRNA 29 (miR-29) is implicated in post-ischemic cardiac remodeling, particularly in regulating myocardial fibrosis. Studies have shown that miR-29 is down-regulated in the region of the heart adjacent to the infarct. The miR-29 family targets mRNAs encoding proteins involved in fibrosis, such as collagens, fibrillins, and elastin. Experimental evidence suggests that down-regulation of miR-29 enhances the fibrotic response, while over-expression reduces collagen expression. These findings highlight miR-29 as a potential therapeutic target for cardiac fibrosis and tissue fibrosis in general. Further research is needed to fully elucidate the role of miR-29 in post-ischemic cardiac remodeling and to address any conflicting evidence in this context.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2778\n",
            "   Self-RAG: 0.1986\n",
            "   Improvement: -28.51% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 257\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is microRNA(miRNA) 30 involved in post-ischemic cardiac remodeling?\n",
            "\n",
            "🎯 Gold Answer: Myocardial remodeling after an ischemic insult involves extracellular matrix proteins with increased fibrosis\n",
            "Initial experimental data indicate that miRNA 30 decreases CTGF a key molecule in the process of fibrosis, by directly downregulating the production of CTGF\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, miR-30 is involved in the control of structural changes in the extracellular matrix of the myocardium by directly downregulating CTGF, a key profibrotic protein. However, the direct involvement of miR-30 in post-ischemic cardiac remodeling is not explicitly mentioned in the provided information.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, miR-30 is involved in post-ischemic cardiac remodeling as it directly downregulates CTGF, a key profibrotic protein, contributing to the control of structural changes in the extracellular matrix of the myocardium.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies miR-30 as being involved in post-ischemic cardiac remodeling.\n",
            "2. The answer provides specific evidence from Document 3 to support the claim that miR-30 directly downregulates CTGF, a profibrotic protein.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not address the broader context of miRNAs involved in post-ischemic cardiac remodeling. While it focuses on miR-30, other miRNAs mentioned in the evidence (miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320) are also implicated in ischemia-reperfusion injury and remodeling after myocardial infarction.\n",
            "2. The answer lacks grounding in the evidence from Document 1, which discusses the involvement of various miRNAs in post-ischemic cardiac remodeling. It would strengthen the answer to incorporate this broader perspective.\n",
            "3. The initial answer does not address the potential limitations or conflicting evidence regarding the role of miR-30 in post-ischemic cardiac remodeling. It would be beneficial to acknowledge any uncertainties in the current understanding of miR-30's role in this process.\n",
            "\n",
            "Overall, while the initial answer correctly identifies miR-30's involvement in post-ischemic cardiac remodeling and provides specific evidence to support this claim, it would benefit from addressing the broader context of miRNAs involved\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "miR-30 is one of several microRNAs implicated in post-ischemic cardiac remodeling. While miR-30 directly downregulates CTGF, a profibrotic protein, contributing to structural changes in the myocardium's extracellular matrix, other miRNAs such as miR-1, miR-21, miR-29, miR-92a, miR-133, miR-199a, and miR-320 are also involved in ischemia-reperfusion injury and remodeling after myocardial infarction. Document 1 highlights the diverse roles of these miRNAs in cardiac remodeling, expanding the context beyond miR-30. It is important to acknowledge the complexity of miRNA interactions in post-ischemic cardiac remodeling and consider potential limitations or conflicting evidence regarding miR-30's specific role in this process.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2069\n",
            "   Self-RAG: 0.1208\n",
            "   Improvement: -41.61% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 258\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Does triiodothyronine (T3) has cardiac angiogenic effects?\n",
            "\n",
            "🎯 Gold Answer: T3-induced cardiac sprouting angiogenesis in adult hypothyroid mice was associated with PDGF-BB, PDGFR-β and downstream activation of Akt.\n",
            "T(3) administration restored TRbeta mRNA expression level in AAC hearts to the control level.\n",
            "TRbeta in the coronary ECs regulates capillary density during cardiac development, and down-regulation of TRbeta results in coronary microvascular rarefaction during pathological hypertrophy.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, triiodothyronine (T3) has been associated with cardiac angiogenic effects in adult hypothyroid mice.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, based on the provided context, triiodothyronine (T3) has been associated with cardiac angiogenic effects in adult hypothyroid mice.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that triiodothyronine (T3) has been associated with cardiac angiogenic effects in adult hypothyroid mice, which is supported by the evidence provided in Document 2. However, the mention of T3 levels during exercise in Document 1 and the normalization of cardiac myosin ATPase in diabetic rats in Document 3 are not directly related to the cardiac angiogenic effects of T3.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main part of the question by confirming that T3 has cardiac angiogenic effects in adult hypothyroid mice. However, it could be more comprehensive by discussing the specific mechanisms and implications of these effects in more detail.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that T3 has cardiac angiogenic effects in adult hypothyroid mice. This grounding in scientific literature strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. However, it could benefit from focusing more on the direct evidence related to cardiac angiogenic effects of T3 to avoid potential confusion.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in specific evidence from scientific literature. To improve, it could focus more on directly relevant evidence and provide a more detailed explanation of the mechanisms underlying the cardiac angiogenic effects of T3.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on the evidence provided, triiodothyronine (T3) has been associated with cardiac angiogenic effects in adult hypothyroid mice through mechanisms involving PDGF-BB, PDGFR-β, and downstream activation of Akt. This suggests a potential role for T3 in promoting cardiac sprouting angiogenesis. The normalization of cardiac myosin ATPase in diabetic rats, as mentioned in Document 3, is not directly related to the cardiac angiogenic effects of T3. Further research is needed to elucidate the specific implications and mechanisms underlying T3-induced cardiac angiogenesis.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1538\n",
            "   Self-RAG: 0.2837\n",
            "   Improvement: +84.40% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 259\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What kind of affinity purification would you use in order to isolate soluble lysosomal proteins?\n",
            "\n",
            "🎯 Gold Answer: The rationale for purification of the soluble lysosomal  proteins resides in their characteristic sugar, the mannose-6-phosphate (M6P),  which allows an easy purification by affinity chromatography on immobilized M6P receptors.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Affinity chromatography on immobilized mannose-6-phosphate receptor (MPR) would be used to isolate soluble lysosomal proteins.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Affinity chromatography on immobilized mannose-6-phosphate receptor (MPR) would be used to isolate soluble lysosomal proteins.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies the use of affinity chromatography on immobilized mannose-6-phosphate receptor (MPR) for isolating soluble lysosomal proteins. This claim is supported by evidence from all three provided PubMed articles, which specifically mention the use of this method for purification.\n",
            "\n",
            "2. COMPLETENESS: The initial answer directly addresses the question by specifying the type of affinity purification method (immobilized MPR) that would be used to isolate soluble lysosomal proteins. It provides a clear and concise response to the question.\n",
            "\n",
            "3. GROUNDING: The initial answer is well-grounded in specific evidence from the provided PubMed articles. Each document explicitly mentions the use of affinity chromatography on immobilized MPR for purifying soluble lysosomal proteins, supporting the accuracy of the initial answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The use of affinity chromatography on immobilized MPR for isolating soluble lysosomal proteins is consistently backed by evidence from the provided PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate, complete, well-grounded in specific evidence, and does not contain any unsupported claims. It effectively addresses the question by providing a scientifically sound response based on the available literature.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Affinity chromatography on immobilized mannose-6-phosphate receptor (MPR) is a suitable method for isolating soluble lysosomal proteins due to their characteristic sugar, mannose-6-phosphate (M6P). This method has been specifically mentioned in the provided PubMed articles as an effective approach for purifying lysosomal proteins containing M6P.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2083\n",
            "   Self-RAG: 0.3291\n",
            "   Improvement: +57.97% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 260\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which is the defective protein causing the lysosomal storage disease Fabry?\n",
            "\n",
            "🎯 Gold Answer: Anderson-Fabry disease (referred to as Fabry disease) is an X-linked disorder characterized by a deficiency of the lysosomal enzyme alpha-galactosidase A and the subsequent accumulation in various tissues of globotriaosylceramide (Gb(3)), the main substrate of the defective enzyme.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The defective protein causing the lysosomal storage disease Fabry is alpha-galactosidase A (Gla).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The defective protein causing the lysosomal storage disease Fabry is alpha-galactosidase A.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies alpha-galactosidase A as the defective protein causing Fabry disease.\n",
            "2. The answer is supported by evidence from multiple PubMed articles, which strengthens its credibility.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have provided a more direct and concise response to the question without unnecessary elaboration.\n",
            "2. While the evidence supports the claim that alpha-galactosidase A is the defective protein in Fabry disease, the answer could have been more explicit in directly linking the protein to the disease without excessive detail.\n",
            "3. The answer could have been more focused on directly addressing the question without including extraneous information.\n",
            "4. The answer could have been improved by directly quoting or referencing specific statements from the provided PubMed articles to strengthen the connection between the defective protein and Fabry disease.\n",
            "\n",
            "Overall, the initial answer is generally accurate but could benefit from more direct and concise language, as well as more specific references to the evidence provided.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The defective protein causing the lysosomal storage disease Fabry is alpha-galactosidase A, which leads to the accumulation of globotriaosylceramide (Gb3) in major organs such as the heart and kidney. This deficiency of alpha-galactosidase A results in the incomplete breakdown of Gb3, contributing to the pathogenesis of Fabry disease.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2143\n",
            "   Self-RAG: 0.2826\n",
            "   Improvement: +31.88% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 261\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the major transcription factors regulating glycolysis in mammals?\n",
            "\n",
            "🎯 Gold Answer: The main positive transcriptional regulator of Glycolysis in mammals is HIF1-alpha (Hypoxia Inducible Factor 1a). HIF1-alpha is upregulated by the oncogenes c-Myc and Src, which therefore also positively regulate glycolysis. Several reports have linked HIF-1α induction with STAT3 activation. SIRT6 appears to function as a corepressor of the transcription factor Hif1alpha. NF-κB also stimulates glycolysis through the inhibition of PDK4 expression. Loss of the widely expressed transcription factor Oct1 induces a coordinated metabolic shift: mitochondrial activity and amino acid oxidation are increased, while glucose metabolism is reduced. HNF4alpha is critical for regulating glucose transport and glycolysis and in doing so is crucial for maintaining glucose homeostasis.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The major transcription factors regulating glycolysis in mammals are Hypoxia-inducible factor (HIF)-1 and Myc.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The major transcription factors regulating glycolysis in mammals are Hypoxia-inducible factor (HIF)-1 and Myc.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies Hypoxia-inducible factor (HIF)-1 and Myc as major transcription factors regulating glycolysis in mammals.\n",
            "2. The evidence provided from PubMed articles supports the roles of HIF-1 and Myc in regulating glycolysis.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from providing more comprehensive evidence to strengthen the claims made. While the evidence supports the roles of HIF-1 and Myc in glycolysis regulation, additional studies could further solidify these claims.\n",
            "2. The initial answer does not mention other potential transcription factors that may also play a role in regulating glycolysis in mammals. It would be more complete to acknowledge the complexity of transcriptional regulation in glycolysis.\n",
            "3. The initial answer lacks a direct comparison or analysis of the relative importance or interactions between HIF-1 and Myc in glycolysis regulation. Providing such insights would enhance the depth of the response.\n",
            "\n",
            "Overall, the initial answer is on the right track by identifying key transcription factors involved in glycolysis regulation, but it could be improved by providing a more thorough analysis supported by additional evidence and considering the broader context of transcriptional regulation in glycolysis.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The major transcription factors regulating glycolysis in mammals include Hypoxia-inducible factor (HIF)-1 and Myc. HIF-1 acts as a master transcription factor that up-regulates glycolysis in response to hypoxia, while Myc directly regulates the expression of glycolytic genes such as lactate dehydrogenase A (LDHA). While these factors play significant roles in glycolysis regulation, it is important to note that there may be other transcription factors contributing to the complex regulatory network of glycolysis. Further studies are needed to fully elucidate the interactions and relative importance of various transcription factors in controlling glycolytic pathways.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1890\n",
            "   Self-RAG: 0.2512\n",
            "   Improvement: +32.93% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 262\n",
            "================================================================================\n",
            "\n",
            "📝 Question: The CXCR2 receptor is targeted in cancer. Name five antagonists.\n",
            "\n",
            "🎯 Gold Answer: There are numerous CXCR2 receptor antagonists, such as SB225002, G31P, SCH-527123, AZ10397767, SCH-479833.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "1. SCH-527123\n",
            "2. SCH-479833\n",
            "3. SB225002\n",
            "\n",
            "(Note: The context provided mentions three CXCR2 antagonists: SCH-527123, SCH-479833, and SB225002. There is no mention of two additional CXCR2 antagonists in the provided context.)\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "1. SCH-527123\n",
            "2. SCH-479833\n",
            "3. SB225002\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer provides three specific antagonists targeting the CXCR2 receptor.\n",
            "2. The evidence from PubMed articles supports the use of SCH-527123, SCH-479833, and SB225002 as CXCR2 antagonists in cancer treatment.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer only lists three antagonists, while the question asked for five.\n",
            "2. The evidence provided does not mention five specific CXCR2 antagonists, potentially limiting the completeness of the answer.\n",
            "3. The initial answer could benefit from including additional evidence or sources to support the claim that these antagonists are commonly used or well-established in cancer treatment.\n",
            "4. The answer does not address potential side effects, efficacy comparisons, or other relevant information about these antagonists, which could enhance the completeness and depth of the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "1. SCH-527123\n",
            "2. SCH-479833\n",
            "3. SB225002\n",
            "4. AZD5069\n",
            "5. Reparixin\n",
            "\n",
            "The CXCR2 receptor antagonists commonly used in cancer treatment include SCH-527123, SCH-479833, SB225002, AZD5069, and Reparixin. Evidence from PubMed articles supports their efficacy in inhibiting tumor growth and metastasis through various mechanisms. Further research is needed to fully understand their potential side effects and comparative efficacy in different cancer types.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2400\n",
            "   Self-RAG: 0.1728\n",
            "   Improvement: -27.98% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 263\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the available biomedical text mining tools for the detection of protein-protein interactions?\n",
            "\n",
            "🎯 Gold Answer: Protein-protein interactions (PPI) can be extracted from biomedical literature using text mining approaches. These approaches have been classified into two categories, the statistical calculation of the co-occurrence of proteins and the computational linguistic method. Moreover, bioinformatics methods based on sequence, structural, or evolutionary information have been developed to predict protein-protein interactions. The available state-of-the-art biomedical text mining tools are: eFIP (Extracting Functional Impact of Phosphorylation), a system for text mining of protein interaction networks of phosphorylated proteins; GeneView, a suite of state-of-the-art text-mining tools designed for the automated identification of protein–protein interactions; PPI finder, a text mining tool for human protein-protein interactions based on computational linguistic methods. PPI Finder system consists of the Information Retrieval module and Information Extraction module; PreBIND and Textomy are two components of a biomedical literature-mining system optimized to discover protein-protein interactions using a support vector machine; BioMap system is optimized for the identification of protein-protein interactions from large biomedical literature datasets; Protopia searches for and integrates protein-protein interactions and the information about them contained in five different Protein Interaction Web Databases; STRING uses Natural Language Processing to extract a subset of semantically specified known and predicted protein-protein interactions.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the available biomedical text mining tools for the detection of protein-protein interactions are not explicitly mentioned.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Some available biomedical text mining tools for the detection of protein-protein interactions include tools focused on information extraction methods in the biomedical domain.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly mentions that there are text mining tools for detecting protein-protein interactions in the biomedical domain, which is supported by the evidence provided from the PubMed articles. The evidence clearly indicates that there is a focus on extracting protein-protein interactions from biomedical literature.\n",
            "\n",
            "2. COMPLETENESS: The initial answer could be more specific in listing out the actual names of the available text mining tools for detecting protein-protein interactions. While it mentions the focus on information extraction methods in the biomedical domain, it does not provide a comprehensive list of specific tools.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from the provided PubMed articles to support the claim that there are text mining tools available for detecting protein-protein interactions. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the evidence provided from the PubMed articles regarding the existence of text mining tools for detecting protein-protein interactions.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in evidence from the provided PubMed articles. However, it could be improved by providing a more comprehensive list of specific biomedical text mining tools for detecting protein-protein interactions.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Some specific biomedical text mining tools for detecting protein-protein interactions include tools such as BioGRID, STRING, and APID. These tools utilize information extraction methods in the biomedical domain to extract and analyze protein-protein interactions from the vast amount of biomedical literature. This is supported by evidence from PubMed articles highlighting the importance of automated extraction of protein-protein interactions in biomedical text mining.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1293\n",
            "   Self-RAG: 0.1964\n",
            "   Improvement: +51.85% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 264\n",
            "================================================================================\n",
            "\n",
            "📝 Question: The protein NONO forms heterodimers. With which proteins?\n",
            "\n",
            "🎯 Gold Answer: The protein NONO forms heterodimers with PSPC1, SFPQ.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The protein NONO forms heterodimers with paraspeckle protein component 1.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The protein NONO forms heterodimers with paraspeckle protein component 1.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies that the protein NONO forms heterodimers.\n",
            "2. The evidence from PubMed articles supports the claim that NONO forms heterodimers with paraspeckle protein component 1.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in stating that NONO forms heterodimers only with paraspeckle protein component 1. The evidence provided does not conclusively prove that this is the only protein with which NONO forms heterodimers. It would be more accurate to state that NONO forms heterodimers with paraspeckle protein component 1 among other potential binding partners.\n",
            "2. The evidence provided does not directly address the question of which proteins NONO forms heterodimers with, apart from paraspeckle protein component 1. Additional evidence or references would be needed to support a more comprehensive answer.\n",
            "3. The initial answer does not address the potential for NONO to form heterodimers with other proteins beyond paraspeckle protein component 1, which could limit the completeness of the response.\n",
            "\n",
            "Overall, while the initial answer is partially supported by evidence, it could benefit from more specificity and additional references to provide a more comprehensive and accurate response to the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The protein NONO forms heterodimers with paraspeckle protein component 1 among other potential binding partners. While evidence supports the interaction between NONO and paraspeckle protein component 1, additional research is needed to identify other proteins with which NONO may form heterodimers.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.6667\n",
            "   Self-RAG: 0.2449\n",
            "   Improvement: -63.27% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 265\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the computational tools for the prediction of beta-barrel transmembrane proteins?\n",
            "\n",
            "🎯 Gold Answer: The computational tools for the prediction of beta-barrel transmembrane proteins (TMBs) are based mainly on the following methodologies: Hidden Markov Models (HMMs), hydrophobicity, structural data, k-nearest neighbor algorithm, Neural Networks and Support Vector Machines. The state-of-the-art computational tools for the prediction of TMBs are: BETAWARE, BOCTOPUS, BOMP, BTMX, HMM-B2TMR, OMPdb,PRED-TMBB, PROB, ProfTMB, PV, TMBETA-NET, TMB finding pipeline, TMBETADISC-RBF, TMBETAPRED-RBF, TMBHMM, TMB-Hunt, TMB-Hunt2, TMBKNN, TMBpro, transFold.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the computational tools for the prediction of beta-barrel transmembrane proteins include BETAWARE and tools that search for restricted domains.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "BETAWARE and searching for restricted domains are computational tools for predicting beta-barrel transmembrane proteins.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies BETAWARE as a computational tool for predicting beta-barrel transmembrane proteins, which is supported by evidence from Document 1 and Document 2.\n",
            "2. The mention of searching for restricted domains as another computational tool is also supported by evidence from Document 3.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in describing the computational tool \"searching for restricted domains.\" It would be beneficial to provide more details or specific references to support this claim.\n",
            "2. The answer could be improved by providing a more comprehensive list of computational tools for predicting beta-barrel transmembrane proteins, as there may be other relevant tools not mentioned in the initial response.\n",
            "3. The evidence provided is limited to only three documents, which may not fully represent the breadth of computational tools available for this prediction task.\n",
            "\n",
            "Overall, the initial answer is partially accurate but could benefit from more detailed and comprehensive information supported by a wider range of evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Computational tools for predicting beta-barrel transmembrane proteins include BETAWARE, a machine-learning tool specifically designed for this task. Additionally, the prediction of beta-barrel membrane proteins can be facilitated by searching for restricted domains, as suggested in relevant literature. Further exploration of computational tools beyond these mentioned may provide a more comprehensive approach to predicting beta-barrel transmembrane proteins.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2718\n",
            "   Self-RAG: 0.2029\n",
            "   Improvement: -25.36% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 266\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is single-cell analysis (SCA) possible in proteomics?\n",
            "\n",
            "🎯 Gold Answer: No, it is not yet feasible, although smaller pilot studies has been performed where a limited number of proteins has been analysed.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, single-cell analysis (SCA) is possible in proteomics, as demonstrated by the successful identification of unique proteins in single-cell samples using nanoLC-MS/MS proteomic analysis in Arabidopsis thaliana.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, single-cell analysis (SCA) is possible in proteomics as demonstrated by the successful identification of unique proteins in single-cell samples using nanoLC-MS/MS proteomic analysis.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that single-cell analysis (SCA) is possible in proteomics, supported by evidence from Document 3 where unique proteins were identified in single-cell samples using nanoLC-MS/MS proteomic analysis. This claim is factually accurate based on the provided evidence.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main question of whether single-cell analysis is possible in proteomics. It provides a specific example of successful single-cell proteomic analysis using nanoLC-MS/MS technology. However, it could have elaborated more on the challenges and limitations of single-cell proteomics to provide a more comprehensive answer.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 3, which describes the successful identification of unique proteins in single-cell samples using nanoLC-MS/MS proteomic analysis in Arabidopsis thaliana. This grounding strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claims made are supported by evidence from scientific literature.\n",
            "\n",
            "Overall, the initial answer is factually accurate, grounded in specific evidence, and does not include unsupported claims. However, it could be improved by providing a more comprehensive discussion on the challenges and limitations of single-cell proteomics to offer a more well-rounded evaluation.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Yes, single-cell analysis (SCA) is indeed possible in proteomics, as evidenced by successful identification of unique proteins in single-cell samples using nanoLC-MS/MS proteomic analysis, as demonstrated in Arabidopsis thaliana. While this technology has shown promise, it is important to note that challenges such as sample heterogeneity, low protein abundance, and technical variability exist in single-cell proteomics, which can impact data interpretation and analysis. Further research and advancements are needed to address these limitations and enhance the robustness of single-cell proteomic studies.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1132\n",
            "   Self-RAG: 0.0721\n",
            "   Improvement: -36.34% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 267\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which type of lung cancer is the most strongly associated with Lambert-Eaton syndrome?\n",
            "\n",
            "🎯 Gold Answer: Small-cell lung cancer is most commonly associated with Lambert-Eaton syndrome. Case reports suggest that other non-small-cell lung cancer types, such as large-cell neuroendocrine carcinoma and squamous cell carcinoma,  can be also very rarely associated this syndrome.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Small cell lung cancer is the type most strongly associated with Lambert-Eaton syndrome based on the provided context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Small cell lung cancer is the type most strongly associated with Lambert-Eaton syndrome.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies small cell lung cancer as being associated with Lambert-Eaton syndrome.\n",
            "2. The answer is supported by evidence from PubMed articles, specifically mentioning cases of Lambert-Eaton syndrome in patients with small cell lung cancer.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in stating the exact proportion or percentage of small cell lung cancer cases associated with Lambert-Eaton syndrome, as this would provide a clearer understanding of the strength of the association.\n",
            "2. The answer could benefit from mentioning other types of lung cancer that may also be associated with Lambert-Eaton syndrome, to provide a more comprehensive overview of the topic.\n",
            "3. The evidence provided does not cover all aspects of the question, such as potential associations between other types of lung cancer and Lambert-Eaton syndrome.\n",
            "4. The answer could be improved by discussing the underlying mechanisms or reasons for the association between small cell lung cancer and Lambert-Eaton syndrome, to provide a more in-depth analysis.\n",
            "\n",
            "Overall, the initial answer is generally accurate and supported by evidence, but it could be enhanced by providing more specific details and addressing other relevant aspects of the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Small cell lung cancer is the type most strongly associated with Lambert-Eaton syndrome, with approximately 3% of small cell lung cancer cases being linked to Lambert-Eaton syndrome based on documented cases. While small cell lung cancer is the most commonly associated type, Lambert-Eaton syndrome can also rarely occur in other types of lung cancer. The underlying mechanism of this association is thought to involve the immune system targeting shared antigens between the tumor and neuromuscular junction. Treatment of small cell lung cancer may lead to improvement in Lambert-Eaton syndrome symptoms, highlighting the importance of recognizing this association for patient management.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3667\n",
            "   Self-RAG: 0.2993\n",
            "   Improvement: -18.37% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 268\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is miR-126 involved in heart failure?\n",
            "\n",
            "🎯 Gold Answer: Yes, miR-126 is associated with heart failure.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, based on the provided context, miR-126 is involved in heart failure as its plasma concentration is negatively correlated with age and NYHA class, and it has been suggested as a potential biomarker for heart failure. Additionally, in patients with heart failure, the plasma concentrations of miR-126 were up-regulated with improvement in NYHA class.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, miR-126 is involved in heart failure as its plasma concentration is negatively correlated with age and NYHA class, and it can serve as a useful biomarker for heart failure. Additionally, in patients with heart failure, plasma concentrations of miR-126 were up-regulated with improvement of the NYHA class.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that miR-126 is involved in heart failure based on the provided evidence from PubMed articles.\n",
            "2. The answer highlights the relationship between miR-126 plasma concentration and age/NYHA class, as well as its potential as a biomarker for heart failure.\n",
            "3. The answer references specific evidence from Document 1 and Document 2 to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not address the broader context of miR-126's role in heart failure beyond its plasma concentration and biomarker potential. It could benefit from discussing the mechanistic involvement of miR-126 in heart failure.\n",
            "2. The answer could be strengthened by including additional evidence or studies that further support the role of miR-126 in heart failure beyond the provided documents.\n",
            "3. The mention of other miRNAs like miR-1, miR-133, and miR-208a in Document 3, while interesting, does not directly relate to the involvement of miR-126 in heart failure as per the question.\n",
            "\n",
            "Overall, the initial answer provides a good foundation by citing specific evidence to support the involvement of miR-126 in heart failure. However, it could be improved by expanding on the mechanistic aspects and incorporating additional relevant studies to strengthen the argument.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "miR-126 is indeed involved in heart failure, with its plasma concentration showing a negative correlation with age and NYHA class, suggesting its potential as a biomarker for heart failure. Evidence from Document 1 supports this relationship. Furthermore, Document 2 indicates that in heart failure patients, plasma concentrations of miR-126 increased with an improvement in NYHA class. While miR-1, miR-133, and miR-208a are associated with cardiac hypertrophy, they are not directly linked to the involvement of miR-126 in heart failure. To further enhance our understanding, exploring the mechanistic role of miR-126 in heart failure beyond its plasma concentration would be beneficial.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2154\n",
            "   Self-RAG: 0.1217\n",
            "   Improvement: -43.48% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 269\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the clinical value of MammaPrint?\n",
            "\n",
            "🎯 Gold Answer: MammaPrint has a prognostic value for distant metastasis and death, as well as predictive value for response to adjuvant chemotherapy in patients with breast cancer. However, the EGAPP Working Group found no evidence regarding the clinical utility of the MammaPrint.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the clinical value of MammaPrint is unclear. The EWG found no evidence regarding its clinical utility, indicating a lack of conclusive information on its effectiveness in clinical practice.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The clinical value of MammaPrint is currently unclear, with conflicting evidence regarding its utility and potential for both benefit and harm.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer acknowledges the conflicting evidence regarding the clinical value of MammaPrint.\n",
            "2. It references specific evidence from PubMed articles to support the statement.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not provide a clear conclusion or summary of the current understanding of MammaPrint's clinical value.\n",
            "2. It does not directly address the question of the clinical value of MammaPrint, leaving the reader without a definitive answer.\n",
            "3. The evidence provided from PubMed articles does not directly support the claim of potential benefit and harm associated with MammaPrint, as it only mentions the prognostic value and FDA clearance of the test.\n",
            "4. The statement about potential benefit and harm lacks specific evidence or context to explain how these conclusions were reached.\n",
            "\n",
            "Overall, the initial answer provides some insight into the uncertainty surrounding the clinical value of MammaPrint but lacks a clear and comprehensive evaluation supported by specific evidence. It would benefit from a more detailed analysis of the available research to provide a more informative response to the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The clinical value of MammaPrint remains uncertain, with conflicting evidence regarding its utility. While MammaPrint has shown prognostic value in certain studies, the overall clinical utility is still debated. The recent FDA clearance of MammaPrint indicates a step towards clinical validation, but further research is needed to determine its true benefit in guiding treatment decisions. The potential for both benefit and harm associated with MammaPrint, as suggested by the Evidence Working Group, underscores the importance of continued evaluation and validation of this test in clinical practice.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2466\n",
            "   Self-RAG: 0.1905\n",
            "   Improvement: -22.75% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 270\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which protein is affected by dusp8 activation?\n",
            "\n",
            "🎯 Gold Answer: dusp8 (M3/6) is a dual-specificity phosphatase selective for JNK.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The protein affected by DUSP8 activation is JNK (c-Jun N-terminal kinase).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "JNK (c-Jun N-terminal kinase) is affected by DUSP8 activation.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies JNK as a protein affected by DUSP8 activation, which is supported by evidence from Document 1 and Document 2.\n",
            "2. The answer provides specific references to PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from mentioning that DUSP8 also affects p38 MAPKs to provide a more complete answer. This information is supported by evidence from Document 2.\n",
            "2. The evidence provided does not directly address the activation of DUSP8, only its role in dephosphorylation and inactivation of JNK and p38 MAPKs. Therefore, the claim about DUSP8 activation affecting JNK could be more explicitly supported.\n",
            "3. The mention of potential loss of non-target proteins due to non-specific binding in Document 3 is not directly relevant to the question and could be considered extraneous information.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in evidence but could be improved by addressing the completeness of the response and providing more direct evidence supporting the claim about DUSP8 activation affecting JNK.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "DUSP8 activation affects both JNK (c-Jun N-terminal kinase) and p38 MAPKs by dephosphorylating and inactivating them, as supported by evidence from Document 2. While DUSP8's role in modulating JNK phosphorylation is well-established, its direct activation mechanism requires further investigation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2500\n",
            "   Self-RAG: 0.0714\n",
            "   Improvement: -71.43% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 271\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which scales are recommended by the American Heart Association for depression screening in cardiovascular patients? \n",
            "\n",
            "🎯 Gold Answer: Patient Health Questionnaire-2 (PHQ-2) and Patient Health Questionnaire-9 (PHQ-9) are recommended by the American Heart Association for depression screening in cardiovascular patients.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The American Heart Association recommends the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9) for depression screening in cardiovascular patients.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The American Heart Association recommends using the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9) for depression screening in cardiovascular patients.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that the American Heart Association recommends using the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9) for depression screening in cardiovascular patients. This is supported by evidence from all three provided documents, which specifically mention the use of these scales for depression screening in cardiac patients.\n",
            "\n",
            "2. COMPLETENESS: The initial answer adequately addresses all parts of the question by specifying the recommended scales (PHQ-2 and PHQ-9) for depression screening in cardiovascular patients as per the American Heart Association guidelines.\n",
            "\n",
            "3. GROUNDING: The initial answer is well-grounded in specific evidence from the provided PubMed articles. Each document cited supports the use of the PHQ-2 and PHQ-9 for depression screening in cardiac patients as recommended by the American Heart Association.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The recommendation of using the PHQ-2 and PHQ-9 for depression screening in cardiovascular patients is consistently backed by evidence from the provided documents.\n",
            "\n",
            "Overall, the initial answer is factually accurate, complete, well-grounded in specific evidence, and does not include any unsupported claims. It effectively addresses the question regarding the recommended scales for depression screening in cardiovascular patients according to the American Heart Association guidelines.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The American Heart Association recommends using the 2-item Patient Health Questionnaire (PHQ-2) followed by the 9-item Patient Health Questionnaire (PHQ-9) for depression screening in cardiovascular patients, as supported by recent AHA guidelines and evidence from multiple studies.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5818\n",
            "   Self-RAG: 0.4776\n",
            "   Improvement: -17.91% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 272\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which pharmacogenetic test is available for abacavir?\n",
            "\n",
            "🎯 Gold Answer: The pharmacogenetic test recommended prior to abacavir administration is the HLA B*5701 genotyping.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "HLA-B*5701 screening is the available pharmacogenetic test for abacavir.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "HLA-B*5701 testing is available for abacavir.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies HLA-B*5701 testing as relevant for abacavir. The evidence from the provided PubMed articles supports this claim by highlighting the association between HLA-B*5701 and abacavir hypersensitivity.\n",
            "\n",
            "2. COMPLETENESS: The initial answer adequately addresses the question by specifying the pharmacogenetic test available for abacavir, which is HLA-B*5701 testing. It provides a clear and concise response to the question.\n",
            "\n",
            "3. GROUNDING: The initial answer is grounded in specific evidence from the provided PubMed articles. The references to HLA-B*5701 testing in relation to abacavir hypersensitivity are directly supported by the excerpts provided.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The statement about HLA-B*5701 testing for abacavir is well-supported by the evidence presented.\n",
            "\n",
            "Overall, the initial answer is factually accurate, complete, well-grounded in specific evidence, and does not contain any unsupported claims. It effectively addresses the question regarding the pharmacogenetic test available for abacavir.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "HLA-B*5701 testing is specifically available for identifying patients at risk for abacavir-associated hypersensitivity reactions. This pharmacogenetic test has shown to be a cost-effective strategy in reducing the risk of hypersensitivity reactions to abacavir, particularly in predominantly white populations where the majority of patients do not carry the HLA-B*5701 allele.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3200\n",
            "   Self-RAG: 0.2254\n",
            "   Improvement: -29.58% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 273\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which two catechol-O-methyl transferase (COMT) inhibitors can be used for treatment of Parkinson disease?\n",
            "\n",
            "🎯 Gold Answer: Tolcapone (central and peripheral) and entacapone (peripheral) are catechol-O-methyl transferase inhibitors that are used for treatment of Parkinson disease.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The two catechol-O-methyl transferase (COMT) inhibitors used for the treatment of Parkinson's disease are tolcapone and entacapone.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Tolcapone and entacapone\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies tolcapone and entacapone as COMT inhibitors used for the treatment of Parkinson's disease.\n",
            "2. The evidence provided from PubMed articles supports the use of both tolcapone and entacapone in Parkinson's disease treatment.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could have been more specific in stating that entacapone is typically used in combination with levodopa/dopa decarboxylase inhibitor for Parkinson's disease patients experiencing end-of-dose wearing-off, as indicated in Document 2.\n",
            "2. The evidence provided does not explicitly mention tolcapone being used in combination with levodopa, which could have been clarified for completeness.\n",
            "3. The initial answer could have included additional information on the specific roles and differences between tolcapone and entacapone in the treatment of Parkinson's disease for a more comprehensive understanding.\n",
            "4. The initial answer does not mention any potential side effects or contraindications associated with the use of tolcapone and entacapone, which could have been important to address for a more well-rounded evaluation.\n",
            "\n",
            "Overall, the initial answer is mostly accurate but could benefit from providing more specific details and addressing potential side effects or limitations associated with the use of tolcapone and entacapone in Parkinson's disease treatment.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Tolcapone and entacapone are two catechol-O-methyl transferase (COMT) inhibitors used in the treatment of Parkinson's disease. Entacapone is typically administered in combination with levodopa/dopa decarboxylase inhibitor for Parkinson's disease patients experiencing end-of-dose wearing-off, as supported by Document 2. While both tolcapone and entacapone have been introduced as adjuncts to levodopa in Parkinson's disease treatment, specific roles and differences between the two inhibitors warrant further investigation. Additionally, potential side effects and contraindications associated with the use of tolcapone and entacapone should be considered for a comprehensive evaluation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5366\n",
            "   Self-RAG: 0.2414\n",
            "   Improvement: -55.02% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 274\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which genes are involved in patient response to warfarin?\n",
            "\n",
            "🎯 Gold Answer: The following genes have been associated with patient response to warfarin: CYP2C9, VKORC1, ORM1, CYP4F2, EPHX1, CYP2C18, CYP2C19, CYP3A5, protein S, clotting factor V, PROC, GGCX.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The genes involved in patient response to warfarin include CYP4F2 and VKORC1.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "CYP4F2, VKORC1, and other genetic polymorphisms are involved in patient response to warfarin.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies CYP4F2 and VKORC1 as genes involved in patient response to warfarin, which is supported by evidence from PubMed articles.\n",
            "2. The answer acknowledges the presence of other genetic polymorphisms that may also play a role in patient response to warfarin.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in detailing the role of each gene in patient response to warfarin. For example, it could mention that VKORC1 is involved in the vitamin K cycle and warfarin's mechanism of action.\n",
            "2. The answer could benefit from providing more detailed evidence from the PubMed articles to support the claims made about the involvement of CYP4F2 and VKORC1 in patient response to warfarin.\n",
            "3. The answer does not mention specific genetic variants or polymorphisms within CYP4F2 or VKORC1 that are associated with warfarin response, which could enhance the completeness of the response.\n",
            "4. The answer does not address the potential interactions between genetic polymorphisms and other factors that influence warfarin response, such as drug-drug interactions or environmental factors.\n",
            "\n",
            "Overall, the initial answer provides a good starting point by correctly identifying key genes involved in patient response to warfarin and acknowledging the presence of other genetic polymorphisms. However, it could be strengthened by providing more specific details and evidence to support these claims.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "CYP4F2 and VKORC1 are key genes involved in patient response to warfarin. Variants in CYP4F2 have been associated with warfarin dose requirements, while VKORC1 plays a crucial role in the vitamin K cycle and warfarin's mechanism of action. Specific genetic variants within these genes have been linked to variations in warfarin response. Additionally, other genetic polymorphisms beyond CYP4F2 and VKORC1 may also influence warfarin response, as genetic polymorphisms have been shown to significantly impact responses to both warfarin and clopidogrel. Further research is needed to explore potential interactions between genetic polymorphisms and other factors affecting warfarin response, such as drug-drug interactions and environmental influences.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3684\n",
            "   Self-RAG: 0.1343\n",
            "   Improvement: -63.54% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 275\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What pharmacological and non-pharmacological interventions can be considered as prophylactic therapies in Cluster Headache patients?\n",
            "\n",
            "🎯 Gold Answer: Verapamil, a calcium channel blocker, is considered the mainstay of prophylactic therapy of Cluster Headache patients. Lithium carbonate, topiramate, valproic acid, gabapentin, baclofen, methysergide, melatonin, ketoprofen and indomethacin can also be tried for prophylactic therapy of Cluster Headaches patients. Non-pharmacological prophylactic measures, such as peripheral (mostly occipital nerve) and central (hypothalamic) neurostimulation, ablative surgery, and botulinum toxin type-A (BTX-A) injection, can be also considered.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Pharmacological interventions for prophylactic treatment of Cluster Headache include lithium carbonate, verapamil, ketoprofen, botulinum toxin type-A (BTX-A), and topiramate. Non-pharmacological interventions were not mentioned in the provided context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Pharmacological interventions for prophylactic treatment of Cluster Headache include lithium carbonate, verapamil, ketoprofen, botulinum toxin type-A (BTX-A), and topiramate. Non-pharmacological interventions may also be considered, but specific details are not provided in the context.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately lists pharmacological interventions supported by the evidence, including lithium carbonate, verapamil, ketoprofen, botulinum toxin type-A (BTX-A), and topiramate. These interventions have been studied and shown efficacy in cluster headache patients.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the pharmacological interventions comprehensively. However, it lacks specific details on non-pharmacological interventions that can be considered as prophylactic therapies in cluster headache patients. It would have been more complete if it had included information on non-pharmacological options supported by evidence.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the pharmacological interventions mentioned. This grounding strengthens the credibility of the answer and shows that the recommendations are based on scientific research.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All the interventions listed are supported by evidence from the provided PubMed articles.\n",
            "\n",
            "Overall, the initial answer is strong in terms of factual accuracy and grounding in evidence. However, it could be improved by including information on specific non-pharmacological interventions supported by evidence for prophylactic treatment of cluster headache.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Pharmacological interventions for prophylactic treatment of Cluster Headache include lithium carbonate, verapamil, ketoprofen, botulinum toxin type-A (BTX-A), and topiramate, as supported by evidence. Non-pharmacological interventions such as oxygen therapy, nerve stimulation, and behavioral therapies have also shown efficacy in cluster headache patients. Studies have demonstrated the effectiveness of these non-pharmacological approaches in reducing the frequency and severity of cluster headache attacks.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2653\n",
            "   Self-RAG: 0.2273\n",
            "   Improvement: -14.34% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 276\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the mechanism of action of abiraterone?\n",
            "\n",
            "🎯 Gold Answer: Abiraterone acts by inhibiting cytochrome P450 17α-hydroxylase (CYP17A1), a critical step in androgen biosynthesis, thus leading to inhibition of androgen biosynthesis.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The mechanism of action of abiraterone involves inhibition of CYP17A1, a key enzyme involved in androgen biosynthesis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Abiraterone inhibits human cytochrome P45017alpha, specifically CYP17A1, which is involved in androgen biosynthesis.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies that abiraterone inhibits human cytochrome P45017alpha, specifically CYP17A1.\n",
            "2. The answer is supported by evidence from PubMed articles, specifically Document 1 and Document 3, which confirm the mechanism of action of abiraterone as an inhibitor of CYP17A1.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more comprehensive by providing additional context on how the inhibition of CYP17A1 affects androgen biosynthesis.\n",
            "2. The answer could benefit from referencing more evidence to strengthen the argument, such as additional studies or clinical trials supporting the mechanism of action of abiraterone.\n",
            "3. The initial answer does not address the full complexity of the mechanism of action of abiraterone, such as the downstream effects of inhibiting CYP17A1 on androgen biosynthesis pathways.\n",
            "4. There are no unsupported claims or hallucinations in the initial answer.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in specific evidence from PubMed articles. However, it could be improved by providing a more comprehensive explanation of the mechanism of action of abiraterone and referencing additional supporting evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Abiraterone inhibits human cytochrome P45017alpha, specifically CYP17A1, which plays a crucial role in androgen biosynthesis. By blocking CYP17A1, abiraterone disrupts the synthesis of androgens, including testosterone and dihydrotestosterone, which are essential for the growth of prostate cancer cells. This inhibition ultimately leads to decreased levels of circulating androgens, contributing to the therapeutic effect of abiraterone in treating castration-resistant prostate cancer. Multiple studies, including Document 1 and Document 3, support abiraterone's mechanism of action as a potent inhibitor of CYP17A1.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3590\n",
            "   Self-RAG: 0.2330\n",
            "   Improvement: -35.09% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 277\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Mutation of which gene and which chromosome cause Neurofibromatosis type I?\n",
            "\n",
            "🎯 Gold Answer: Neurofibromatosis Type I is an autosomal dominant condition associated with NF-1 gene mutation that is located in the long arm of chromosome 17 (17q11.2). In the majority (95%) of Neurofibromatosis Type I individuals, the mutation is found in the NF1 gene, while the remaining 5% of the patients have different types of genetic abnormalities.\n",
            "\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Mutation of the NF1 gene on chromosome 17 causes Neurofibromatosis type I.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Mutation of the NF1 gene on chromosome 17 causes Neurofibromatosis type I.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies the NF1 gene as being involved in Neurofibromatosis type I, which is supported by the evidence from Document 1 and Document 3. However, the claim that the mutation occurs on chromosome 17 is not entirely accurate based on the evidence provided.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the gene involved in Neurofibromatosis type I but fails to accurately specify the chromosome where the mutation occurs. This omission reduces the completeness of the answer.\n",
            "\n",
            "3. GROUNDING: The initial answer lacks specific evidence to support the claim that the mutation occurs on chromosome 17. While Document 2 mentions a mutation in chromosome 17 in a patient with neurofibromatosis type I, it does not specify that the NF1 gene mutation is located on this chromosome.\n",
            "\n",
            "4. HALLUCINATIONS: The claim that the NF1 gene mutation occurs on chromosome 17 is not directly supported by the evidence provided and could be considered an unsupported claim.\n",
            "\n",
            "Overall, the initial answer correctly identifies the NF1 gene as being involved in Neurofibromatosis type I but inaccurately states that the mutation occurs on chromosome 17. To improve accuracy and completeness, the answer should specify that the NF1 gene is located on chromosome 17q11.2 but mutations can occur throughout the gene.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Mutation of the NF1 gene located on chromosome 17q11.2 causes Neurofibromatosis type I. The NF1 gene mutations can occur throughout the gene, leading to the development of the condition. This information is supported by evidence from Document 1 and Document 3, which confirm the involvement of the NF1 gene on chromosome 17 in Neurofibromatosis type I.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2059\n",
            "   Self-RAG: 0.2832\n",
            "   Improvement: +37.55% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 278\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is there a difference in the rate between gene fusion and gene fission?\n",
            "\n",
            "🎯 Gold Answer: Yes. Several studies have estimated that gene fusion and fission are relatively rare events and the gene fusion/fission rate is approximately between 2 and 6. A conflicting case has been discovered in an analysis of plant genomes, where in Oryza sativa the opposite trend was observed.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, gene fusions are more prevalent than gene fissions.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Gene fusions are more prevalent than gene fissions based on the provided context from the scientific literature.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Critique:\n",
            "\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that gene fusions are more prevalent than gene fissions based on the provided evidence from Document 2 and Document 3. This claim is supported by the literature cited.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the question by comparing the rates of gene fusion and gene fission, providing a clear conclusion based on the evidence presented.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 2 and Document 3) to support the claim that gene fusions are more prevalent than gene fissions. This strengthens the argument and provides credibility to the conclusion.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. The claims made are backed by evidence from scientific literature, enhancing the reliability of the conclusion.\n",
            "\n",
            "Overall, the initial answer is well-supported by specific evidence from scientific literature, providing a clear and accurate comparison of the rates of gene fusion and gene fission. The answer is grounded in research and does not include any unsupported claims, making it a strong evaluation of the question.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Based on the evidence from Document 2 and Document 3, gene fusions are indeed more prevalent than gene fissions in genomic events. This conclusion is supported by quantitative analyses showing that gene fusions occur more frequently compared to gene fissions. The literature consistently indicates that gene fissions are relatively rare events in comparison to gene fusions, highlighting the prevalence difference between the two processes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1667\n",
            "   Self-RAG: 0.2124\n",
            "   Improvement: +27.43% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 279\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Is marijuana use associated with increased risk for stroke?\n",
            "\n",
            "🎯 Gold Answer: Yes, the use of marijuana is associated with increased risk for ischemic stroke, especially in young adults. The mechanisms underlying such association remain largely unclear, but increased vascular reactivity and increased cerebrovascular resistance were implicated.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, chronic abuse and episodic use of marijuana may be associated with an increased risk for stroke, particularly in childhood and involving the posterior circulation. Additional research and data may be needed to further establish this association.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Based on the provided context from PubMed articles, chronic and episodic marijuana use may be associated with an increased risk for stroke.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly references evidence from PubMed articles to support the claim that marijuana use may be associated with an increased risk for stroke.\n",
            "2. The answer addresses both chronic and episodic marijuana use in relation to stroke risk.\n",
            "\n",
            "Weaknesses:\n",
            "1. The evidence provided is limited to a few documents and may not represent a comprehensive review of all available literature on the topic.\n",
            "2. The answer does not specify the strength of the association between marijuana use and stroke risk, which is important for understanding the magnitude of the potential risk.\n",
            "3. The answer does not mention any potential confounding factors or limitations of the studies cited, which are crucial for interpreting the findings accurately.\n",
            "4. The answer does not acknowledge any conflicting evidence or alternative interpretations of the relationship between marijuana use and stroke risk.\n",
            "\n",
            "Overall, while the initial answer provides some evidence to support the association between marijuana use and stroke risk, it lacks depth in terms of discussing the strength of the association, potential confounders, limitations of the evidence, and conflicting findings in the literature. A more comprehensive review of the available evidence would strengthen the answer.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on a review of available literature, there is evidence suggesting that chronic abuse of marijuana may be a risk factor for stroke. Additionally, episodic marijuana use, particularly in childhood, may also pose a risk for stroke, especially in the posterior circulation. However, it is important to note that the strength of this association and potential confounding factors require further investigation. The existing evidence highlights the need for a more comprehensive analysis to fully understand the relationship between marijuana use and stroke risk.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3421\n",
            "   Self-RAG: 0.1695\n",
            "   Improvement: -50.46% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 280\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which drug should be used as an antidote in benzodiazepine overdose?\n",
            "\n",
            "🎯 Gold Answer: Flumazenil should be used in all patients presenting with suspected benzodiazepine overdose. Flumazenil is a  potent benzodiazepine receptor antagonist that competitively blocks the central effects of benzodiazepines and reverses behavioral, neurologic, and electrophysiologic effects of benzodiazepine overdose. Clinical efficacy and safety of flumazenil in treatment of benzodiazepine overdose has been confirmed in a number of rigorous clinical trials. In addition, flumazenil is also useful to to reverse benzodiazepine induced sedation and to and to diagnose benzodiazepine overdose.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Flumazenil is the drug that should be used as an antidote in benzodiazepine overdose, based on the provided context.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Flumazenil\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies Flumazenil as the antidote for benzodiazepine overdose, which is supported by the evidence provided from PubMed articles.\n",
            "2. The evidence cited from Document 1, Document 2, and Document 3 supports the claim that Flumazenil is used in the treatment of benzodiazepine overdose.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be improved by providing more specific details on the efficacy and safety of Flumazenil in the treatment of benzodiazepine overdose. While the evidence supports the claim that Flumazenil is effective and safe, more specific data or statistics could strengthen the argument.\n",
            "2. The initial answer does not address potential contraindications or limitations of using Flumazenil as an antidote in benzodiazepine overdose. Including this information would provide a more comprehensive answer.\n",
            "3. The evidence provided does not mention the differential diagnosis of a coma of unknown origin as a specific indication for Flumazenil use. While it may have some relevance, the initial answer could be more focused on the use of Flumazenil specifically in benzodiazepine overdose.\n",
            "\n",
            "Overall, the initial answer is generally accurate and supported by evidence, but it could be enhanced by providing more specific details and addressing potential limitations of Flumazenil use in benzodiazepine overdose.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Flumazenil is the antidote used in benzodiazepine overdose. Evidence supports its efficacy and safety in treating benzodiazepine overdose. Flumazenil, a specific benzodiazepine antagonist, has been shown to be effective and safe in managing benzodiazepine overdose. However, it is important to note that Flumazenil should be used cautiously in patients with a history of seizures or benzodiazepine dependence, as it can precipitate withdrawal symptoms or seizures.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1667\n",
            "   Self-RAG: 0.2535\n",
            "   Improvement: +52.11% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 281\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which diseases can Oncotype DX be used for?\n",
            "\n",
            "🎯 Gold Answer: Oncotype can be used for predicting breast cancer and colon cancer recurrence.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Oncotype DX can be used for prognosis estimation and treatment decisions in cancer.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Oncotype DX can be used for prognosis estimation and treatment decisions in cancer.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that Oncotype DX can be used for prognosis estimation and treatment decisions in cancer, which is supported by the evidence provided from PubMed articles.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not specify which types of cancer Oncotype DX can be used for. It would be more complete if it mentioned that Oncotype DX is primarily used in breast cancer but can also be used in other types of cancer such as prostate cancer and colon cancer.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that Oncotype DX can be used for prognosis estimation and treatment decisions in cancer. This strengthens the credibility of the statement.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All claims are backed up by evidence from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence. To improve, it could be more complete by specifying the types of cancer for which Oncotype DX is commonly used.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Oncotype DX is primarily used for prognosis estimation and treatment decisions in breast cancer. It can also be utilized in other types of cancer such as prostate cancer and colon cancer. The genomic assay aids in avoiding over or under therapy, as supported by evidence from PubMed articles.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.5600\n",
            "   Self-RAG: 0.2667\n",
            "   Improvement: -52.38% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 282\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How functional connectivity of the default mode network changes in patients with disorders of consciousness?\n",
            "\n",
            "🎯 Gold Answer: Functional connectivity in the default mode network (DMN) is reduced in patients with different disorders of consciousness, and correlates with the level of consciousness. \n",
            "Specifically, functional connectivity in the default mode network was shown to be absent in brain death patients, extremely low in vegetative state patients and slightly decreased in minimally conscious state patients when compared to healthy subjects. Therefore, functional connectivity in the default mode network was suggested to be valuable in differentiating patients with different disorders of consciousness. Clinically, functional connectivity in the default mode network was also shown to be an indicator of the extent of cortical disruption and predict reversible impairments in consciousness.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Functional connectivity in the default mode network is known to be reduced in patients with disorders of consciousness, with the extent of reduction varying based on the clinical severity of the condition.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Functional connectivity in the default mode network is reduced in patients with disorders of consciousness, with the extent of reduction varying based on clinical severity.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that functional connectivity in the default mode network is reduced in patients with disorders of consciousness.\n",
            "2. The answer acknowledges that the extent of reduction varies based on clinical severity, which is supported by the evidence provided.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specific references to the evidence provided from PubMed articles. It would strengthen the response to directly cite the relevant studies.\n",
            "2. The answer could benefit from further elaboration on the potential implications of changes in functional connectivity within the default mode network for patients with disorders of consciousness.\n",
            "3. The answer does not address the potential mechanisms underlying the observed changes in functional connectivity within the default mode network in patients with disorders of consciousness.\n",
            "4. There are no unsupported claims or hallucinations in the initial answer.\n",
            "\n",
            "Overall, the initial answer is generally accurate but could be improved by providing more specific references to the evidence and expanding on the implications and mechanisms related to changes in functional connectivity within the default mode network in patients with disorders of consciousness.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Functional connectivity in the default mode network is reduced in patients with disorders of consciousness, as evidenced by studies such as Document 2 from PubMed. This reduction varies in severity depending on the clinical status of the patient. Assessing functional connectivity in the resting-state default-mode network, as suggested in Document 1, may serve as a valuable marker of consciousness disturbance, even in cases with reversible brain lesions. The default mode network is proposed to play a role in basic functions related to consciousness, as indicated in Document 3. Further research is needed to elucidate the underlying mechanisms driving these changes and their implications for patient outcomes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3143\n",
            "   Self-RAG: 0.3611\n",
            "   Improvement: +14.90% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 283\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which pituitary adenoma is common cause of infertility is women?\n",
            "\n",
            "🎯 Gold Answer: Prolactinoma is a pituitary adenoma that is strongly associated with infertility in women mainly due to increased prolactin secretion causing hyperprolactinemia. Other pituitary lesions can also be associated with infertility.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Prolactinoma is the pituitary adenoma commonly associated with infertility in women.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Prolactinoma is the pituitary adenoma commonly associated with infertility in women.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies prolactinoma as a pituitary adenoma commonly associated with infertility in women.\n",
            "2. The answer is grounded in evidence from PubMed articles, specifically Document 1 and Document 3.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it does not mention other pituitary adenomas that can also cause infertility in women, such as non-functioning adenomas or gonadotroph adenomas.\n",
            "2. The answer could benefit from referencing more evidence to support the claim, such as additional studies or clinical guidelines.\n",
            "3. There is a potential weakness in grounding as the answer does not directly address the evidence from Document 2, which also supports the association between hyperprolactinemic amenorrhea and infertility caused by pituitary adenomas.\n",
            "\n",
            "Overall, while the initial answer is partially accurate and grounded in some evidence, it could be improved by addressing the weaknesses mentioned above for a more comprehensive and well-supported response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Prolactinoma is a common pituitary adenoma associated with infertility in women, particularly through hyperprolactinemic amenorrhea. However, other pituitary adenomas, such as non-functioning adenomas or gonadotroph adenomas, can also contribute to infertility. Evidence from Document 2 supports the association between hyperprolactinemic amenorrhea and infertility caused by pituitary adenomas.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4390\n",
            "   Self-RAG: 0.4103\n",
            "   Improvement: -6.55% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 284\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Intact macromolecular assemblies are analysed by advanced mass spectrometry. How large complexes (in molecular weight) have been studied?\n",
            "\n",
            "🎯 Gold Answer: 2.3 megadalton\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Intact macromolecular assemblies with molecular weights approaching one megadalton have been studied using advanced mass spectrometry techniques.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Intact macromolecular assemblies approaching one megadalton in molecular weight have been studied using advanced mass spectrometry techniques.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that intact macromolecular assemblies approaching one megadalton in molecular weight have been studied using advanced mass spectrometry techniques. This claim is supported by evidence from Document 1, which mentions the measurement of protein assemblies of molecular weights approaching one megadalton using the Orbitrap mass analyzer.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main part of the question by stating that macromolecular assemblies approaching one megadalton have been studied. However, it could be more comprehensive by mentioning the specific techniques and instruments used in these studies, as evidenced in Document 3 which discusses the use of high-field Fourier transform ion cyclotron resonance (FTICR)-mass spectrometry.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claim that macromolecular assemblies approaching one megadalton have been studied using advanced mass spectrometry techniques. This grounding strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the information provided in the evidence from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate and grounded in specific evidence from scientific literature. However, it could be improved by providing more details about the specific techniques and instruments used in studying large macromolecular assemblies.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Intact macromolecular assemblies approaching one megadalton in molecular weight have been studied using advanced mass spectrometry techniques, such as high-field Fourier transform ion cyclotron resonance (FTICR)-mass spectrometry. These techniques have enabled the characterization of large complexes and their modifications, providing insights into the heterogeneity of macromolecular assemblies. This information is supported by evidence from scientific literature, demonstrating the capability of mass spectrometry in analyzing complex biological structures.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1000\n",
            "   Self-RAG: 0.0278\n",
            "   Improvement: -72.22% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 285\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which enzyme is involved in the maintenance of DNA (cytosine-5-)-methylation?\n",
            "\n",
            "🎯 Gold Answer: The mammalian DNA (cytosine-5) methyltransferase 1, DNMT1 is the major enzyme responsible for the maintenance of the DNA methylation patterns on the newly synthesized strand after DNA replication. DNMT1 prefers hemimethylated DNA and during DNA replication methylates hemimethylated CpG sites by copying methylation patterns from the parental DNA strand to the newly synthesized daughter strand. The equivalent of DNMT1 in plants is MET1.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The enzyme involved in the maintenance of DNA (cytosine-5-)-methylation is DNA cytosine-5 methyltransferase (MTase).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "DNA cytosine-5 methyltransferase (MTase) is involved in the maintenance of DNA (cytosine-5-) methylation.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies DNA cytosine-5 methyltransferase (MTase) as the enzyme involved in the maintenance of DNA (cytosine-5-) methylation. This claim is supported by the evidence provided in Document 2, which describes DNA cytosine-5 methyltransferase as the enzyme responsible for maintaining methylation patterns.\n",
            "\n",
            "2. COMPLETENESS: The initial answer adequately addresses the main aspect of the question by identifying the enzyme involved in the maintenance of DNA methylation. However, it could have provided more context on the different types of DNA methylation processes mentioned in Document 3, such as de novo methylation.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 2 to support the claim that DNA cytosine-5 methyltransferase is involved in the maintenance of DNA methylation. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. It accurately reflects the information provided in the evidence from PubMed articles.\n",
            "\n",
            "Overall, the initial answer is factually accurate, adequately addresses the main question, references specific evidence, and does not include unsupported claims. It provides a solid foundation based on the available evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "DNA cytosine-5 methyltransferase (MTase) is the enzyme responsible for maintaining DNA (cytosine-5-) methylation patterns. This enzyme, as described in Document 2, plays a crucial role in establishing and preserving methylation patterns across DNA replication cycles. Additionally, DNA methylation processes involve both maintenance-type methylation, ensuring fidelity in methylation inheritance, and de novo methylation, initiating new methylation patterns.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1975\n",
            "   Self-RAG: 0.3089\n",
            "   Improvement: +56.40% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 286\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Have Quantitative Trait Loci affecting splicing (splicing QTLs) been linked to disease?\n",
            "\n",
            "🎯 Gold Answer: Yes, mutations in the DNA that affect the splicing pattern of genes have been linked in transcriptome population studies to a number of diseases.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, splicing QTLs have been linked to disease, as evidenced by the somatic mutations in the SF3B1 gene, which is involved in splicing and is mutated in a subset of affected individuals.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, splicing Quantitative Trait Loci (sQTLs) have been linked to disease, as evidenced by the somatic mutations in the SF3B1 gene, which is involved in splicing and is mutated in a subset of affected individuals.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies that splicing Quantitative Trait Loci (sQTLs) have been linked to disease.\n",
            "2. The mention of somatic mutations in the SF3B1 gene, which is involved in splicing and is mutated in a subset of affected individuals, provides specific evidence to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The evidence provided from PubMed articles does not directly support the claim that sQTLs have been linked to disease. While the mention of sequence variations affecting splice sites is relevant to splicing, it does not specifically address the link between sQTLs and disease.\n",
            "2. The evidence provided does not directly link the SF3B1 gene mutations to sQTLs, which weakens the connection between sQTLs and disease.\n",
            "3. The initial answer could benefit from more direct references to studies or research that specifically link sQTLs to disease, rather than general information about splicing and mutations in the SF3B1 gene.\n",
            "\n",
            "Overall, the initial answer provides some relevant information but lacks direct evidence linking sQTLs to disease. It would be strengthened by referencing specific studies or research that establish this connection.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "While sequence variations affecting splice sites have been identified in certain genes like Acox2, Trak2, and Pex11b, potentially leading to aberrant splicing, the direct link between splicing Quantitative Trait Loci (sQTLs) and disease remains an area of ongoing research. Somatic mutations in the SF3B1 gene, a component of the spliceosomal U2 small nuclear ribonucleoprotein (snRNP), have been observed in a subset of affected individuals, indicating a role in disease pathogenesis. However, further studies are needed to establish a definitive connection between sQTLs and disease.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2857\n",
            "   Self-RAG: 0.2182\n",
            "   Improvement: -23.64% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 287\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the catalytic mechanism of DNA (cytosine-5) methyltransferases? \n",
            "\n",
            "🎯 Gold Answer: The catalytic mechanism of the DNA (Cytosine-5-)-methyltransferase involves nucleophilic attack of the C6 of the substrate cytosine by the single conserved cysteine of the enzyme, followed by C5 nucleophilic replacement of the methyl group of the cofactor S-adenosyl-L-methionine (AdoMet) to produce 5-methyl-6-Cys-81-S-5,6-dihydrocytosine. It has been also demonstrated that Phe and Glu, which are found in the catalytic motifs I and II of the enzyme are important for AdoMet binding and catalysis.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The catalytic mechanism of DNA (cytosine-5) methyltransferases involves attack of the C6 of substrate cytosines by an enzyme nucleophile and formation of a transient covalent adduct.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The catalytic mechanism of DNA (cytosine-5) methyltransferases involves attack of the C6 of substrate cytosines by an enzyme nucleophile and formation of a transient covalent adduct.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that the catalytic mechanism of DNA (cytosine-5) methyltransferases involves the attack of the C6 of substrate cytosines by an enzyme nucleophile and the formation of a transient covalent adduct. This claim is supported by evidence from Document 1 and Document 2.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the catalytic mechanism of DNA (cytosine-5) methyltransferases, specifically focusing on the attack of C6 of substrate cytosines. However, it does not mention other aspects of the catalytic mechanism, such as the role of the conserved cysteine or the necessity of covalent intermediate formation, as discussed in Document 2 and Document 3, respectively.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles (Document 1, Document 2, and Document 3) to support the claims made about the catalytic mechanism of DNA (cytosine-5) methyltransferases. This grounding strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. It accurately reflects the information provided in the referenced documents.\n",
            "\n",
            "Overall, the initial answer provides an accurate description of the catalytic mechanism of DNA (cytosine-5) methyltransferases based on the evidence presented. However, it could be improved by addressing additional aspects of the mechanism\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The catalytic mechanism of DNA (cytosine-5) methyltransferases involves the attack of the C6 of substrate cytosines by an enzyme nucleophile, typically a conserved cysteine, which activates the normally inert C5 position. This process leads to the formation of a transient covalent adduct. While covalent intermediate formation was previously thought to be essential for methyl group transfer, recent studies suggest that it may not be necessary for some enzymes like murine Dnmt3a.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3784\n",
            "   Self-RAG: 0.3462\n",
            "   Improvement: -8.52% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 288\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the function of TALENs?\n",
            "\n",
            "🎯 Gold Answer: Transcription Activator-Like Effector Nucleases (TALENs) consist of a nuclease domain fused to a DNA binding domain which is engineered to bind to any genomic sequence. These chimeric enzymes can be used to introduce a double strand break at a specific genomic site which then can become the substrate for error-prone non-homologous end joining (NHEJ), generating mutations at the site of cleavage. TALENs provide a powerful new approach for targeted genome editing and functional genomic applications.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The function of TALENs is to introduce a double-strand break at a specific genomic site, which can lead to mutations through error-prone non-homologous end joining (NHEJ).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The function of TALENs is to introduce a double strand break at a specific genomic site, which can lead to error-prone non-homologous end joining and generate mutations at the site of cleavage.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that the function of TALENs is to introduce a double strand break at a specific genomic site.\n",
            "2. The answer accurately mentions that this can lead to error-prone non-homologous end joining and generate mutations at the site of cleavage.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in terms of the mechanism of action of TALENs. It could have provided more details on how TALENs bind to specific genomic sequences and induce double strand breaks.\n",
            "2. The answer does not mention the fusion of the nuclease domain with the DNA binding domain in TALENs, which is crucial for their function.\n",
            "3. The evidence provided from PubMed articles supports the claims made in the initial answer, but the answer could have directly referenced specific statements from these articles to strengthen its grounding.\n",
            "4. The initial answer does not include any hallucinations or unsupported claims.\n",
            "\n",
            "Overall, the initial answer is generally accurate but lacks specificity and direct referencing to the evidence provided. It could be improved by providing more detailed information on the mechanism of action of TALENs and directly citing specific statements from the supporting documents.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The function of TALENs involves a nuclease domain fused to a DNA binding domain, allowing them to bind to specific genomic sequences and induce double strand breaks at targeted sites. This process triggers error-prone non-homologous end joining, leading to mutations at the cleavage site. TALENs are programmable nucleases that combine the FokI endonuclease with the modular DNA-binding domain of TALEs, enabling precise genome editing. This mechanism provides a powerful tool for targeted genome editing and functional genomic applications in various organisms, as supported by recent studies (Document 1, Document 2, Document 3).\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.4112\n",
            "   Self-RAG: 0.4855\n",
            "   Improvement: +18.08% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 289\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the clinical trial outcomes of metformin use in polycystic ovary disease?\n",
            "\n",
            "🎯 Gold Answer: Metformin treatment vs placebo significantly but modestly improves ovulation frequency in women with abnormal ovarian function/oligomenorrhea and polycystic ovaries,  the lower BMI women were more likely to become pregnant.  While in naturally conceiving normal weight PCOS women pre-treatment with metformin tends to improve pregnancy rates, pre-treatment with metformin prior to conventional IVF/ICSI in women with PCOS does not improve stimulation or clinical outcome.\n",
            "Metformin is an effective addition to Clomifene Citrate in term of reestablishment of ovulation and full-term pregnancies achievement.\n",
            "Studies on the effect of metformin on serum Anti-Mullerian Hormone levels /AMH concentrations bring conflicting results, from Metformin having no effect on AMH  to Metformin treatment resulting in significant decrease of AMH levels, antral follicle numbers and ovarian volume. \n",
            "Metformin has been shown to cause significant weight loss (and leptin reduction) in PCOS.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The clinical trial outcomes of metformin use in polycystic ovary disease include improved ovulation frequency in women with abnormal ovarian function and polycystic ovaries, as well as modest improvement in cardiovascular risk factors with protracted treatment.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Metformin treatment in women with polycystic ovary syndrome has been shown to improve ovulation frequency significantly but to a modest degree. Additionally, protracted treatment with metformin has been found to improve cardiovascular risk factors in these women.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer accurately states that metformin treatment in women with polycystic ovary syndrome improves ovulation frequency significantly but to a modest degree, and that protracted treatment can improve cardiovascular risk factors. These claims are supported by the evidence provided from PubMed articles.\n",
            "\n",
            "2. COMPLETENESS: The initial answer addresses the main outcomes of metformin use in polycystic ovary syndrome, focusing on ovulation frequency improvement and cardiovascular risk factor improvement. However, it could be more comprehensive by discussing other potential outcomes or side effects of metformin use in this context.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the claims made about the clinical trial outcomes of metformin use in polycystic ovary syndrome. This strengthens the credibility of the answer.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All statements are grounded in the evidence provided from PubMed articles.\n",
            "\n",
            "Overall, the initial answer provides a factual and well-supported overview of the clinical trial outcomes of metformin use in polycystic ovary syndrome. It accurately summarizes the findings from the referenced studies and avoids making unsupported claims. However, it could be more comprehensive by discussing other potential outcomes or side effects of metformin use in this context.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Metformin treatment in women with polycystic ovary syndrome has been shown to significantly improve ovulation frequency to a modest degree. Protracted treatment with metformin has also been found to improve cardiovascular risk factors in these women, as supported by a large randomized placebo-controlled trial. While the main outcomes of metformin use in polycystic ovary syndrome include improved ovulation frequency and cardiovascular risk factors, other potential outcomes and side effects should be considered for a more comprehensive understanding.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1932\n",
            "   Self-RAG: 0.1927\n",
            "   Improvement: -0.27% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 290\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the role of deadenylases in the cell?\n",
            "\n",
            "🎯 Gold Answer: The 3'-poly(A) tail, found on mRNAs, is enzymatically shortened by a process referred to as \"deadenylation\" which is carried out by deadenylases. Deadenylases are magnesium dependent exoribonucleases that specifically catalyze the degradation of eukaryotic mRNA poly(A) tail in the 3'-->5' direction with the release of 5'-AMP as the product. They consist of three potential RNA-binding domains: the catalytic nuclease domain, the R3H domain and the RRM domain.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Deadenylases play a role in the regulated shortening of the poly(A) tail of mRNA, which is a key first step in mRNA turnover. Additionally, deadenylases are involved in P-body formation and regulation, contributing both structurally and functionally to these processes. Some of the identified deadenylases in eukaryotic cells include PARN, Nocturnin, and Angel.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Deadenylases play a role in mRNA turnover by regulating the shortening of the poly(A) tail, and they are also involved in P-body formation and regulation in the cell.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that deadenylases play a role in mRNA turnover by regulating the shortening of the poly(A) tail, which is supported by evidence from Document 1.\n",
            "2. The answer also mentions the involvement of deadenylases in P-body formation and regulation, which is supported by evidence from Document 2.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in mentioning the different deadenylases involved in these processes. Document 3 provides examples such as PARN, Nocturnin, and Angel, which could have been included for completeness.\n",
            "2. The answer could have provided more detailed information on how deadenylases specifically contribute to P-body formation and regulation, beyond just stating their involvement.\n",
            "3. The answer could have been strengthened by providing more context on the significance of deadenylases in these cellular processes, such as their impact on gene expression regulation.\n",
            "\n",
            "Overall, the initial answer is generally accurate and supported by evidence, but it could benefit from more specific details and context to enhance its completeness and depth.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Deadenylases, including enzymes like PARN, Nocturnin, and Angel, are crucial in mRNA turnover by regulating the shortening of the poly(A) tail. These deadenylases also play a significant role in P-body formation and regulation within the cell, contributing structurally and functionally to these processes. The involvement of multiple deadenylases highlights the complexity of mRNA degradation and cellular regulation mechanisms. Further research is needed to fully understand the specific contributions of each deadenylase and their impact on gene expression regulation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2031\n",
            "   Self-RAG: 0.1961\n",
            "   Improvement: -3.47% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 291\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the DNA (cytosine-5-)-methyltransferases inhibitors?\n",
            "\n",
            "🎯 Gold Answer: DNA (Cytosine-5-)-methyltransferases are a family of enzymes that methylate DNA at the C5 position of cytosine residues. Given that methylation of tumour suppressor gene promoters leads to carcinogenesis, inhibition of DNA (Cytosine-5-)-methyltransferases is a promising strategy for the treatment of cancer. There are several inhibitors of DNA (Cytosine-5-)-methyltransferases that uses different modes of action: 5-azacytidine (5-aza-CR, Vidaza®), 5-azadeoxycytidine (5-aza-CdR, decitabine, Dacogen®), 5-azacytosine (ZCyt), 5-fluorodeoxycytidine (FdC), 5,6-dihydro-5-azacytosine (DZCyt), 4'-thio-2'-deoxycytidine, hydralazine, 2-(1H)-pyrimidinone riboside (zebularine), 2-(1H)-pyrimidinone (zebularine aglycon), procaine, procainamide, psammaplin A, and RSC133, a new synthetic derivative of indoleacrylic acid/indolepropionic acid.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the DNA (cytosine-5-)-methyltransferase inhibitor mentioned is 5-azacytosine.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The DNA (cytosine-5-)-methyltransferases inhibitors include 5-azacytosine.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies 5-azacytosine as a DNA (cytosine-5-)-methyltransferases inhibitor, which is supported by evidence from Document 1 and Document 2.\n",
            "2. The answer provides specific evidence from PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks completeness as it only mentions 5-azacytosine as a DNA (cytosine-5-)-methyltransferases inhibitor. There are other inhibitors of DNA methyltransferases that could have been included for a more comprehensive answer.\n",
            "2. The answer could benefit from providing a broader range of inhibitors or discussing the mechanism of action of these inhibitors to enhance understanding.\n",
            "3. The evidence provided does not fully explain the mechanism of inhibition by 5-azacytosine, which could have been elaborated on for a more thorough evaluation.\n",
            "\n",
            "Overall, the initial answer is partially accurate and grounded in evidence but lacks completeness and depth in discussing DNA (cytosine-5-)-methyltransferases inhibitors.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "DNA (cytosine-5-)-methyltransferases inhibitors include 5-azacytosine as a mechanism-based inhibitor. In addition to 5-azacytosine, other inhibitors of DNA methyltransferases, such as RG108 and decitabine, are also known. The mechanism of inhibition by 5-azacytosine likely involves methyl transfer to the inhibitor, affecting the methylation process. Further research is needed to fully elucidate the mechanisms of action of these inhibitors.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1231\n",
            "   Self-RAG: 0.1778\n",
            "   Improvement: +44.44% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 292\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How does trimetazidine affect intracellular kinase signaling in the heart?\n",
            "\n",
            "🎯 Gold Answer: Trimetazidine activates AMPK in diabetic myocardium. Trimetazidine  when administered before reperfusion results in activation of p38 mitogen-activated protein kinase and Akt signaling. Trimetazidine  when administered during reperfusion does not affect p38MAPK and JNK activation.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Trimetazidine activates AMPK and reduces PGC-1 alpha expression in the hearts of db/db mice, suggesting that it affects intracellular kinase signaling by modulating AMPK and PGC-1 alpha pathways.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Trimetazidine activates AMPK and reduces PGC-1 alpha expression in the hearts of db/db mice, suggesting that it affects intracellular kinase signaling by modulating AMPK activation and PGC-1 alpha expression.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that trimetazidine activates AMPK and reduces PGC-1 alpha expression in the hearts of db/db mice, which is supported by evidence from multiple PubMed articles.\n",
            "2. The answer acknowledges the involvement of AMPK activation and PGC-1 alpha expression modulation in the intracellular kinase signaling affected by trimetazidine.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in explaining how trimetazidine affects intracellular kinase signaling beyond AMPK activation and PGC-1 alpha expression modulation. It would be beneficial to provide more detailed information on other signaling pathways affected by trimetazidine.\n",
            "2. While the answer is supported by evidence from PubMed articles, it would be stronger if it directly quoted or referenced specific data from these articles to provide a more robust grounding for the claims made.\n",
            "3. The answer does not address potential limitations or conflicting evidence regarding the effects of trimetazidine on intracellular kinase signaling in the heart. It is important to consider the broader context and potential nuances in the research findings.\n",
            "\n",
            "Overall, the initial answer provides a basic understanding of how trimetazidine affects intracellular kinase signaling in the heart but could benefit from more detailed and specific information, as well as a more comprehensive evaluation of the existing evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Trimetazidine affects intracellular kinase signaling in the heart primarily by activating AMPK and reducing PGC-1 alpha expression, as evidenced in studies on db/db mice. Additionally, trimetazidine has been shown to improve cardiac function by attenuating lipotoxicity and enhancing cardiac oxidation status. While the exact mechanisms beyond AMPK and PGC-1 alpha modulation require further investigation, these pathways play a significant role in the cardioprotective effects of trimetazidine. Further research is needed to elucidate the full scope of intracellular kinase signaling affected by trimetazidine in the heart.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2424\n",
            "   Self-RAG: 0.1626\n",
            "   Improvement: -32.93% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 293\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the correlation between SPARC expression and growth inhibition in human cancer?\n",
            "\n",
            "🎯 Gold Answer: Secreted protein acidic and rich in cysteine (SPARC) is a multi-faceted protein-modulating cell-cell and cell-matrix interactions. SPARC seems to act as a tumour suppressor, as it has been found that loss of SPARC accelerates the development of certain types of cancer, whereas its expression impairs tumor growth. However it has also been associated with a aggressive phenotypes of some tumours. The role of SPARC may depend on its subcellular localization.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The correlation between SPARC expression and growth inhibition in human cancer varies depending on the type of cancer. In some cancers, such as breast cancer and pancreatic ductal adenocarcinoma (PDAC), SPARC has been shown to inhibit tumor growth and act as a tumor suppressor. However, in other cancers like melanoma and glioma, SPARC may have stimulatory effects on proliferation and migration.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The correlation between SPARC expression and growth inhibition in human cancer varies depending on the type of cancer. SPARC has been shown to delay tumor growth in some cancers such as breast cancer and pancreatic ductal adenocarcinoma (PDAC), suggesting a potential tumor suppressor role. However, SPARC may have different effects in other cancers such as melanoma and glioma, where it can stimulate proliferation and migration.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer acknowledges the variability in the correlation between SPARC expression and growth inhibition in different types of human cancers.\n",
            "2. The answer provides specific examples of the effects of SPARC in different cancers, such as breast cancer, PDAC, melanoma, and glioma.\n",
            "3. The answer references specific evidence from PubMed articles to support the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from a more detailed explanation of the mechanisms underlying the observed effects of SPARC in different cancers.\n",
            "2. While the answer mentions the effects of SPARC in breast cancer, PDAC, melanoma, and glioma, it could be strengthened by including more diverse examples to provide a broader perspective on the correlation between SPARC expression and growth inhibition in human cancer.\n",
            "3. The answer could be improved by discussing any conflicting or inconclusive evidence regarding the correlation between SPARC expression and growth inhibition in human cancer.\n",
            "\n",
            "Overall, the initial answer provides a good overview of the correlation between SPARC expression and growth inhibition in human cancer, supported by specific evidence. However, it could be enhanced by providing more detailed explanations and additional examples to strengthen the argument.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The correlation between SPARC expression and growth inhibition in human cancer is complex and varies across different cancer types. For instance, SPARC has been shown to delay tumor growth in some cancers like breast cancer and pancreatic ductal adenocarcinoma (PDAC), indicating a potential tumor suppressor role. In breast cancer, SPARC inhibits cell proliferation without stimulating migration. Conversely, in melanoma and glioma, SPARC can promote proliferation and migration. Additionally, SPARC levels can influence the malignant phenotype of PDAC cells, suggesting a potential tumor-suppressive role in this cancer type. The effects of SPARC on tumor growth and invasion correlate with its expression levels in various cancers. Further research is needed to elucidate the underlying mechanisms and explore the broader spectrum of SPARC's effects in different cancer types.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1926\n",
            "   Self-RAG: 0.1891\n",
            "   Improvement: -1.84% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 294\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are chromomethylases present in animal genomes?\n",
            "\n",
            "🎯 Gold Answer: No. Multiple lines of experimental evidence suggest that chromomethylases (CMTs) have been hitherto identified in plant genomes(Arabidopsis, maize, tomato). CMTs maintain CpNpG (N = A, T, C, or G) methylation and they are unique to the plant kingdom. The lack of CMT homologs in animal genomes could be explained based on the fact that, in contrast to plants, animals maintain primarily CG methylation. Therefore, the presence of CMTs is not required in the animal genomes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, chromomethylases have been characterized in plants (P. oceanica and maize), but there is no direct mention of chromomethylases in animal genomes.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Based on the provided context, chromomethylases have been characterized in plant genomes (P. oceanica and maize), but there is no mention of their presence in animal genomes.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that chromomethylases have been characterized in plant genomes such as P. oceanica and maize, which is supported by evidence from Document 1 and Document 2.\n",
            "2. The answer acknowledges the absence of mention of chromomethylases in animal genomes, which aligns with the evidence provided.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from explicitly stating that there is no evidence of chromomethylases in animal genomes, rather than just mentioning the lack of mention. This would provide a more definitive conclusion.\n",
            "2. The answer could be strengthened by discussing the implications of the absence of chromomethylases in animal genomes and potential reasons for this difference compared to plant genomes.\n",
            "3. The answer could also elaborate on the significance of chromomethylases in plant genomes and their role in DNA methylation processes.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in specific evidence from PubMed articles. However, it could be improved by providing a more definitive conclusion regarding the presence of chromomethylases in animal genomes and discussing the broader implications of this absence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Based on current evidence, chromomethylases have been characterized in plant genomes such as P. oceanica and maize, as documented in PubMed articles. There is no conclusive evidence supporting the presence of chromomethylases in animal genomes. The absence of chromomethylases in animal genomes raises questions about the differences in DNA methylation processes between plants and animals. Further research is needed to explore the significance of chromomethylases in plant genomes and their specific roles in DNA methylation mechanisms.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1980\n",
            "   Self-RAG: 0.2914\n",
            "   Improvement: +47.15% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 295\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Are transcription and splicing connected?\n",
            "\n",
            "🎯 Gold Answer: Yes. There is strong evidence that splicing and transcription are intimately coupled in metazoans, with  genome wide surveys show that most splicing occurs during transcription. Chromatin structure, RNA polymerase dynamics, and recruitment of splicing factors through the transcriptional machinery are factors that explain a role for transcription in the regulation of splicing.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, transcription and splicing are connected as they are functionally coupled processes, and the rate of transcription elongation has been linked to alternative splicing. Splicing regulation depends on factors related to transcription, such as protein recruitment to the transcribing machinery and elongation kinetics.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, transcription and splicing are connected as they are functionally coupled processes, and the rate of transcription elongation has been linked to alternative splicing.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that transcription and splicing are functionally coupled processes.\n",
            "2. The answer provides specific evidence from PubMed articles to support the connection between transcription and splicing.\n",
            "3. The answer acknowledges the link between transcription elongation rate and alternative splicing.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more explicit in stating that transcription and splicing are connected through their cotranscriptional nature.\n",
            "2. The answer could provide more detailed examples or mechanisms of how transcription and splicing are connected.\n",
            "3. The answer does not explicitly mention the role of splicing factors in the connection between transcription and splicing, which is an important aspect to consider.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and grounded in evidence but could benefit from further elaboration and specificity in explaining the connection between transcription and splicing.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "Transcription and splicing are intricately connected through their cotranscriptional nature. Splicing is not a separate event following transcription but is functionally coupled to the transcription process. The rate of transcription elongation has been shown to influence alternative splicing outcomes. This connection is mediated by factors such as splicing factor binding to pre-mRNA target sites and interactions with the transcription machinery. The coordination between transcription and splicing is essential for proper gene expression regulation and mRNA processing.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2105\n",
            "   Self-RAG: 0.1832\n",
            "   Improvement: -12.98% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 296\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is the treatment of acute pericarditis?\n",
            "\n",
            "🎯 Gold Answer: A multidisciplinary approach is frequently necessary to treat acute pericarditis; the most frequent treatments are: antiinflammatory steroid and non-steroid drugs, antibiotic therapy, pericardial drainage and, less frequently ,intrapericardial irrigation of fibrinolytics;  antituberculous chemotherapy in presence of Tuberculous Agent\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The treatment of acute pericarditis typically involves appropriate antibiotic therapy and surgical drainage for purulent pericarditis. In some cases, prednisolone may be used in addition to antituberculous chemotherapy for effusive pericarditis. Recurrences of acute pericarditis may occur in up to 20-50% of patients, with the etiology often remaining unknown.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The treatment of acute pericarditis typically involves appropriate antibiotic therapy, surgical drainage if necessary, and in some cases, the addition of prednisolone to antituberculous chemotherapy.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly mentions the use of appropriate antibiotic therapy and surgical drainage in the treatment of acute pericarditis, which is supported by evidence from Document 1.\n",
            "2. The addition of prednisolone to antituberculous chemotherapy for effusive pericarditis is also supported by evidence from Document 2.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not mention the importance of nonsteroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for acute pericarditis, which is a significant omission in the treatment approach.\n",
            "2. The claim about the use of antibiotics as a standard treatment for acute pericarditis is not entirely accurate. While antibiotics may be used in cases of purulent pericarditis, they are not routinely indicated for all cases of acute pericarditis.\n",
            "3. The statement about the etiology of recurrent pericarditis being obscure in most cases is not directly relevant to the treatment of acute pericarditis and seems to be included without clear grounding in the context of treatment.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and grounding in specific evidence. It would benefit from including information on the use of NSAIDs as a first-line treatment and clarifying the role of antibiotics in acute pericarditis treatment based on the available evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The treatment of acute pericarditis typically involves nonsteroidal anti-inflammatory drugs (NSAIDs) as first-line therapy to reduce inflammation and pain. In cases of purulent pericarditis, appropriate antibiotic therapy and surgical drainage may be necessary. Prednisolone can be considered as an adjunct to antituberculous chemotherapy in effusive pericarditis cases. Recurrences of acute pericarditis can occur in up to 20-50% of patients, with many cases labeled as idiopathic due to unclear etiology.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2022\n",
            "   Self-RAG: 0.1802\n",
            "   Improvement: -10.91% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 297\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Other than protein coding potential, what features set apart long non-coding RNAs from protein coding genes?\n",
            "\n",
            "🎯 Gold Answer: Compared to protein coding genes, long non-coding RNAs (lncRNAs) display a bias towards two-exon transcripts. They are predominantly localized in the chromatin and nucleous. They are lower expressed and display a more tissue-specific expression pattern. LncRNAs are overall more weakly conserved than protein coding genes.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Long non-coding RNAs (lncRNAs) differ from protein coding genes in their various functions in transcriptional, posttranscriptional, and epigenetic mechanisms of gene regulation.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Long non-coding RNAs (lncRNAs) differ from protein coding genes in their functions in transcriptional, posttranscriptional, and epigenetic mechanisms of gene regulation.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies that long non-coding RNAs (lncRNAs) are involved in transcriptional, posttranscriptional, and epigenetic mechanisms of gene regulation.\n",
            "2. The evidence from PubMed articles supports the claim that lncRNAs have functions in these regulatory processes.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in detailing the exact features that set apart lncRNAs from protein coding genes. It broadly mentions functions in gene regulation without delving into specific differences.\n",
            "2. While the evidence from PubMed articles supports the involvement of lncRNAs in gene regulation, it does not explicitly address the specific features that distinguish lncRNAs from protein coding genes.\n",
            "3. The initial answer does not provide a comprehensive comparison of lncRNAs and protein coding genes beyond their functions in gene regulation. It could benefit from discussing other distinguishing features such as sequence characteristics, evolutionary conservation, or subcellular localization.\n",
            "4. The initial answer does not mention any potential limitations or controversies in the field regarding the distinction between lncRNAs and protein coding genes.\n",
            "\n",
            "Overall, the initial answer provides a general overview of the functions of lncRNAs compared to protein coding genes but lacks specificity and depth in addressing the unique features that differentiate the two. It would benefit from a more detailed and evidence-based comparison to enhance its accuracy and completeness.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Long non-coding RNAs (lncRNAs) are distinguished from protein coding genes by several features beyond their protein coding potential. In addition to their roles in transcriptional, posttranscriptional, and epigenetic gene regulation, lncRNAs exhibit distinct sequence characteristics, often lack evolutionary conservation compared to protein-coding genes, and frequently localize to specific subcellular compartments. While lncRNAs play crucial roles in gene regulation, their specific features and mechanisms of action set them apart from protein-coding genes. It is important to note that ongoing research continues to uncover the complexities and nuances of lncRNA functions and their distinction from protein-coding genes.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2254\n",
            "   Self-RAG: 0.1905\n",
            "   Improvement: -15.48% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 298\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which histone modifications have been associated to alternative splicing?\n",
            "\n",
            "🎯 Gold Answer: H3K36m3 has been systematically associated to exon inclusion in almost all published studies. Other marks have been associated as well in specific studies to exon expression, but it can not be concluded that the effect of these marks in exon expression it is not a consequence of their effect in gene expression.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Histone modifications such as H3K36me3 and H3K79me1 have been associated with alternative splicing.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "H3K36me3 and H3K79me1 histone modifications have been associated with alternative splicing.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies H3K36me3 as a histone modification associated with alternative splicing, which is supported by evidence from Document 1.\n",
            "2. The answer also correctly mentions H3K79me1 as another histone modification linked to alternative splicing, supported by the mention of specific histone marks influencing splicing factor recruitment in Document 2.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer lacks specificity in explaining the relationship between H3K79me1 and alternative splicing. While Document 1 provides evidence for H3K36me3's association with alternative splicing, the evidence for H3K79me1's direct involvement is not explicitly stated.\n",
            "2. The answer could be improved by providing more comprehensive evidence from additional sources to strengthen the claims made.\n",
            "3. The answer does not address the broader context of histone modifications and alternative splicing, such as other modifications that may also play a role in this process.\n",
            "\n",
            "Overall, the initial answer is partially accurate but could benefit from more detailed evidence and a broader perspective on the topic.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "H3K36me3 has been well-documented as a histone modification associated with alternative splicing, as evidenced by its correlation with alternative exon inclusion or exclusion. While H3K79me1 has been suggested to influence splicing factor recruitment, direct evidence linking it to alternative splicing is not explicitly stated in the provided documents. Further research is needed to fully elucidate the role of H3K79me1 in alternative splicing. Additionally, the broader context of histone modifications and alternative splicing suggests a complex interplay that may involve other modifications beyond H3K36me3 and H3K79me1.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0923\n",
            "   Self-RAG: 0.1857\n",
            "   Improvement: +101.19% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 299\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which genes are regulated by MEF-2 in the heart?\n",
            "\n",
            "🎯 Gold Answer: COX-2, ANF, estrogen receptor (ER)alpha gene, calsequestrin gene, casq2, cTnT, MCK, alpha-cardiac actin, sarco(endo)plasmic reticulum Ca2+-ATPase, SERCA, MLC-2, alpha-cardiac myosin heavy chain gene, phosphoglycerate mutase and PGAM-M are regulated by MEF-2 in the heart\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "MEF-2 regulates the expression of the MLC-2 gene and the alpha-cardiac myosin heavy chain gene in the heart.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "MEF-2 regulates the expression of the MLC-2 gene and the alpha-cardiac myosin heavy chain gene in the heart.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies two genes, MLC-2 and alpha-cardiac myosin heavy chain, that are regulated by MEF-2 in the heart.\n",
            "2. The evidence from PubMed articles supports the regulation of these genes by MEF-2 through specific regulatory elements.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could be more specific in stating that MEF-2 regulates the expression of the MLC-2v isoform, as indicated by the evidence from Document 3.\n",
            "2. The initial answer could benefit from providing more context on the regulatory mechanisms involved in the MEF-2-mediated regulation of these genes, such as the specific binding sites and enhancer elements involved.\n",
            "3. The initial answer does not explicitly mention the HF-1b element in the MLC-2 gene, which is crucial for its cardiac tissue-specific expression as indicated by Document 1.\n",
            "\n",
            "Overall, the initial answer is generally accurate in identifying the genes regulated by MEF-2 in the heart, but it could be improved by providing more specific details and referencing all relevant evidence.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "MEF-2 regulates the expression of the MLC-2v isoform and the alpha-cardiac myosin heavy chain gene in the heart. In the MLC-2 gene, the HF-1b element, containing a consensus MEF-2 site, is crucial for cardiac tissue-specific expression. Additionally, a 28 bp HF-la/MEF-2 element in the MLC-2v promoter region confers cardiac ventricular chamber-specific gene expression during murine cardiogenesis. The regulatory mechanisms involve specific binding sites and enhancer elements as supported by the evidence from Document 1 and Document 3.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3692\n",
            "   Self-RAG: 0.1805\n",
            "   Improvement: -51.13% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 300\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which genes are regulated by TRalpha2  in the heart?\n",
            "\n",
            "🎯 Gold Answer: ARB1, ARB2, TAK1, p38, TRalpha1\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The context provided does not specify which genes are regulated by TRalpha2 in the heart.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "TRalpha2 regulates the expression of TRalpha1 and beta1 mRNA in the heart.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies TRalpha2 as a regulator in the heart.\n",
            "2. The answer provides evidence from PubMed articles to support the claim.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer only mentions the regulation of TRalpha1 and beta1 mRNA by TRalpha2, but it does not provide a comprehensive list of all genes regulated by TRalpha2 in the heart.\n",
            "2. The evidence provided does not directly support the claim that TRalpha2 regulates TRalpha1 and beta1 mRNA expression in the heart. While the evidence mentions interactions between TRalpha2, TRalpha1, and beta1, it does not explicitly state that TRalpha2 regulates the expression of TRalpha1 and beta1 mRNA.\n",
            "3. The answer does not address other potential genes regulated by TRalpha2 in the heart, which could provide a more complete picture of TRalpha2's regulatory role in cardiac gene expression.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and specificity in addressing the question of which genes are regulated by TRalpha2 in the heart. More specific evidence directly linking TRalpha2 to the regulation of TRalpha1 and beta1 mRNA expression would strengthen the answer. Additionally, a more comprehensive exploration of other genes regulated by TRalpha2 in the heart would enhance the completeness of the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "TRalpha2 in the heart regulates the expression of TRalpha1 and beta1 mRNA, as evidenced by studies showing that TRalpha2 and TRbeta1 attenuate TRalpha1-induced myocardial growth and gene expression by diminishing TAK1 and p38 activities. Additionally, amiodarone downregulates TRalpha1 and beta1 mRNA levels in the heart. Further research is needed to explore other potential genes regulated by TRalpha2 in cardiac gene expression.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0000\n",
            "   Self-RAG: 0.0870\n",
            "   Improvement: N/A (Baseline ROUGE-L was 0, but Self-RAG ROUGE-L is 0.0870) ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 301\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates?\n",
            "\n",
            "🎯 Gold Answer: There are two major exceptions to the canonical GT-AG dinucleotides at donor and acceptor sites: the GG-AG splice site pairs, recognized through the typical U2 splicing machinery, and the AT-AC splice pairs recognized by the U12 splicing machinery.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are GT-AG (99.24%) for canonical splice sites, followed by GC-AG (0.69%) and AT-AC (0.05%) for non-canonical splice sites. Other types of non-canonical splice sites are rare, comprising only 0.02%.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The most frequent non-canonical sequence motifs at the donor and acceptor splice sites in vertebrates are GT-AG.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly states that GT-AG is the most frequent canonical splice site motif in vertebrates. However, the claim that GT-AG is the most frequent non-canonical splice site motif is not supported by the evidence provided. The evidence mentions GC-AG and AT-AC as non-canonical splice site motifs, which suggests that GT-AG may not be the most frequent non-canonical motif.\n",
            "\n",
            "2. COMPLETENESS: The initial answer only mentions GT-AG as the most frequent non-canonical splice site motif and does not address other non-canonical motifs such as GC-AG and AT-AC. This lack of completeness limits the overall understanding of the diversity of non-canonical splice site motifs in vertebrates.\n",
            "\n",
            "3. GROUNDING: The initial answer does reference specific evidence from PubMed articles to support the claim about the frequency of non-canonical splice site motifs. However, the evidence provided does not directly support the claim that GT-AG is the most frequent non-canonical motif, as it mentions other motifs like GC-AG and AT-AC.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims, but it does make an assumption about the frequency of non-canonical splice site motifs without strong evidence to support this claim.\n",
            "\n",
            "Overall, the initial answer is partially accurate but lacks completeness and strong evidence to support the claim about the most frequent non-canonical splice site motifs in vertebrates.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "The most frequent canonical splice site motif in vertebrates is GT-AG. Non-canonical splice site motifs such as GC-AG and AT-AC also exist, with frequencies of 0.69% and 0.05%, respectively, based on evidence from PubMed articles. These non-canonical motifs contribute to the diversity of splice site recognition in vertebrates.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.3000\n",
            "   Self-RAG: 0.2245\n",
            "   Improvement: -25.17% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 302\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Can protein coding exons originate from ALU sequences?\n",
            "\n",
            "🎯 Gold Answer: Yes. Intronic ALUs can evolve into exons by the activation of splice signals residing within the ALU sequence. While most ALU exons do not add or modify the coding capacity of the resulting transcript, examples have been identified of ALU exons becoming protein coding.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, protein coding exons can originate from ALU sequences through exonization of intronic sequences, with a preference for occurring at the beginning of protein coding sequences.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, protein coding exons can originate from ALU sequences through exonization of intronic sequences, with a preference for occurring at the beginning of protein coding sequences.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly states that protein coding exons can originate from ALU sequences through exonization of intronic sequences.\n",
            "2. The answer is supported by evidence from PubMed articles, which adds credibility to the claims made.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer claims a preference for ALU-driven exons to occur at the beginning of protein coding sequences, but this claim is not explicitly supported by the provided evidence. While one document mentions exonizations occurring preferentially at the beginning of protein coding sequences, it does not specifically link this preference to ALU-driven exons.\n",
            "2. The answer could benefit from providing more specific references to the evidence presented in the PubMed articles to strengthen the grounding of the claims.\n",
            "3. The initial answer does not address the potential limitations or conflicting evidence regarding the origin of protein coding exons from ALU sequences. It would be beneficial to acknowledge any opposing viewpoints or uncertainties in the field.\n",
            "\n",
            "Overall, the initial answer provides a generally accurate overview of the topic but could be improved by addressing the weaknesses mentioned above to enhance the clarity and reliability of the response.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Protein coding exons can indeed originate from ALU sequences through exonization of intronic sequences. Studies have shown that more than 5% of alternatively spliced internal exons in the human genome are derived from ALU elements. While exonizations can occur preferentially at the beginning of protein coding sequences, this preference is not explicitly linked to ALU-driven exons in the provided evidence. The Alu element has been a significant source of new exons during primate evolution, with thousands of human genes containing spliced exons derived from Alu elements. It is important to note that while evidence supports the exonization of ALU sequences, there may be limitations or conflicting viewpoints in the field that warrant further investigation.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2857\n",
            "   Self-RAG: 0.1887\n",
            "   Improvement: -33.96% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 303\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What are the major classes of retrotransposons active in the human genome?\n",
            "\n",
            "🎯 Gold Answer: LINE-1 (L1), Alu, SVA\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The major classes of retrotransposons active in the human genome are Alu, L1, and SVA elements.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The major classes of retrotransposons active in the human genome are Alu, L1, and SVA elements.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer correctly identifies Alu, L1, and SVA elements as major classes of retrotransposons active in the human genome, which is supported by the evidence provided.\n",
            "2. Grounding: The answer references specific evidence from PubMed articles to support the claims made about the major classes of retrotransposons in the human genome.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the initial answer correctly identifies Alu, L1, and SVA elements as major classes of retrotransposons, it does not mention other active retrotransposons such as HERVs (Human Endogenous Retroviruses) which are also important in the human genome.\n",
            "2. Hallucinations: The initial answer does not include any unsupported claims and is based on evidence from reputable sources.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence but lacks completeness by not mentioning other active retrotransposons like HERVs.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The major classes of retrotransposons active in the human genome include Alu, L1, SVA elements, and HERVs (Human Endogenous Retroviruses). These retrotransposons contribute to human genomic diversity and polymorphism. Alu elements are more densely distributed in GC-rich isochores compared to AT-rich isochores. While Alu, L1, SVA, and HERVs are among the active retrotransposons in the human genome, only a small fraction of repeated DNA elements are currently active.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1905\n",
            "   Self-RAG: 0.0800\n",
            "   Improvement: -58.00% ❌\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 304\n",
            "================================================================================\n",
            "\n",
            "📝 Question: What is a popular mesaure of gene expression in RNA-seq experiments?\n",
            "\n",
            "🎯 Gold Answer: A commonly used measure for gene expression in RNA-seq experiments is  Reads Per Kilobase per Million mapped reads (RPKM). In ocasions, and to account for partially mapped read, read Fragments per Kilobase per Million mapped reads (FPKM) is alternatively used.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The popular measure of gene expression in RNA-seq experiments is the use of reference genes to reduce variations derived from different amounts of starting materials and different efficiencies of RNA extraction and cDNA synthesis.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "A popular measure of gene expression in RNA-seq experiments is the expression profiles of miRNAs, which are 20–24 nt long RNA molecules known to play roles in development, tumorigenesis, and viral infection.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer correctly identifies miRNAs as important molecules in gene expression regulation. However, it does not specifically mention that miRNAs are the measure of gene expression in RNA-seq experiments. The evidence provided does support the role of miRNAs in gene expression regulation but does not explicitly state that they are a measure of gene expression in RNA-seq experiments.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not fully address all parts of the question. While it mentions miRNAs and their roles in gene expression, it does not provide a comprehensive overview of popular measures of gene expression in RNA-seq experiments. Other common measures such as FPKM (fragments per kilobase of transcript per million mapped reads) or TPM (transcripts per million) could have been mentioned for a more complete answer.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles to support the importance of miRNAs in gene expression regulation. However, the evidence does not directly support the claim that miRNAs are a popular measure of gene expression in RNA-seq experiments.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims. However, it could benefit from more explicit connections between the evidence provided and the specific question about popular measures of gene expression in RNA-seq experiments.\n",
            "\n",
            "Overall, the initial answer provides some accurate information about miRNAs and their roles in gene expression but lacks specificity in addressing\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "A popular measure of gene expression in RNA-seq experiments is the quantification of gene expression levels using metrics such as FPKM (fragments per kilobase of transcript per million mapped reads) or TPM (transcripts per million). While miRNAs play crucial roles in gene expression regulation, they are not typically used as direct measures of gene expression in RNA-seq experiments. Studies in pharmacogenomics, toxicogenomics, and small RNA expression analysis highlight the importance of gene expression analysis using reference genes to minimize variations arising from different experimental conditions.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2368\n",
            "   Self-RAG: 0.2812\n",
            "   Improvement: +18.75% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 305\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the known human transmembrane nucleoporins?\n",
            "\n",
            "🎯 Gold Answer: Transmembrane nucleoporins (NUPs) are integral membrane components of the eukaryotic nuclear pore, playing an important role in the Nuclear Pore Complex (NPC) assembly. Even though the NPC is a conserved feature of all eukaryotes, different lineages possess some distinct transmembrane NUP subunits. Currently, four human transmembrane NUPs have been characterized, namely: NDC1 (also known as TMEM48 or NET3 or hNDC1), POM121 (also known as Nup121), GP210 (also known as Nuclear pore membrane glycoprotein 210 or Nuclear envelope pore membrane protein POM 210, POM210 or Nup210) and TMEM33 (or DB83).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The known human transmembrane nucleoporins are NDC1 and Pom121.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "NDC1 and Pom121 are known human transmembrane nucleoporins.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer correctly identifies NDC1 and Pom121 as known human transmembrane nucleoporins.\n",
            "2. The evidence provided from PubMed articles supports the presence of NDC1 and Pom121 as transmembrane nucleoporins in humans.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer could benefit from providing more comprehensive evidence to further support the claim. While the evidence mentions NDC1 and Pom121 as transmembrane nucleoporins, additional references or studies could strengthen the argument.\n",
            "2. The initial answer does not mention other potential transmembrane nucleoporins that may exist in humans. It would be more complete to acknowledge the possibility of other known or unknown transmembrane nucleoporins in humans.\n",
            "3. The initial answer lacks specific details on the functions or roles of NDC1 and Pom121 as transmembrane nucleoporins in humans. Providing more context on their biological significance would enhance the answer's grounding and completeness.\n",
            "\n",
            "Overall, the initial answer is on the right track by correctly identifying NDC1 and Pom121 as human transmembrane nucleoporins and providing supporting evidence. However, it could be improved by including more comprehensive evidence, addressing potential additional nucleoporins, and providing more context on the roles of NDC1 and Pom121.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Revised Answer:\n",
            "NDC1 and Pom121 are known human transmembrane nucleoporins, supported by evidence from PubMed articles. While NDC1 and Pom121 have been identified as transmembrane nucleoporins in humans, there may be other undiscovered nucleoporins with similar characteristics. Further research is needed to explore additional transmembrane nucleoporins in humans. The functions and roles of NDC1 and Pom121 as transmembrane nucleoporins in humans warrant further investigation to fully understand their biological significance.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1020\n",
            "   Self-RAG: 0.1132\n",
            "   Improvement: +10.94% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 306\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which is the receptor for substrates of Chaperone Mediated Autophagy?\n",
            "\n",
            "🎯 Gold Answer: Chaperone-mediated autophagy (CMA) is a lysosomal pathway for selective removal of damaged cytosolic proteins. The LAMP2A (Lysosome-associated membrane protein 2 isoform A) functions as a receptor for cytosolic proteins and also as essential component of the CMA translocation complex [28]. Cytosolic substrate proteins bind to monomers of LAMP-2A, which then multimerizes to form the complex required for substrate transmembrane import.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Lysosomal-membrane protein type 2A (LAMP-2A) acts as the receptor for substrates of Chaperone-Mediated Autophagy (CMA).\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Lysosomal-membrane protein type 2A (LAMP-2A) is the receptor for substrates of Chaperone-Mediated Autophagy (CMA).\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer correctly identifies Lysosomal-membrane protein type 2A (LAMP-2A) as the receptor for substrates of Chaperone-Mediated Autophagy (CMA). This is supported by evidence from multiple PubMed articles.\n",
            "2. Grounding: The answer references specific evidence from PubMed articles to support the claim about LAMP-2A being the receptor for CMA substrates.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the answer correctly identifies LAMP-2A as the receptor for CMA substrates, it could have provided more context or explanation about the role of LAMP-2A in CMA.\n",
            "2. Hallucinations: There are no unsupported claims in the initial answer, which is a strength.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence. However, it could be improved by providing more context or details about the role of LAMP-2A in Chaperone-Mediated Autophagy.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Lysosomal-membrane protein type 2A (LAMP-2A) serves as the receptor for substrates of Chaperone-Mediated Autophagy (CMA). LAMP-2A plays a crucial role in the selective degradation of cytosolic proteins in lysosomes through CMA. As documented in various studies, the levels of LAMP-2A decrease with age, contributing to the decline in CMA efficiency.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.1975\n",
            "   Self-RAG: 0.2881\n",
            "   Improvement: +45.87% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 307\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Which are the Atg8 homologs in human?\n",
            "\n",
            "🎯 Gold Answer: Autophagy (Autophagy-related protein 8 or Atg8p or APG8 or AUT7 or CVT5) is a yeast protein involved in cytoplasm to vacuole transport (Cvt) vesicles and autophagosomes formation. In yeast it is represented by a single gene, the ATG8 family in humans contains 6 members (microtubule-associated protein-1 light chain 3A (MAP1LC3A), MAP1LC3B, MAP1LC3C, GABA(A) receptor-associated protein (GABARAP), GABARAPL1, and GABARAPL2/GATE-16).\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Based on the provided context, the six human Atg8 homologs are not specifically mentioned.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "There are six human Atg8 homologs.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Critique:\n",
            "\n",
            "1. FACTUAL ACCURACY: The initial answer states that there are six human Atg8 homologs, which is not entirely accurate based on the evidence provided. Document 1 mentions six human Atg8 homologs, but Document 3 suggests that there are at least eight different Atg8 orthologs in mammalian cells. Therefore, the claim of six human Atg8 homologs is not fully supported by the evidence.\n",
            "\n",
            "2. COMPLETENESS: The initial answer does not address the full spectrum of Atg8 homologs in humans. It only mentions the existence of six homologs based on one document, while another document suggests there are at least eight different Atg8 orthologs in mammalian cells. This lack of completeness in addressing the potential diversity of Atg8 homologs in humans is a weakness.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from Document 1 to support the claim of six human Atg8 homologs. However, it fails to acknowledge the conflicting information presented in Document 3, which suggests a higher number of Atg8 orthologs in mammalian cells. This lack of acknowledgment weakens the grounding of the initial answer.\n",
            "\n",
            "4. HALLUCINATIONS: The initial answer does not include any unsupported claims, but it does not fully consider the broader context of Atg8 homologs in humans, as suggested by Document 3. This\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "There are at least eight different Atg8 orthologs in humans, belonging to two subfamilies: LC3 and GATE-16/GABARAP. While Document 1 mentions six human Atg8 homologs, Document 3 provides evidence for a higher number of Atg8 orthologs in mammalian cells. The individual roles and modes of action of these Atg8 orthologs are still largely unknown.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0500\n",
            "   Self-RAG: 0.1148\n",
            "   Improvement: +129.51% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 308\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Describe the known functions for the prothymosin alpha c-terminal peptide?\n",
            "\n",
            "🎯 Gold Answer: Prothymosin alpha (ProTα) (encoded in human by the PTMA gene) is a ubiquitous, highly acidic nuclear polypeptide. During early apoptosis, proTα is cleaved by activated caspase-3, with a primary attach site being D99, close to its carboxyl-terminus. The role of the cleaved decapeptide -- proTα(100-109) -- is not fully understood. proTα(100-109), which contains the nuclear localization signal (NLS) for ProTα, has been demonstrated to have immunostimulatory properties, such as to stimulate lymphocytes and neutrophils and induce dendritic cell maturation.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The known functions for the prothymosin alpha C-terminal peptide include immunostimulatory properties and nuclear migration in Xenopus.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The known functions for the prothymosin alpha C-terminal peptide include immunostimulatory properties and nuclear migration.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. Factual Accuracy: The initial answer accurately mentions the immunostimulatory properties and nuclear migration as known functions of the prothymosin alpha C-terminal peptide, which is supported by the evidence provided from PubMed articles.\n",
            "2. Grounding: The answer references specific evidence from PubMed articles to support the claims made about the functions of the prothymosin alpha C-terminal peptide.\n",
            "\n",
            "Weaknesses:\n",
            "1. Completeness: While the answer correctly mentions two known functions of the prothymosin alpha C-terminal peptide, it could be more comprehensive by potentially including additional functions if they are known.\n",
            "2. Hallucinations: The initial answer does not include any unsupported claims, which is a strength in terms of factual accuracy.\n",
            "\n",
            "Overall, the initial answer is mostly accurate and well-supported by evidence from PubMed articles. To improve, it could be more comprehensive by potentially including any additional known functions of the prothymosin alpha C-terminal peptide.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The known functions for the prothymosin alpha C-terminal peptide include immunostimulatory properties, nuclear migration, and potential involvement in regulating gene expression. Studies have shown that the carboxyl (C)-terminus of prothymosin alpha is responsible for its immunostimulatory effects. Additionally, the C-terminal region, particularly the KKQK sequence, plays a crucial role in nuclear migration. Further research suggests a possible role in gene expression regulation, although more studies are needed to fully elucidate this function.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0990\n",
            "   Self-RAG: 0.1392\n",
            "   Improvement: +40.63% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 309\n",
            "================================================================================\n",
            "\n",
            "📝 Question: Has field-programmable gate array (FPGA) technology been used to solve sequence alignment problems?\n",
            "\n",
            "🎯 Gold Answer: Yes. Field-Programmable Gate Arrays (FPGAs) are reconfigurable computing platforms that have found several applications in diverse domains, including  digital signal processing, medical imaging and bioinformatics. Specific applications of FPGAs for biological sequence alignment have been reported for dynamic programming-based pairwise (local or global) sequence alignment, progressive multiple sequence alignment, profile alignment, Burrows-Wheeler transform (BWT) based alignment, heuristic pairwise alignment.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "Yes, field-programmable gate array (FPGA) technology has been used to solve sequence alignment problems, as described in the provided context from PubMed articles.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "Yes, field-programmable gate array (FPGA) technology has been used to solve sequence alignment problems.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "1. FACTUAL ACCURACY: The initial answer is factually accurate as it is supported by evidence from multiple PubMed articles that mention the use of FPGA technology for solving sequence alignment problems.\n",
            "\n",
            "2. COMPLETENESS: The initial answer adequately addresses the question by confirming that FPGA technology has indeed been utilized for sequence alignment problems.\n",
            "\n",
            "3. GROUNDING: The initial answer references specific evidence from PubMed articles, including mentions of FPGA technology being used for biological sequence alignment acceleration, dynamic programming methods for sequence alignment, and FPGA-accelerated pairwise alignment algorithms.\n",
            "\n",
            "4. HALLUCINATIONS: There are no unsupported claims in the initial answer. All claims are backed by evidence from reputable sources.\n",
            "\n",
            "Overall, the initial answer is well-supported by specific evidence from scientific literature, demonstrating the use of FPGA technology for solving sequence alignment problems.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "Yes, field-programmable gate array (FPGA) technology has been extensively utilized to accelerate biological sequence alignment processes. Reconfigurable computing hardware, such as FPGAs, has been employed to speed up sequence alignment algorithms, including dynamic programming methods for global and local sequence alignment, approximate string matching, and longest common subsequence. Specific implementations on FPGAs have demonstrated significant improvements in pairwise alignment algorithms. This evidence is supported by research articles in PubMed, highlighting the effectiveness of FPGA technology in addressing sequence alignment challenges.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.2093\n",
            "   Self-RAG: 0.2517\n",
            "   Improvement: +20.28% ✅\n",
            "\n",
            "\n",
            "================================================================================\n",
            "EXAMPLE 310\n",
            "================================================================================\n",
            "\n",
            "📝 Question: How many selenoproteins are encoded in the human genome?\n",
            "\n",
            "🎯 Gold Answer: 25. 15kDa, DI1, DI2, DI3, GPx1, GPx2, GPx3, GPx4, GPx6, SelH, SelI, SelK, SelM, SelN, SelO, SelP, SelR, SelS, SPS2, SelT, TR1, TR2, TR3, SelV and SelW.\n",
            "\n",
            "🔵 Baseline RAG Answer:\n",
            "The human genome encodes 25 selenoproteins.\n",
            "\n",
            "🟢 Self-RAG Initial Answer:\n",
            "The human genome encodes 25 selenoproteins.\n",
            "\n",
            "🔍 Self-RAG Critique:\n",
            "Strengths:\n",
            "1. The initial answer provides a specific number (25) for the selenoproteins encoded in the human genome.\n",
            "2. The evidence from Document 1 directly supports the claim of 25 selenoproteins in the human selenoproteome.\n",
            "\n",
            "Weaknesses:\n",
            "1. The initial answer does not address the fact that selenoproteins may not be present in all organisms, as evidenced by Document 2 and Document 3.\n",
            "2. The evidence from Document 2 and Document 3 suggests that selenoproteins may not be present in certain insect genomes, which raises questions about the universality of the claim that the human genome encodes 25 selenoproteins.\n",
            "3. The initial answer does not acknowledge the potential variability in selenoprotein content across different species, which could impact the accuracy of the claim for humans specifically.\n",
            "\n",
            "Overall, while the initial answer provides a specific number supported by evidence, it lacks completeness in addressing the potential variability and absence of selenoproteins in other organisms, which could impact the accuracy of the claim for the human genome.\n",
            "\n",
            "✅ Self-RAG Revised Answer:\n",
            "The human selenoproteome consists of 25 selenoproteins, as supported by Document 1. However, it is important to note that selenoproteins may not be present in all organisms, as evidenced by Document 2 and Document 3, which report the absence of selenoproteins in certain insect genomes. This variability across species suggests that the presence of selenoproteins in the human genome may not be universal.\n",
            "\n",
            "📊 ROUGE-L Scores:\n",
            "   Baseline: 0.0606\n",
            "   Self-RAG: 0.0444\n",
            "   Improvement: -26.67% ❌\n",
            "\n"
          ]
        }
      ],
      "source": [
        "# Compare answers for each question\n",
        "for i, (baseline, selfrag) in enumerate(zip(baseline_results, selfrag_results)):\n",
        "    print(\"\\n\" + \"=\"*80)\n",
        "    print(f\"EXAMPLE {i+1}\")\n",
        "    print(\"=\"*80)\n",
        "\n",
        "    print(f\"\\n📝 Question: {baseline['question']}\")\n",
        "\n",
        "    print(f\"\\n🎯 Gold Answer: {baseline['gold_answer']}\")\n",
        "\n",
        "    print(f\"\\n🔵 Baseline RAG Answer:\\n{baseline['answer']}\")\n",
        "\n",
        "    print(f\"\\n🟢 Self-RAG Initial Answer:\\n{selfrag['initial_answer']}\")\n",
        "\n",
        "    print(f\"\\n🔍 Self-RAG Critique:\\n{selfrag['critique']}\")\n",
        "\n",
        "    print(f\"\\n✅ Self-RAG Revised Answer:\\n{selfrag['revised_answer']}\")\n",
        "\n",
        "    # Calculate ROUGE for this example\n",
        "    baseline_rouge = scorer.score(baseline['gold_answer'], baseline['answer'])['rougeL'].fmeasure\n",
        "    selfrag_rouge = scorer.score(selfrag['gold_answer'], selfrag['revised_answer'])['rougeL'].fmeasure\n",
        "\n",
        "    print(f\"\\n📊 ROUGE-L Scores:\")\n",
        "    print(f\"   Baseline: {baseline_rouge:.4f}\")\n",
        "    print(f\"   Self-RAG: {selfrag_rouge:.4f}\")\n",
        "    if baseline_rouge > 0:\n",
        "        if selfrag_rouge > baseline_rouge:\n",
        "            improvement = ((selfrag_rouge - baseline_rouge) / baseline_rouge) * 100\n",
        "            print(f\"   Improvement: +{improvement:.2f}% ✅\")\n",
        "        else:\n",
        "            improvement = ((selfrag_rouge - baseline_rouge) / baseline_rouge) * 100\n",
        "            print(f\"   Improvement: {improvement:.2f}% ❌\")\n",
        "    else:\n",
        "        if selfrag_rouge > 0:\n",
        "            print(f\"   Improvement: N/A (Baseline ROUGE-L was 0, but Self-RAG ROUGE-L is {selfrag_rouge:.4f}) ✅\")\n",
        "        else:\n",
        "            print(f\"   Improvement: N/A (Both ROUGE-L scores are 0)\")\n",
        "    print()"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "3VSz-h69dfnh"
      },
      "source": [
        "## 10. Cost Analysis"
      ]
    },
    {
      "cell_type": "code",
      "source": [
        "print(\"=\"*60)\n",
        "print(\"COST ANALYSIS\")\n",
        "print(\"=\"*60)\n",
        "print(f\"Total Budget:        $5.00\")\n",
        "print(f\"Total Cost:          $0.39\")\n",
        "print(f\"Budget Remaining:    $4.61 (92% under budget)\")\n",
        "print(f\"Cost per Question:   $0.00126\")\n",
        "print(f\"\\nConclusion: Highly cost-efficient implementation.\")\n",
        "print(\"=\"*60)"
      ],
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "LGAvYI39wEVu",
        "outputId": "147f9bfa-483e-4e05-b1e8-8743b4283f31"
      },
      "execution_count": null,
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "============================================================\n",
            "COST ANALYSIS\n",
            "============================================================\n",
            "Total Budget:        $5.00\n",
            "Total Cost:          $0.39\n",
            "Budget Remaining:    $4.61 (92% under budget)\n",
            "Cost per Question:   $0.00126\n",
            "\n",
            "Conclusion: Highly cost-efficient implementation.\n",
            "============================================================\n"
          ]
        }
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "38jLR3Q9dfni"
      },
      "source": [
        "## 11. Save Results"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/",
          "height": 17
        },
        "id": "359-o49ndfni",
        "outputId": "8c2adc2d-4138-4325-eccb-38e643387169"
      },
      "outputs": [
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_74263f5a-eb3e-4e44-9463-2b7f99b603bb\", \"baseline_results.json\", 1691525)"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_3c85917c-f6f6-429e-86c6-5572e2ed0461\", \"selfrag_results.json\", 2426967)"
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "\n",
              "    async function download(id, filename, size) {\n",
              "      if (!google.colab.kernel.accessAllowed) {\n",
              "        return;\n",
              "      }\n",
              "      const div = document.createElement('div');\n",
              "      const label = document.createElement('label');\n",
              "      label.textContent = `Downloading \"${filename}\": `;\n",
              "      div.appendChild(label);\n",
              "      const progress = document.createElement('progress');\n",
              "      progress.max = size;\n",
              "      div.appendChild(progress);\n",
              "      document.body.appendChild(div);\n",
              "\n",
              "      const buffers = [];\n",
              "      let downloaded = 0;\n",
              "\n",
              "      const channel = await google.colab.kernel.comms.open(id);\n",
              "      // Send a message to notify the kernel that we're ready.\n",
              "      channel.send({})\n",
              "\n",
              "      for await (const message of channel.messages) {\n",
              "        // Send a message to notify the kernel that we're ready.\n",
              "        channel.send({})\n",
              "        if (message.buffers) {\n",
              "          for (const buffer of message.buffers) {\n",
              "            buffers.push(buffer);\n",
              "            downloaded += buffer.byteLength;\n",
              "            progress.value = downloaded;\n",
              "          }\n",
              "        }\n",
              "      }\n",
              "      const blob = new Blob(buffers, {type: 'application/binary'});\n",
              "      const a = document.createElement('a');\n",
              "      a.href = window.URL.createObjectURL(blob);\n",
              "      a.download = filename;\n",
              "      div.appendChild(a);\n",
              "      a.click();\n",
              "      div.remove();\n",
              "    }\n",
              "  "
            ]
          },
          "metadata": {}
        },
        {
          "output_type": "display_data",
          "data": {
            "text/plain": [
              "<IPython.core.display.Javascript object>"
            ],
            "application/javascript": [
              "download(\"download_c660ab0f-be5d-48ef-ac44-e07a48f0a536\", \"comparison_results.json\", 531)"
            ]
          },
          "metadata": {}
        }
      ],
      "source": [
        "# Save results to JSON files\n",
        "import json\n",
        "\n",
        "with open('baseline_results.json', 'w') as f:\n",
        "    json.dump(baseline_results, f, indent=2)\n",
        "\n",
        "with open('selfrag_results.json', 'w') as f:\n",
        "    json.dump(selfrag_results, f, indent=2)\n",
        "\n",
        "# Save comparison metrics\n",
        "comparison = {\n",
        "    'baseline_metrics': baseline_metrics,\n",
        "    'selfrag_metrics': selfrag_metrics,\n",
        "    'num_questions': len(formatted_questions)\n",
        "}\n",
        "\n",
        "with open('comparison_results.json', 'w') as f:\n",
        "    json.dump(comparison, f, indent=2)\n",
        "\n",
        "# Download files\n",
        "try:\n",
        "    from google.colab import files\n",
        "    files.download('baseline_results.json')\n",
        "    files.download('selfrag_results.json')\n",
        "    files.download('comparison_results.json')\n",
        "except:\n",
        "    pass"
      ]
    },
    {
      "cell_type": "markdown",
      "metadata": {
        "id": "sOp_S_Yydfni"
      },
      "source": [
        "## 12. Summary & Key Takeaways"
      ]
    },
    {
      "cell_type": "code",
      "execution_count": null,
      "metadata": {
        "colab": {
          "base_uri": "https://localhost:8080/"
        },
        "id": "knOmz7g3dfni",
        "outputId": "4590fced-a6b1-475e-dd1d-4cea53f36f39"
      },
      "outputs": [
        {
          "output_type": "stream",
          "name": "stdout",
          "text": [
            "\n",
            "================================================================================\n",
            "PROJECT SUMMARY\n",
            "================================================================================\n",
            "  1. Baseline RAG: Standard retrieval-augmented generation\n",
            "  2. Self-RAG: RAG with self-reflection loop (novel approach!)\n",
            "\n",
            " Key Results:\n",
            "  rouge1: -15.6% improvement\n",
            "  rouge2: -33.6% improvement\n",
            "  rougeL: -26.8% improvement\n",
            "  partial_match: -25.0% improvement\n"
          ]
        }
      ],
      "source": [
        "print(\"\\n\" + \"=\"*80)\n",
        "print(\"PROJECT SUMMARY\")\n",
        "print(\"=\"*80)\n",
        "print(\"  1. Baseline RAG: Standard retrieval-augmented generation\")\n",
        "print(\"  2. Self-RAG: RAG with self-reflection loop (novel approach!)\")\n",
        "\n",
        "print(\"\\n Key Results:\")\n",
        "for metric in ['rouge1', 'rouge2', 'rougeL', 'partial_match']:\n",
        "    baseline_val = baseline_metrics[metric]\n",
        "    selfrag_val = selfrag_metrics[metric]\n",
        "    if baseline_val > 0:\n",
        "        improvement = ((selfrag_val - baseline_val) / baseline_val) * 100\n",
        "        sign = \"+\" if improvement >= 0 else \"\"\n",
        "        print(f\"  {metric}: {sign}{improvement:.1f}% improvement\")"
      ]
    }
  ],
  "metadata": {
    "kernelspec": {
      "display_name": "Python 3",
      "name": "python3"
    },
    "language_info": {
      "codemirror_mode": {
        "name": "ipython",
        "version": 3
      },
      "file_extension": ".py",
      "mimetype": "text/x-python",
      "name": "python",
      "nbconvert_exporter": "python",
      "pygments_lexer": "ipython3",
      "version": "3.8.0"
    },
    "colab": {
      "provenance": [],
      "machine_shape": "hm",
      "gpuType": "A100",
      "include_colab_link": true
    },
    "accelerator": "GPU",
    "widgets": {
      "application/vnd.jupyter.widget-state+json": {
        "d6ff0d71a0034c029857815d4abfde22": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_d755d07a3bb248cda818e65052e52bb8",
              "IPY_MODEL_c5d6401498be4e2bacd00bb771a5f010",
              "IPY_MODEL_12f9c0c9cfe0444b91f3ebd2344121a8"
            ],
            "layout": "IPY_MODEL_c5b9180c063e4adbaa640f06599e04c3"
          }
        },
        "d755d07a3bb248cda818e65052e52bb8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_de29b508a7dc480d9d8b235fb98f13b2",
            "placeholder": "​",
            "style": "IPY_MODEL_7a201a89917846c1b939457e1f6fb00a",
            "value": "modules.json: 100%"
          }
        },
        "c5d6401498be4e2bacd00bb771a5f010": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_61626b42599f427f8ad2d54b41782734",
            "max": 349,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_5442059401504b759542a7b6b0b3f87e",
            "value": 349
          }
        },
        "12f9c0c9cfe0444b91f3ebd2344121a8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_8a85cbec512f4c9fa3268729d85c5287",
            "placeholder": "​",
            "style": "IPY_MODEL_455e557bbd744bdd90b2457f06978c06",
            "value": " 349/349 [00:00&lt;00:00, 44.8kB/s]"
          }
        },
        "c5b9180c063e4adbaa640f06599e04c3": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "de29b508a7dc480d9d8b235fb98f13b2": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7a201a89917846c1b939457e1f6fb00a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "61626b42599f427f8ad2d54b41782734": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "5442059401504b759542a7b6b0b3f87e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "8a85cbec512f4c9fa3268729d85c5287": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "455e557bbd744bdd90b2457f06978c06": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "4e74e0979e6d4c58bc9f487ccb3e7ca6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_3cd4ccb8b7bf495ea0d7feb89d5e6ae3",
              "IPY_MODEL_6bc4dcb7d78c420d8ab0c8bef6b8b36d",
              "IPY_MODEL_bfc01a3e41fb4015bd7f9419b10a797d"
            ],
            "layout": "IPY_MODEL_5575ac5b172b4667bf7c08e79776e4b2"
          }
        },
        "3cd4ccb8b7bf495ea0d7feb89d5e6ae3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3a6b55d0862645a8b016885377b2c0ee",
            "placeholder": "​",
            "style": "IPY_MODEL_0aa8fb6f2a0743fa840f11bdb1e5332d",
            "value": "config_sentence_transformers.json: 100%"
          }
        },
        "6bc4dcb7d78c420d8ab0c8bef6b8b36d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0ae7fd9bca404efc8f00339863d8c186",
            "max": 116,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_45ce807ba9bd4081b60a2ee2bd29e644",
            "value": 116
          }
        },
        "bfc01a3e41fb4015bd7f9419b10a797d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f7d78d50d99b4c1aba88abf12906dcb0",
            "placeholder": "​",
            "style": "IPY_MODEL_c09510a9082c475ea4e22d93c53593d0",
            "value": " 116/116 [00:00&lt;00:00, 15.1kB/s]"
          }
        },
        "5575ac5b172b4667bf7c08e79776e4b2": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3a6b55d0862645a8b016885377b2c0ee": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0aa8fb6f2a0743fa840f11bdb1e5332d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0ae7fd9bca404efc8f00339863d8c186": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "45ce807ba9bd4081b60a2ee2bd29e644": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "f7d78d50d99b4c1aba88abf12906dcb0": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c09510a9082c475ea4e22d93c53593d0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "0c34721ffcc1458cbc38bf82ad96af9b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_4815d70798d841ea915ef33163de7550",
              "IPY_MODEL_7533b3ef720f4b8a8591d5628ac33a6e",
              "IPY_MODEL_36fde2694aaa4512b1d71a7576b5b2f2"
            ],
            "layout": "IPY_MODEL_530623b1924044e8bcf19c885a6104fd"
          }
        },
        "4815d70798d841ea915ef33163de7550": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_091a5cef870a49daba36a128716f707f",
            "placeholder": "​",
            "style": "IPY_MODEL_676b22d2d0d24d0896179a5c9c1d8abf",
            "value": "README.md: "
          }
        },
        "7533b3ef720f4b8a8591d5628ac33a6e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c839105fbfdf43ad97fb13f90d829010",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_c97bd31884c04845a8f3e4e9140df3cb",
            "value": 1
          }
        },
        "36fde2694aaa4512b1d71a7576b5b2f2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_59aec64d73e941bfbbfdaca581b73bb9",
            "placeholder": "​",
            "style": "IPY_MODEL_c3d64e8c06d64b33af4134c4355376c2",
            "value": " 10.5k/? [00:00&lt;00:00, 1.12MB/s]"
          }
        },
        "530623b1924044e8bcf19c885a6104fd": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "091a5cef870a49daba36a128716f707f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "676b22d2d0d24d0896179a5c9c1d8abf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c839105fbfdf43ad97fb13f90d829010": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "c97bd31884c04845a8f3e4e9140df3cb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "59aec64d73e941bfbbfdaca581b73bb9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c3d64e8c06d64b33af4134c4355376c2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "8b4b4c83c21b4fe5bba06c923ac4cf08": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_89c43be710404d11835aacd1590f8dc9",
              "IPY_MODEL_7fa64d696a01454bbd23db19f890e975",
              "IPY_MODEL_26fd9161fbbf4a08a14d3b8911ed514b"
            ],
            "layout": "IPY_MODEL_79346c66a04c4e5599090b8886dbecef"
          }
        },
        "89c43be710404d11835aacd1590f8dc9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_a0b9825417ca4d4f9e43fee63b1e153f",
            "placeholder": "​",
            "style": "IPY_MODEL_f69c473f1c0d4743927311b021e21e4a",
            "value": "sentence_bert_config.json: 100%"
          }
        },
        "7fa64d696a01454bbd23db19f890e975": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_36f36d324e0b4e1b97329dcb9cfa3eb1",
            "max": 53,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_6e7c700bcba84ca4ad693d7fff1c12f4",
            "value": 53
          }
        },
        "26fd9161fbbf4a08a14d3b8911ed514b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_1ed922d793d6413ca021f36dda3b621d",
            "placeholder": "​",
            "style": "IPY_MODEL_bc7864eef1ee47c6813f0c36194125df",
            "value": " 53.0/53.0 [00:00&lt;00:00, 7.19kB/s]"
          }
        },
        "79346c66a04c4e5599090b8886dbecef": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a0b9825417ca4d4f9e43fee63b1e153f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f69c473f1c0d4743927311b021e21e4a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "36f36d324e0b4e1b97329dcb9cfa3eb1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "6e7c700bcba84ca4ad693d7fff1c12f4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "1ed922d793d6413ca021f36dda3b621d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "bc7864eef1ee47c6813f0c36194125df": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c87f85cad1154a5b93391dfb16de643d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_b8d8b5e4f3eb4fbbafa6caec37eb6fcb",
              "IPY_MODEL_66c439fe12d4412eb6b2b170264f68d7",
              "IPY_MODEL_450ed0de6abc451293f8e41c4aa46cf6"
            ],
            "layout": "IPY_MODEL_8f85a970570d444c99d813591d9b6a2e"
          }
        },
        "b8d8b5e4f3eb4fbbafa6caec37eb6fcb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0812d6324edb481e8fa0e7bc3c64505b",
            "placeholder": "​",
            "style": "IPY_MODEL_79a42462349542dcb34460e74bc84bca",
            "value": "config.json: 100%"
          }
        },
        "66c439fe12d4412eb6b2b170264f68d7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_3075d3386aea42309a5f186dd8df09b1",
            "max": 612,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_938067455f984d55b21b3c7806b70772",
            "value": 612
          }
        },
        "450ed0de6abc451293f8e41c4aa46cf6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_6c50fbffeb58411196e18351e5bc96a4",
            "placeholder": "​",
            "style": "IPY_MODEL_29996aa0a7634c78a34ccf9a483a0c4b",
            "value": " 612/612 [00:00&lt;00:00, 78.8kB/s]"
          }
        },
        "8f85a970570d444c99d813591d9b6a2e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0812d6324edb481e8fa0e7bc3c64505b": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "79a42462349542dcb34460e74bc84bca": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "3075d3386aea42309a5f186dd8df09b1": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "938067455f984d55b21b3c7806b70772": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "6c50fbffeb58411196e18351e5bc96a4": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "29996aa0a7634c78a34ccf9a483a0c4b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "3a06b40411634b1aba41cfe8be4e0062": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_61a1f62c03c3452db1e9ac7244ccde70",
              "IPY_MODEL_83bb2e8d13614ff5af748ad40718fc5d",
              "IPY_MODEL_842352a62c6a48a988b4801f4c229e77"
            ],
            "layout": "IPY_MODEL_787cfa65745b4ab2ac65bf91cf1c8337"
          }
        },
        "61a1f62c03c3452db1e9ac7244ccde70": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_de2f15ee252b4883b22a31f69aee3abb",
            "placeholder": "​",
            "style": "IPY_MODEL_d96e4ac9f31646b1b7ef8a038cf5c434",
            "value": "model.safetensors: 100%"
          }
        },
        "83bb2e8d13614ff5af748ad40718fc5d": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_189240616c2a41daa085a9d27e0fb5db",
            "max": 90868376,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_a75f8e7214e2499cbc3b7d8978742cd3",
            "value": 90868376
          }
        },
        "842352a62c6a48a988b4801f4c229e77": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_29d55688bb704f6daae829be9e32e87a",
            "placeholder": "​",
            "style": "IPY_MODEL_3b015c0dea5447a59c80f62a8065d533",
            "value": " 90.9M/90.9M [00:01&lt;00:00, 396kB/s]"
          }
        },
        "787cfa65745b4ab2ac65bf91cf1c8337": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "de2f15ee252b4883b22a31f69aee3abb": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d96e4ac9f31646b1b7ef8a038cf5c434": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "189240616c2a41daa085a9d27e0fb5db": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a75f8e7214e2499cbc3b7d8978742cd3": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "29d55688bb704f6daae829be9e32e87a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "3b015c0dea5447a59c80f62a8065d533": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e948794adc1b4b5f932021e04d37c2eb": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_c20df740df7f413c8270d6aae684b018",
              "IPY_MODEL_c133f1f810df4fe7ac862526c04b31ee",
              "IPY_MODEL_d09c51240ce44586aaa27af82a624244"
            ],
            "layout": "IPY_MODEL_dc3e17fce7a946cdad58df6cec06381e"
          }
        },
        "c20df740df7f413c8270d6aae684b018": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_8d240053902746af9da57a727277e082",
            "placeholder": "​",
            "style": "IPY_MODEL_8f4549d3d49d47feac5673805ad36508",
            "value": "tokenizer_config.json: 100%"
          }
        },
        "c133f1f810df4fe7ac862526c04b31ee": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_368713cfa91c48daaf244b536fda278d",
            "max": 350,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_179f44b6155c4b31bef93e924db007ae",
            "value": 350
          }
        },
        "d09c51240ce44586aaa27af82a624244": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_eb7e555987e54221aa853dab81735a68",
            "placeholder": "​",
            "style": "IPY_MODEL_f2bc85da32da4c8ca85b30055706a1cf",
            "value": " 350/350 [00:00&lt;00:00, 43.8kB/s]"
          }
        },
        "dc3e17fce7a946cdad58df6cec06381e": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8d240053902746af9da57a727277e082": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8f4549d3d49d47feac5673805ad36508": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "368713cfa91c48daaf244b536fda278d": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "179f44b6155c4b31bef93e924db007ae": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "eb7e555987e54221aa853dab81735a68": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f2bc85da32da4c8ca85b30055706a1cf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "3855db11a6274023a42436915aff6410": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_37d2b7c5481445eb9be819b8505a55a9",
              "IPY_MODEL_f5668710bbe2472ca5410a95850193af",
              "IPY_MODEL_e3b10ee06823495aaec7fbbdfc98cba4"
            ],
            "layout": "IPY_MODEL_54464a9d342346c0a21a1d668f781f05"
          }
        },
        "37d2b7c5481445eb9be819b8505a55a9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_8ca8c8ea93824ccdb1b822f0ab3eb874",
            "placeholder": "​",
            "style": "IPY_MODEL_a485bfc6847747819c04b90b30e2cac2",
            "value": "vocab.txt: "
          }
        },
        "f5668710bbe2472ca5410a95850193af": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_bb8b845904714a8f9e3f29ad70953576",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_d9eed644488f49e7a90c0a50bba3d312",
            "value": 1
          }
        },
        "e3b10ee06823495aaec7fbbdfc98cba4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f25671aab90d4ce0adbd38dbb242a2d9",
            "placeholder": "​",
            "style": "IPY_MODEL_34e436945ebc452bb4e4605b4e5b0c6a",
            "value": " 232k/? [00:00&lt;00:00, 19.9MB/s]"
          }
        },
        "54464a9d342346c0a21a1d668f781f05": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "8ca8c8ea93824ccdb1b822f0ab3eb874": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "a485bfc6847747819c04b90b30e2cac2": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "bb8b845904714a8f9e3f29ad70953576": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "d9eed644488f49e7a90c0a50bba3d312": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "f25671aab90d4ce0adbd38dbb242a2d9": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "34e436945ebc452bb4e4605b4e5b0c6a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "b2fedf203b9e430fbbc605a32937dc97": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_b6a3b73896eb47ea80d9000829246ca7",
              "IPY_MODEL_5e90d3bc27ff43ec80a262663af0d523",
              "IPY_MODEL_24d1225c700a42e79387968862f2a2ae"
            ],
            "layout": "IPY_MODEL_0ff08adecd774a93bf41916a9e755de8"
          }
        },
        "b6a3b73896eb47ea80d9000829246ca7": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d94a3f4aa6b645fbb510d926e4239843",
            "placeholder": "​",
            "style": "IPY_MODEL_cc8d264270824cd996bb5d0d4d63a074",
            "value": "tokenizer.json: "
          }
        },
        "5e90d3bc27ff43ec80a262663af0d523": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_e6f39323bbd344dc8355b4cef48bee9f",
            "max": 1,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_a7a53555a77c44569ab4de1cc86a01e0",
            "value": 1
          }
        },
        "24d1225c700a42e79387968862f2a2ae": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_786ad26c50e54e63b82b6441a7d34474",
            "placeholder": "​",
            "style": "IPY_MODEL_10f0f39230474fabaf9cd53e41d35bd8",
            "value": " 466k/? [00:00&lt;00:00, 39.2MB/s]"
          }
        },
        "0ff08adecd774a93bf41916a9e755de8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d94a3f4aa6b645fbb510d926e4239843": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "cc8d264270824cd996bb5d0d4d63a074": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "e6f39323bbd344dc8355b4cef48bee9f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": "20px"
          }
        },
        "a7a53555a77c44569ab4de1cc86a01e0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "786ad26c50e54e63b82b6441a7d34474": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "10f0f39230474fabaf9cd53e41d35bd8": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "8a9d29f55b7c45b89f2209bad5fc924e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_2b07ffdd6d1b4c809185497c28c7f73e",
              "IPY_MODEL_13febc0a030d4f4ab655aaf5e77e5d04",
              "IPY_MODEL_a623618fa84b463f81ddb9f8be163744"
            ],
            "layout": "IPY_MODEL_73a785dbabef4b7985a3c2b4bc156746"
          }
        },
        "2b07ffdd6d1b4c809185497c28c7f73e": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_20c4f5c155e7463490957a5a1e321ff8",
            "placeholder": "​",
            "style": "IPY_MODEL_d406381b63a44660bf9d109a453f10df",
            "value": "special_tokens_map.json: 100%"
          }
        },
        "13febc0a030d4f4ab655aaf5e77e5d04": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_22c33c05a50a4cbeaa4609b5a2ca8143",
            "max": 112,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_038c52c2f9374ea897f1991c852fe603",
            "value": 112
          }
        },
        "a623618fa84b463f81ddb9f8be163744": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0cfceaa8979043418fc537b392e67734",
            "placeholder": "​",
            "style": "IPY_MODEL_7e1d287bd06146b6aa14f9890f0b962b",
            "value": " 112/112 [00:00&lt;00:00, 15.7kB/s]"
          }
        },
        "73a785dbabef4b7985a3c2b4bc156746": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "20c4f5c155e7463490957a5a1e321ff8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d406381b63a44660bf9d109a453f10df": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "22c33c05a50a4cbeaa4609b5a2ca8143": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "038c52c2f9374ea897f1991c852fe603": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "0cfceaa8979043418fc537b392e67734": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "7e1d287bd06146b6aa14f9890f0b962b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "74b3c94dce264be8a0a4632eea3ca8a5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_07958068b7d04109a4fc984530d02024",
              "IPY_MODEL_b8df89847b5c4d3ca3b1998d4bc8ced9",
              "IPY_MODEL_df4a762f76bc49f2bc035f0a181cd46b"
            ],
            "layout": "IPY_MODEL_f0605306287c448cb325eac9af9df392"
          }
        },
        "07958068b7d04109a4fc984530d02024": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d94ddc40c6c0497692b47f34c31a62ba",
            "placeholder": "​",
            "style": "IPY_MODEL_84daaf1ab6da46da893fe0cd9e17fed4",
            "value": "config.json: 100%"
          }
        },
        "b8df89847b5c4d3ca3b1998d4bc8ced9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_ad3ce1673b544f2b801afb4ea8b844a8",
            "max": 190,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_1076d3378ed94a4f8f68087f0a09b7e6",
            "value": 190
          }
        },
        "df4a762f76bc49f2bc035f0a181cd46b": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_a057f3e449964951a3933995399b7ca0",
            "placeholder": "​",
            "style": "IPY_MODEL_1f64284422c046798effef051462ef8a",
            "value": " 190/190 [00:00&lt;00:00, 20.2kB/s]"
          }
        },
        "f0605306287c448cb325eac9af9df392": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d94ddc40c6c0497692b47f34c31a62ba": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "84daaf1ab6da46da893fe0cd9e17fed4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "ad3ce1673b544f2b801afb4ea8b844a8": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1076d3378ed94a4f8f68087f0a09b7e6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "a057f3e449964951a3933995399b7ca0": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "1f64284422c046798effef051462ef8a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "d8272666fda94e09820c897842dc0964": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_10c314a05e3f4020820b48680710be92",
              "IPY_MODEL_bb3ec7f8dec54c2e81fb9cb8d69670f6",
              "IPY_MODEL_a1fa50856c7d4c9fab99f587423fa3f5"
            ],
            "layout": "IPY_MODEL_1ff03b36372d42759950961d74a2aa14"
          }
        },
        "10c314a05e3f4020820b48680710be92": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_9a92340df23a4a8a94e951085ef1cd40",
            "placeholder": "​",
            "style": "IPY_MODEL_e175f32f3ec948c8957ca215c69353d6",
            "value": "Batches: 100%"
          }
        },
        "bb3ec7f8dec54c2e81fb9cb8d69670f6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c10607130af24939865a04c11294a169",
            "max": 723,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_9da398406a17462289af7d05bcdfc96a",
            "value": 723
          }
        },
        "a1fa50856c7d4c9fab99f587423fa3f5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_935fb54735d941ad82b9fc0af4fe6c4f",
            "placeholder": "​",
            "style": "IPY_MODEL_fedd9330595043b6ae04a9df48d35569",
            "value": " 723/723 [00:05&lt;00:00, 170.38it/s]"
          }
        },
        "1ff03b36372d42759950961d74a2aa14": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9a92340df23a4a8a94e951085ef1cd40": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "e175f32f3ec948c8957ca215c69353d6": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "c10607130af24939865a04c11294a169": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "9da398406a17462289af7d05bcdfc96a": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "935fb54735d941ad82b9fc0af4fe6c4f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "fedd9330595043b6ae04a9df48d35569": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "91959786c0084ecbb3d62a7cb2a57228": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_a0acf0cb11f144788e94592d989987e5",
              "IPY_MODEL_1f15e93774e4406c8db889cc98961ec4",
              "IPY_MODEL_f90b51a698474e848ea82b9b38ccb3a9"
            ],
            "layout": "IPY_MODEL_8ed32e0482c94176ba53ed7b038af481"
          }
        },
        "a0acf0cb11f144788e94592d989987e5": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_f73cebc52818445e9d8d0542257f9590",
            "placeholder": "​",
            "style": "IPY_MODEL_d2f21d8c93884d1481de26e7efdf3611",
            "value": "Baseline RAG: 100%"
          }
        },
        "1f15e93774e4406c8db889cc98961ec4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_865c1eac162f40868e66d827a609ba5f",
            "max": 310,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_db7c2d3a4e994896a69622b8242c0336",
            "value": 310
          }
        },
        "f90b51a698474e848ea82b9b38ccb3a9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_d490293583a84ed28083f65ba887fe33",
            "placeholder": "​",
            "style": "IPY_MODEL_73bc625713ca4712b74f700f5f5b9ffc",
            "value": " 310/310 [04:05&lt;00:00,  1.39it/s]"
          }
        },
        "8ed32e0482c94176ba53ed7b038af481": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f73cebc52818445e9d8d0542257f9590": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "d2f21d8c93884d1481de26e7efdf3611": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "865c1eac162f40868e66d827a609ba5f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "db7c2d3a4e994896a69622b8242c0336": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "d490293583a84ed28083f65ba887fe33": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "73bc625713ca4712b74f700f5f5b9ffc": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "1b36e3a881204cefb852f6b304e9af90": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HBoxModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HBoxModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HBoxView",
            "box_style": "",
            "children": [
              "IPY_MODEL_224b399b2dc34b00ba2d40a0569783e0",
              "IPY_MODEL_39cee23a70ed4874b826c69060b8a9a4",
              "IPY_MODEL_b1be59dffe3a4250b09e6e76249664f9"
            ],
            "layout": "IPY_MODEL_26b38568872f4051a2f103c1250cc29f"
          }
        },
        "224b399b2dc34b00ba2d40a0569783e0": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_0446068a527c4f00a95f87158fe82b42",
            "placeholder": "​",
            "style": "IPY_MODEL_c22450a74590473fa49d83ec23961faf",
            "value": "Self-RAG: 100%"
          }
        },
        "39cee23a70ed4874b826c69060b8a9a4": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "FloatProgressModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "FloatProgressModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "ProgressView",
            "bar_style": "success",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_7bd1696d6c38464b9a5ad7288a8d201a",
            "max": 310,
            "min": 0,
            "orientation": "horizontal",
            "style": "IPY_MODEL_37d1a39471de484d9e33f806a50dd685",
            "value": 310
          }
        },
        "b1be59dffe3a4250b09e6e76249664f9": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "HTMLModel",
          "model_module_version": "1.5.0",
          "state": {
            "_dom_classes": [],
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "HTMLModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/controls",
            "_view_module_version": "1.5.0",
            "_view_name": "HTMLView",
            "description": "",
            "description_tooltip": null,
            "layout": "IPY_MODEL_c9dc0b7298774e0b9123620c71b36f05",
            "placeholder": "​",
            "style": "IPY_MODEL_f55e04102b114c73be6079954cb53267",
            "value": " 310/310 [32:13&lt;00:00,  3.95s/it]"
          }
        },
        "26b38568872f4051a2f103c1250cc29f": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "0446068a527c4f00a95f87158fe82b42": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "c22450a74590473fa49d83ec23961faf": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        },
        "7bd1696d6c38464b9a5ad7288a8d201a": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "37d1a39471de484d9e33f806a50dd685": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "ProgressStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "ProgressStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "bar_color": null,
            "description_width": ""
          }
        },
        "c9dc0b7298774e0b9123620c71b36f05": {
          "model_module": "@jupyter-widgets/base",
          "model_name": "LayoutModel",
          "model_module_version": "1.2.0",
          "state": {
            "_model_module": "@jupyter-widgets/base",
            "_model_module_version": "1.2.0",
            "_model_name": "LayoutModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "LayoutView",
            "align_content": null,
            "align_items": null,
            "align_self": null,
            "border": null,
            "bottom": null,
            "display": null,
            "flex": null,
            "flex_flow": null,
            "grid_area": null,
            "grid_auto_columns": null,
            "grid_auto_flow": null,
            "grid_auto_rows": null,
            "grid_column": null,
            "grid_gap": null,
            "grid_row": null,
            "grid_template_areas": null,
            "grid_template_columns": null,
            "grid_template_rows": null,
            "height": null,
            "justify_content": null,
            "justify_items": null,
            "left": null,
            "margin": null,
            "max_height": null,
            "max_width": null,
            "min_height": null,
            "min_width": null,
            "object_fit": null,
            "object_position": null,
            "order": null,
            "overflow": null,
            "overflow_x": null,
            "overflow_y": null,
            "padding": null,
            "right": null,
            "top": null,
            "visibility": null,
            "width": null
          }
        },
        "f55e04102b114c73be6079954cb53267": {
          "model_module": "@jupyter-widgets/controls",
          "model_name": "DescriptionStyleModel",
          "model_module_version": "1.5.0",
          "state": {
            "_model_module": "@jupyter-widgets/controls",
            "_model_module_version": "1.5.0",
            "_model_name": "DescriptionStyleModel",
            "_view_count": null,
            "_view_module": "@jupyter-widgets/base",
            "_view_module_version": "1.2.0",
            "_view_name": "StyleView",
            "description_width": ""
          }
        }
      }
    }
  },
  "nbformat": 4,
  "nbformat_minor": 0
}